

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	4	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	5	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS	6	SEP 11	CA/CAplus enhanced with more pre-1907 records
NEWS	7	SEP 21	CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS	8	SEP 25	CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS	9	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS	10	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS	11	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS	12	OCT 19	LOGOFF HOLD duration extended to 120 minutes
NEWS	13	OCT 19	E-mail format enhanced
NEWS	14	OCT 23	Option to turn off MARPAT highlighting enhancements available
NEWS	15	OCT 23	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	16	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	17	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	18	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	19	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS	20	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	21	NOV 13	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS	22	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS	23	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS	24	NOV 20	CA/CAplus patent kind codes will be updated
NEWS EXPRESS			NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8
NEWS X25			X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:14:41 ON 22 NOV 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 10:14:51 ON 22 NOV 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 NOV 2006 HIGHEST RN 913686-03-0

DICTIONARY FILE UPDATES: 20 NOV 2006 HIGHEST RN 913686-03-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10522254a.str



chain nodes :
 16 17 18 19 22 23
 ring nodes :
 1 2 3 4 5 6 7 8 9 10
 chain bonds :
 1-23 2-22 7-18 7-19 9-16 9-17
 ring bonds :
 1-2 1-5 2-3 3-4 3-6 4-5 4-10 6-7 7-8 8-9 9-10
 exact/norm bonds :
 1-2 1-5 2-3 3-4 3-6 4-5 4-10 6-7 7-8 7-18 7-19 8-9 9-10 9-16 9-17
 exact bonds :
 1-23 2-22
 isolated ring systems :
 containing 1 :

G1:C,H


Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 16:CLASS 17:CLASS 18:CLASS 19:CLASS 22:CLASS 23:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 C,H

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 10:15:12 FILE 'REGISTRY.'
SAMPLE SCREEN SEARCH COMPLETED - 7902 TO ITERATE

25.3% PROCESSED 2000 ITERATIONS 32 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 152712 TO 163368
PROJECTED ANSWERS: 1854 TO 3202

L2 32 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 10:15:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 154329 TO ITERATE

100.0% PROCESSED 154329 ITERATIONS 1672 ANSWERS
SEARCH TIME: 00.00.01

L3 1672 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	166.94	167.15

FILE 'CAPLUS' ENTERED AT 10:15:20 ON 22 NOV 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Nov 2006 VOL 145 ISS 22
FILE LAST UPDATED: 21 Nov 2006 (20061121/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13 full
L4 40 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 40 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:1012671 CAPLUS

DOCUMENT NUMBER: 145:377381

TITLE: Preparation of quinazolines as modulators of ion channels

INVENTOR(S): Gonzalez, Jesus E.; Wilson, Dean M.; Termin, Andreas P.; Grootenhuis, Peter D. J.; Zhang, Yulian; Petzoldt, Benjamin J.; Fanning, Lev Tyler Dewey; Neubert, Timothy D.; Tung, Roger D.; Martinborough, Esther; Zimmerman, Nicole

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 351pp., Cont.-in-part of U.S. Ser. No. 792,688.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006217377	A1	20060928	US 2004-935008	20040902
US 2004248890	A1	20041209	US 2004-792688	20040303
PRIORITY APPLN. INFO.:			US 2003-451458P	P 20030303
			US 2003-463797P	P 20030418
			US 2004-792688	A2 20040303

OTHER SOURCE(S): MARPAT 145:377381

GI




AB The title compds. [I; NR1R2 = (un)substituted 3-12 membered monocyclic or bicyclic (un)saturated ring having 0-3 heteroatoms selected from N, S or O; ring A = (un)substituted 5-7 membered aryl, 8-10 membered bicyclic aryl having 0-3 heteroatoms selected from N, S or O, etc.; x = 0-4; R3 = QR (wherein Q = a bond, alkylidene wherein up to two non-adjacent methylene units are optionally replaced by S, O, CS, etc.; R = halo, NO2, CN, etc.); with provisos], useful as inhibitors of voltage-gated sodium channels and calcium channels, were prepared Thus, reacting 2-(4-chloro-7-methylquinazolin-2-yl)phenol with 4-aminopiperidine in the presence of Et3N in CH2Cl2 afforded 89% II. Representative compds. I were found to possess desired N-type calcium channel modulation activity and selectivity (no specific data given). Also, representative compds. I were found to possess desired voltage gated sodium channel activity and selectivity (no specific data given). The invention also provides pharmaceutically acceptable compns. comprising the compds. I and methods of using the compns. in the treatment of various disorders.

IT 757982-54-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of quinazolines as modulators of ion channels for treating pain associated with various diseases)

RN 757982-54-0 CAPLUS

CN 3H-Pyrazolo[3,4-c]pyridin-3-one, 6-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-1,2,4,5,6,7-hexahydro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L4 ANSWER 2 OF 40 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:919654 CAPLUS

DOCUMENT NUMBER: 145:315004

TITLE: Preparation of phthalazine, aza- and diaza-phthalazine compounds as protein kinase, especially p38 kinase, inhibitors for treating inflammation and related conditions

INVENTOR(S): Tasker, Andrew; Zhang, Dawei; Cao, Guo-Qiang; Chakrabarti, Partha, Pratim; Falsey, James, Richard; Herberich, Bradley, J.; Hungate, Randall, W.; Pettus, Liping, H.; Reed, Anthony; Rzasa, Robert, M.; Sham, Kelvin, K. C.; Thaman, Maya, C.; Xu, Shimin

PATENT ASSIGNEE(S): Amgen Inc, USA

SOURCE: PCT Int. Appl., 209pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006094187	A2	20060908	WO 2006-US7583	20060303
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 2006199817	A1	20060907	US 2006-367123	20060302
PRIORITY APPLN. INFO.:			US 2005-659003P	P 20050303
			US 2006-367123	A 20060302
OTHER SOURCE(S):	MARPAT 145:315004			
GI				



AB Title compds. I [A1, A2 = independently N, CH and derivs.; B = a direct bond, CO, O, NH and derivs., etc.; R1 = (CR7R7)_nX, (CR7R8)_nX; n = 0-2; X = NH₂ and derivs., OH and derivs., (un)substituted 5-8 membered monocyclyl, 6-12 membered bicyclyl, etc.; R2 = H, halo, NO₂, CN, (un)substituted alk(en/yn)yl, etc.; R3, R8 = independently (un)substituted partially or fully saturated or unsatd. 5-8 membered monocyclyl, 6-12 membered bicyclyl, or 7-14 membered tricyclyl; R4 = H, halo, NO₂, CO₂H and derivs., etc.; R7 = H, (un)substituted alk(en/yn)yl, cycloalk(en)yl; and their stereoisomers, tautomers, solvates, pharmaceutical acceptable salts, derivs., and

prodrugs] were prepared as p38 protein kinase inhibitors. Thus, amination of 6-bromo-1-chlorophthalazine (preparation given) with pyrrolidin-3-ol and coupling of the bromide with N-cyclopropyl-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide gave phthalazine II. I inhibited the activity of p38 receptor kinase at doses < 25 μ M. I, and their pharmaceutical compns., are useful for the prophylaxis and treatment of kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders.


IT 909187-63-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of diaza/aza/phthalazines as p38 kinase inhibitors for treating inflammations)

RN 909187-63-9 CAPLUS

CN Benzamide, N-cyclopropyl-3-[1-(1,2,3,4,5,7-hexahydro-3-oxo-6H-pyrazolo[3,4-c]pyridin-6-yl)-6-phthalazinyl]-4-methyl- (9CI) (CA INDEX NAME)




IT 654666-65-6P 909187-64-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of diaza/aza/phthalazines as p38 kinase inhibitors for treating inflammations)


RN 654666-65-6 CAPLUS

CN 3H-Pyrazolo[3,4-c]pyridin-3-one, 1,2,4,5,6,7-hexahydro- (9CI) (CA INDEX NAME)



RN 909187-64-0 CAPLUS

CN 3H-Pyrazolo[3,4-c]pyridin-3-one, 1,2,4,5,6,7-hexahydro-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 40 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:736382 CAPLUS

DOCUMENT NUMBER: 145:167240

TITLE: Preparation of substituted pyrazolopyridines as kinase inhibitors, and their compositions and use for treatment of cancer

INVENTOR(S): Ronan, Baptiste; Tabart, Michel; Halley, Frank; Bacque, Eric; Souaille, Catherine; Ugolini, Antonio; Viviani, Fabrice

PATENT ASSIGNEE(S): Aventis Pharma S.A., Fr.

SOURCE: PCT Int. Appl., 83 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006077319	A1	20060727	WO 2006-FR114	20060118
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
FR 2880891	A1	20060721	FR 2005-555	20050119
PRIORITY APPLN. INFO.:			FR 2005-555	A 20050119
			FR 2005-7505	A 20050713
OTHER SOURCE(S):	MARPAT 145:167240			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A, Ar = independently (un)substituted hetero/aryl, cycloalkyl, heterocyclyl; L = a bond, CO, NH, CONH, NHCO, NHSO, NH-CO-NH, etc.; one of X, Y and Z = N, NO, and the other of Z, Y and X = CR₅, CR₆; R₅, R₆ = independently H, halo, CN, OH, alkoxy, etc.] were prepared as kinase inhibitors for treatment especially of cancer. Thus, pyrazolo[3,4-b]pyridine II was prepared via Suzuki coupling of iodide III or its tri-Boc analog with arylpinacolborane IV, and one pot Boc-deprotection/cyclization in DCM in the presence of TFA containing 10% anisole. Its pyrazolo[4,3-c]pyridine analog inhibited FAK, KDR and Tie2 kinases with an IC₅₀ of 73 nM, 33 nM, and 5 nM, resp. Thus, I and their pharmaceutical compns., are useful as anticancer agents (no data).

IT 886457-40-5P 900863-78-7P 900863-83-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrazolopyridines as FAK, KDR and Tie2 kinase inhibitors and their use for treating cancer)

RN 886457-40-5 CAPLUS


CN Urea, N-[4-(3-amino-1H-pyrazolo[3,4-c]pyridin-4-yl)phenyl]-N'-[2-fluoro-5-

(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 900863-78-7 CAPLUS

CN Urea, N-[4-(3-amino-1H-pyrazolo[3,4-c]pyridin-4-yl)phenyl]-N'-(2-methoxy-5-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)



RN 900863-83-4 CAPLUS

CN Benzenesulfonamide, N-[4-(3-amino-1H-pyrazolo[3,4-c]pyridin-4-yl)phenyl]-2,3-dichloro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 40 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:677569 CAPLUS

DOCUMENT NUMBER: 145:145693

TITLE: Preparation of pyrrolopyrazoles as potent kinase inhibitors, particularly PAK4 inhibitors

INVENTOR(S): Bouzida, Djamel; Dong, Liming; Guo, Chuangxing; Hong, Yufeng; Li, Haitao; Marakovits, Joseph Timothy; Yang, Anle; Zhang, Junhu

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: PCT Int. Appl., 101 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006072831	A1	20060713	WO 2005-IB3975	20051228
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				


PRIORITY APPLN. INFO.: US 2005-642900P P 20050110
US 2005-733770P P 20051104

OTHER SOURCE(S): MARPAT 145:145693

GI



I



II

AB Title compds. I [R1 = SO₂H and derivs., (un)substituted cyclo/alk(en/yn)yl, etc.; R2, R3 = independently H, perfluoro/cyclo/alkyl, etc.; R4 = H, CONH₂ and derivs., CO₂H and derivs., etc.; X = (CH₂)_n; n = 1-3; and their pharmaceutically acceptable salts, solvates and hydrates] were prepared as protein kinase inhibitors, particularly p21-activated kinase 4 (PAK4) inhibitors, for treating tumor growth and abnormal cell proliferation. Thus, alkylation of tert-Bu 3-amino-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate with 4-chlorothieno[3,2-d]pyrimidine, and reaction with trans-2-phenylcyclopropyl isocyanate gave pyrrolopyrazole trans-II in > 95% purity. I displayed inhibition against PAK4 in an ELISA assay measuring the PAK4 kinase activity in whole cells. Thus, I and their compns., are useful as antiproliferative agents, especially for treating neoplasm.

IT 898043-54-4P, 6,6-Dimethyl-N-(trans-2-phenylcyclopropyl)-3-[(thieno[3,2-d]pyrimidin-4-yl)amino]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898043-55-5P, 3-[(2-Chlorothieno[3,2-d]pyrimidin-4-yl)amino]-6,6-dimethyl-N-(trans-2-phenylcyclopropyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898043-56-6P, N-[5-[(2S)-2-Benzyl-4-methylpiperazin-1-yl]carbonyl]-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-2-chlorothieno[3,2-d]pyrimidin-4-amine 898043-57-7P, 3-[(2,6-Dichloropyrimidin-4-yl)amino]-6,6-dimethyl-N-(trans-2-phenylcyclopropyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898043-58-8P, N-[(1S)-2-(Dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(thieno[3,2-d]pyrimidin-4-yl)amino]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898043-59-9P, 3-[(2-Chlorothieno[3,2-d]pyrimidin-4-yl)amino]-N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898043-60-2P, 3-[(4-Chloro-6-propoxy-1,3,5-triazin-2-yl)amino]-6,6-dimethyl-N-(trans-2-phenylcyclopropyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898043-61-3P, 3-[(4-Amino-6-chloro-1,3,5-triazin-2-yl)amino]-6,6-dimethyl-N-(trans-2-phenylcyclopropyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898043-62-4P, 3-[(4,6-Dichloro-1,3,5-triazin-2-yl)amino]-6,6-dimethyl-N-(trans-2-phenylcyclopropyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898043-63-5P, 3-[(4-Chloro-6-methoxy-1,3,5-triazin-2-yl)amino]-6,6-dimethyl-N-(trans-2-phenylcyclopropyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898043-64-6P, 6,6-Dimethyl-3-[[2-(methylthio)-6-(trifluoromethyl)pyrimidin-4-yl]amino]-N-(trans-2-phenylcyclopropyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-

carboxamide 898043-65-7P, 3-[(2-Chloroquinazolin-4-yl)amino]-6,6-dimethyl-N-(trans-2-phenylcyclopropyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898043-66-8P 898043-67-9P, 3-[(4,6-Dimethoxy-1,3,5-triazin-2-yl)amino]-6,6-dimethyl-N-(trans-2-phenylcyclopropyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898043-68-0P, 3-[[4-Chloro-6-(dimethylamino)-1,3,5-triazin-2-yl]amino]-6,6-dimethyl-N-(trans-2-phenylcyclopropyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898043-69-1P 898043-70-4P 898043-71-5P 898043-72-6P, 3-[[4-Methoxy-6-(pyrrolidin-1-yl)-1,3,5-triazin-2-yl]amino]-6,6-dimethyl-N-(trans-2-phenylcyclopropyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898043-73-7P 898043-74-8P 898043-75-9P 898043-76-0P 898043-77-1P, 3-[(4,6-Dimethylpyrimidin-2-yl)amino]-6,6-dimethyl-N-(trans-2-phenylcyclopropyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898043-78-2P, 3-[(4-Trifluoromethylpyridin-2-yl)amino]-6,6-dimethyl-N-(trans-2-phenylcyclopropyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898043-79-3P, 3-[(4-Trifluoromethyl-6-methylpyridin-2-yl)amino]-6,6-dimethyl-N-(trans-2-phenylcyclopropyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898043-80-6P, 3-[(6-Trifluoromethylpyridin-2-yl)amino]-6,6-dimethyl-N-(trans-2-phenylcyclopropyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898043-81-7P, 6,6-Dimethyl-N-(trans-2-phenylcyclopropyl)-3-[[4-(trifluoromethyl)pyrimidin-2-yl]amino]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898043-82-8P, 3-[(4-Cyanopyridin-2-yl)amino]-6,6-dimethyl-N-(trans-2-phenylcyclopropyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898043-83-9P, 6,6-Dimethyl-N-(trans-2-phenylcyclopropyl)-3-[[2-(trifluoromethyl)pyrimidin-4-yl]amino]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898043-84-0P, 6,6-Dimethyl-3-[(2-methylthieno[2,3-d]pyrimidin-4-yl)amino]-N-(trans-2-phenylcyclopropyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898043-85-1P, 6,6-Dimethyl-3-[(2-methylthieno[3,2-d]pyrimidin-4-yl)amino]-N-(1R,2S)-2-phenylcyclopropyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898043-86-2P, 3-[(2-Cyanopyrimidin-4-yl)amino]-6,6-dimethyl-N-(trans-2-phenylcyclopropyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898043-87-3P, 6,6-Dimethyl-3-[[2-methyl-6-(morpholin-4-yl)pyrimidin-4-yl]amino]-N-(trans-2-phenylcyclopropyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898043-88-4P, 6,6-Dimethyl-3-[(6-methylthieno[2,3-d]pyrimidin-4-yl)amino]-N-(trans-2-phenylcyclopropyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898043-89-5P, 6,6-Dimethyl-3-[(9-methyl-9H-purin-6-yl)amino]-N-(trans-2-phenylcyclopropyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898043-90-8P, 3-[(2-Ethoxy-5-fluoropyrimidin-4-yl)amino]-6,6-dimethyl-N-(trans-2-phenylcyclopropyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898043-91-9P, 3-[[6-(Dimethylamino)-2-methylpyrimidin-4-yl]amino]-6,6-dimethyl-N-(trans-2-phenylcyclopropyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898043-92-0P, 6,6-Dimethyl-3-[(2-methylpyrimidin-4-yl)amino]-N-(trans-2-phenylcyclopropyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898043-93-1P, 3-[(2-Cyanoquinazolin-4-yl)amino]-6,6-dimethyl-N-(trans-2-phenylcyclopropyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898043-94-2P, 6,6-Dimethyl-3-[(2-methylthieno[3,2-d]pyrimidin-4-yl)amino]-N-(trans-2-phenylcyclopropyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898043-95-3P, 6,6-Dimethyl-N-(trans-2-phenylcyclopropyl)-3-[(thieno[2,3-d]pyrimidin-4-yl)amino]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898043-96-4P, 3-[(5-Fluoro-2-methoxypyrimidin-4-yl)amino]-6,6-dimethyl-N-(trans-2-phenylcyclopropyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898043-97-5P, 3-[(5-Fluoro-2-methylpyrimidin-4-yl)amino]-6,6-dimethyl-N-(trans-2-phenylcyclopropyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898043-98-6P, 6,6-Dimethyl-N-(trans-2-phenylcyclopropyl)-3-[[2-(trifluoromethyl)thieno[3,2-d]pyrimidin-4-yl]amino]-4,6-dihydropyrrolo[3,4-

c]pyrazole-5(1H)-carboxamide 898043-99-7P, 6,6-Dimethyl-3-[(2-methylthieno[2,3-d]pyrimidin-4-yl)amino]-N-((1R,2S)-2-phenylcyclopropyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898044-00-3P, 6,6-Dimethyl-3-[(2-methylthieno[2,3-d]pyrimidin-4-yl)amino]-N-((1S,2R)-2-phenylcyclopropyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898044-01-4P, 3-[(5-Fluoropyrimidin-4-yl)amino]-6,6-dimethyl-N-(trans-2-phenylcyclopropyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898044-02-5P, 6,6-Dimethyl-3-[(7-methylthieno[3,2-d]pyrimidin-4-yl)amino]-N-(trans-2-phenylcyclopropyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898044-03-6P, 6,6-Dimethyl-N-((1R,2S)-2-phenylcyclopropyl)-3-[(thieno[2,3-d]pyrimidin-4-yl)amino]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898044-04-7P, 6,6-Dimethyl-N-((1R,2S)-2-phenylcyclopropyl)-3-[(thieno[3,2-d]pyrimidin-4-yl)amino]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898044-05-8P, 3-[(Furo[3,2-d]pyrimidin-4-yl)amino]-6,6-dimethyl-N-(trans-2-phenylcyclopropyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898044-06-9P, N-[(1S)-2-(Dimethylamino)-1-phenylethyl]-3-[(6-ethylpyrimidin-4-yl)amino]-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898044-07-0P, N-[(1S)-2-(Dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[[2-(trifluoromethyl)pyrimidin-4-yl]amino]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898044-08-1P, N-[(1S)-2-(Dimethylamino)-1-phenylethyl]-3-[(5-fluoro-6-methylpyrimidin-4-yl)amino]-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898044-09-2P, N-[(1S)-2-(Dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(9-methyl-9H-purin-6-yl)amino]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898044-10-5P, N-[(1S)-2-(Dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methylthieno[2,3-d]pyrimidin-4-yl)amino]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898044-11-6P, N-[(1S)-2-(Dimethylamino)-1-phenylethyl]-3-[(2-ethoxy-5-fluoropyrimidin-4-yl)amino]-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898044-12-7P, 3-[(2-Cyanoypyrimidin-4-yl)amino]-N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898044-13-8P, N-[(1S)-2-(Dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(thieno[2,3-d]pyrimidin-4-yl)amino]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898044-14-9P, N-[(1S)-2-(Dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(6-methylthieno[2,3-d]pyrimidin-4-yl)amino]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898044-15-0P, N-[(1S)-2-(Dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methylthieno[3,2-d]pyrimidin-4-yl)amino]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898044-16-1P, 3-[(2-Cyanoquinazolin-4-yl)amino]-N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898044-17-2P, N-[(1S)-2-(Dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methylpyrimidin-4-yl)amino]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898044-18-3P, N-[(1S)-2-(Dimethylamino)-1-phenylethyl]-3-[(5-fluoro-2-methoxypyrimidin-4-yl)amino]-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898044-19-4P, N-[(1S)-2-(Dimethylamino)-1-phenylethyl]-3-[(5-fluoropyrimidin-4-yl)amino]-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898044-20-7P, (1S)-2-(Dimethylamino)-1-phenylethyl 6,6-dimethyl-3-[(thieno[3,2-d]pyrimidin-4-yl)amino]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate 898044-21-8P, (1S)-2-(Dimethylamino)-1-phenylethyl 6,6-dimethyl-3-[(2-methylthieno[2,3-d]pyrimidin-4-yl)amino]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate 898044-22-9P, (1S)-2-(Dimethylamino)-1-phenylethyl 3-[(2-cyanoypyrimidin-4-yl)amino]-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate 898044-23-0P, (1S)-2-(Dimethylamino)-1-phenylethyl 6,6-dimethyl-3-[(6-methylthieno[2,3-d]pyrimidin-4-yl)amino]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate 898044-24-1P, (1S)-2-(Dimethylamino)-1-phenylethyl 3-[(2-ethoxy-5-fluoropyrimidin-4-yl)amino]-6,6-dimethyl-4,6-


dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate 898044-25-2P, (1S)-2-(Dimethylamino)-1-phenylethyl 6,6-dimethyl-3-[(2-methylthieno[3,2-d]pyrimidin-4-yl)amino]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate 898044-26-3P, (1S)-2-(Dimethylamino)-1-phenylethyl 3-[(2-cyanoquinazolin-4-yl)amino]-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate 898044-27-4P, (1S)-2-(Dimethylamino)-1-phenylethyl 6,6-dimethyl-3-[(thieno[2,3-d]pyrimidin-4-yl)amino]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate 898044-28-5P, (1S)-2-(Dimethylamino)-1-phenylethyl 6,6-dimethyl-3-[[2-(trifluoromethyl)pyrimidin-4-yl]amino]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate 898044-29-6P, (1S)-2-(Dimethylamino)-1-phenylethyl 3-[(5-fluoro-6-methylpyrimidin-4-yl)amino]-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate 898044-30-9P, (1S)-2-(Dimethylamino)-1-phenylethyl 6,6-dimethyl-3-[(9-methyl-9H-purin-6-yl)amino]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate 898044-31-0P, (1S)-2-(Dimethylamino)-1-phenylethyl 3-[(5-fluoro-2-methoxypyrimidin-4-yl)amino]-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate 898044-32-1P, (1S)-2-(Dimethylamino)-1-phenylethyl 3-[(5-fluoropyrimidin-4-yl)amino]-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate 898044-33-2P 898044-34-3P 898044-35-4P, N-[(1S)-2-(Dimethylamino)-1-phenylethyl]-3-[(furo[3,2-d]pyrimidin-4-yl)amino]-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898044-36-5P, 3-[(2-Methylquinazolin-4-yl)amino]-6,6-dimethyl-N-(trans-2-phenylcyclopropyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898044-37-6P, 3-[(Quinazolin-4-yl)amino]-6,6-dimethyl-N-(trans-2-phenylcyclopropyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898044-38-7P, 3-[(2-Cyclopropylquinazolin-4-yl)amino]-6,6-dimethyl-N-(trans-2-phenylcyclopropyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrrolopyrazoles as PAK4 inhibitors)

RN 898043-54-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-6,6-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-3-(thieno[3,2-d]pyrimidin-4-ylamino)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-55-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(2-chlorothieno[3,2-d]pyrimidin-4-yl)amino]-4,6-dihydro-6,6-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-56-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, N-(2-chlorothieno[3,2-d]pyrimidin-4-yl)-1,4,5,6-tetrahydro-6,6-dimethyl-5-[[(2S)-4-methyl-2-(phenylmethyl)-1-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-57-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(2,6-dichloro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-58-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-[(1S)-2-(dimethylamino)-1-phenylethyl]-4,6-dihydro-6,6-dimethyl-3-(thieno[3,2-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-59-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(2-chlorothieno[3,2-d]pyrimidin-4-yl)amino]-N-[(1S)-2-(dimethylamino)-1-phenylethyl]-4,6-dihydro-6,6-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-60-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(4-chloro-6-propoxy-1,3,5-triazin-2-yl)amino]-4,6-dihydro-6,6-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-61-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(4-amino-6-chloro-1,3,5-triazin-2-yl)amino]-4,6-dihydro-6,6-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-62-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]-4,6-dihydro-6,6-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-63-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(4-chloro-6-methoxy-1,3,5-triazin-2-yl)amino]-4,6-dihydro-6,6-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-64-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-6,6-dimethyl-3-[[2-(methylthio)-6-(trifluoromethyl)-4-pyrimidinyl]amino]-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-65-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(2-chloro-4-quinazolinyl)amino]-4,6-dihydro-6,6-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-66-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[4-[(2S)-2-(aminocarbonyl)-1-pyrrolidinyl]-6-chloro-1,3,5-triazin-2-yl]amino]-4,6-dihydro-6,6-dimethyl-N-(2-phenylcyclopropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-67-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(4,6-dimethoxy-1,3,5-triazin-2-yl)amino]-4,6-dihydro-6,6-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-68-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[4-chloro-6-(dimethylamino)-1,3,5-triazin-2-yl]amino]-4,6-dihydro-6,6-dimethyl-N-[(1R,2S)-2-

phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-69-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-6-methoxy-1,3,5-triazin-2-yl]amino]-6,6-dimethyl-N-(2-phenylcyclopropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-70-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[4-methoxy-6-[(2S)-2-[(methylamino)carbonyl]-1-pyrrolidinyl]-1,3,5-triazin-2-yl]amino]-6,6-dimethyl-N-(2-phenylcyclopropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-71-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[4-methoxy-6-(2-methyl-1-aziridinyl)-1,3,5-triazin-2-yl]amino]-6,6-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-72-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[4-methoxy-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]-6,6-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-73-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[4-[(2S)-2-cyano-1-pyrrolidinyl]-6-methoxy-1,3,5-triazin-2-yl]amino]-4,6-dihydro-6,6-dimethyl-N-(2-phenylcyclopropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-74-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[4-[(2S)-2-(aminocarbonyl)-1-pyrrolidinyl]-6-methoxy-1,3,5-triazin-2-yl]amino]-4,6-dihydro-6,6-dimethyl-N-(2-phenylcyclopropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-75-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[4-[(2S)-2-(aminocarbonyl)-1-pyrrolidinyl]-6-(dimethylamino)-1,3,5-triazin-2-yl]amino]-4,6-dihydro-6,6-dimethyl-N-(2-phenylcyclopropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-76-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[4-(dimethylamino)-6-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-1,3,5-triazin-2-yl]amino]-4,6-dihydro-6,6-dimethyl-N-(2-phenylcyclopropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-77-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(4,6-dimethyl-2-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-78-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-6,6-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-3-[[4-(trifluoromethyl)-2-pyridinyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-79-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-6,6-dimethyl-3-[[6-methyl-4-(trifluoromethyl)-2-pyridinyl]amino]-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-80-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-6,6-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-3-[[6-(trifluoromethyl)-2-pyridinyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-81-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-6,6-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-3-[[4-(trifluoromethyl)-2-pyrimidinyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-82-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(4-cyano-2-pyridinyl)amino]-4,6-dihydro-6,6-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-83-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-6,6-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-3-[[2-(trifluoromethyl)-4-pyrimidinyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-84-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-6,6-dimethyl-3-[(2-methylthieno[2,3-d]pyrimidin-4-yl)amino]-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-85-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-6,6-dimethyl-3-[(2-methylthieno[3,2-d]pyrimidin-4-yl)amino]-N-[(1R,2S)-2-phenylcyclopropyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-86-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(2-cyano-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-87-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-6,6-dimethyl-3-[[2-methyl-6-(4-morpholinyl)-4-pyrimidinyl]amino]-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-88-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-6,6-dimethyl-3-[(6-methylthieno[2,3-d]pyrimidin-4-yl)amino]-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-89-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-6,6-dimethyl-3-[(9-methyl-9H-purin-6-yl)amino]-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-90-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(2-ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-91-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[6-(dimethylamino)-2-methyl-4-pyrimidinyl]amino]-4,6-dihydro-6,6-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-92-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-6,6-dimethyl-3-[(2-methyl-4-pyrimidinyl)amino]-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-93-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(2-cyanoquinazolin-4-yl)amino]-4,6-dihydro-6,6-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-94-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-6,6-dimethyl-3-[(2-methylthieno[3,2-d]pyrimidin-4-yl)amino]-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-95-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-6,6-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-3-(thieno[2,3-d]pyrimidin-4-ylamino)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-96-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(5-fluoro-2-methoxy-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-97-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(5-fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-98-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-6,6-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-3-[[2-(trifluoromethyl)thieno[3,2-d]pyrimidin-4-yl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898043-99-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-6,6-dimethyl-3-[(2-

methylthieno[2,3-d]pyrimidin-4-yl)amino]-N-[(1R,2S)-2-phenylcyclopropyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-00-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-6,6-dimethyl-3-[(2-methylthieno[2,3-d]pyrimidin-4-yl)amino]-N-[(1S,2R)-2-phenylcyclopropyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-01-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-02-5 CAPLUS
CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-6,6-dimethyl-3-[(7-methylthieno[3,2-d]pyrimidin-4-yl)amino]-N-(trans-2-phenylcyclopropyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-03-6 CAPLUS
CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-6,6-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-3-(thieno[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-04-7 CAPLUS
CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-6,6-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-3-(thieno[3,2-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-05-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-(furo[3,2-d]pyrimidin-4-ylamino)-4,6-dihydro-6,6-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-06-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-[(1S)-2-(dimethylamino)-1-phenylethyl]-3-[(6-ethyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethyl-, rel-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-07-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-[(1S)-2-(dimethylamino)-1-phenylethyl]-4,6-dihydro-6,6-dimethyl-3-[(2-(trifluoromethyl)-4-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-08-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-[(1S)-2-(dimethylamino)-1-phenylethyl]-3-[(5-fluoro-6-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-09-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-[(1S)-2-(dimethylamino)-1-phenylethyl]-4,6-dihydro-6,6-dimethyl-3-[(9-methyl-9H-purin-6-yl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-10-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-[(1S)-2-(dimethylamino)-1-phenylethyl]-4,6-dihydro-6,6-dimethyl-3-[(2-methylthieno[2,3-d]pyrimidin-4-yl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-11-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-[(1S)-2-(dimethylamino)-1-phenylethyl]-3-[(2-ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-12-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(2-cyano-4-pyrimidinyl)amino]-N-[(1S)-2-(dimethylamino)-1-phenylethyl]-4,6-dihydro-6,6-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-13-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-[(1S)-2-(dimethylamino)-1-phenylethyl]-4,6-dihydro-6,6-dimethyl-3-(thieno[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-14-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-[(1S)-2-(dimethylamino)-1-phenylethyl]-4,6-dihydro-6,6-dimethyl-3-[(6-methylthieno[2,3-d]pyrimidin-4-yl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-15-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-[(1S)-2-(dimethylamino)-1-phenylethyl]-4,6-dihydro-6,6-dimethyl-3-[(2-methylthieno[3,2-d]pyrimidin-4-yl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-16-1 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(2-cyano-4-quinazolinyl)amino]-N-[(1S)-2-(dimethylamino)-1-phenylethyl]-4,6-dihydro-6,6-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-17-2 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-[(1S)-2-(dimethylamino)-1-phenylethyl]-4,6-dihydro-6,6-dimethyl-3-[(2-methyl-4-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-18-3 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-[(1S)-2-(dimethylamino)-1-phenylethyl]-3-[(5-fluoro-2-methoxy-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-19-4 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-[(1S)-2-(dimethylamino)-1-phenylethyl]-3-[(5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-20-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 4,6-dihydro-6,6-dimethyl-3-
(thieno[3,2-d]pyrimidin-4-ylamino)-, (1S)-2-(dimethylamino)-1-phenylethyl
ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-21-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 4,6-dihydro-6,6-dimethyl-3-
[(2-methylthieno[2,3-d]pyrimidin-4-yl)amino]-, (1S)-2-(dimethylamino)-1-
phenylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-22-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 3-[(2-cyano-4-

pyrimidinyl)amino]-4,6-dihydro-6,6-dimethyl-, (1S)-2-(dimethylamino)-1-phenylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-23-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 4,6-dihydro-6,6-dimethyl-3-[(6-methylthieno[2,3-d]pyrimidin-4-yl)amino]-, (1S)-2-(dimethylamino)-1-phenylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-24-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 3-[(2-ethoxy-5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethyl-, (1S)-2-(dimethylamino)-1-phenylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-25-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 4,6-dihydro-6,6-dimethyl-3-[(2-methylthieno[3,2-d]pyrimidin-4-yl)amino]-, (1S)-2-(dimethylamino)-1-phenylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-26-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 3-[(2-cyano-4-quinazolinyl)amino]-4,6-dihydro-6,6-dimethyl-, (1S)-2-(dimethylamino)-1-phenylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-27-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 4,6-dihydro-6,6-dimethyl-3-(thieno[2,3-d]pyrimidin-4-ylamino)-, (1S)-2-(dimethylamino)-1-phenylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-28-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 4,6-dihydro-6,6-dimethyl-3-[[2-(trifluoromethyl)-4-pyrimidinyl]amino]-, (1S)-2-(dimethylamino)-1-phenylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-29-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 3-[(5-fluoro-6-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethyl-, (1S)-2-(dimethylamino)-1-phenylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-30-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 4,6-dihydro-6,6-dimethyl-3-[(9-methyl-9H-purin-6-yl)amino]-, (1S)-2-(dimethylamino)-1-phenylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-31-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 3-[(5-fluoro-2-methoxy-4-

pyrimidinyl)amino]-4,6-dihydro-6,6-dimethyl-, (1S)-2-(dimethylamino)-1-phenylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-32-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 3-[(5-fluoro-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethyl-, (1S)-2-(dimethylamino)-1-phenylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-33-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, 5-[[(3S,8aS)-hexahydro-3-methylpyrrolo[1,2-a]pyrazin-2(1H)-yl]carbonyl]-1,4,5,6-tetrahydro-6,6-dimethyl-N-(7-methylthieno[3,2-d]pyrimidin-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-34-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, N-(5-fluoro-6-methyl-4-pyrimidinyl)-5-

[[(3S,8aS)-hexahydro-3-methylpyrrolo[1,2-a]pyrazin-2(1H)-yl]carbonyl]-
1,4,5,6-tetrahydro-6,6-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-35-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-[(1S)-2-(dimethylamino)-1-phenylethyl]-3-(furo[3,2-d]pyrimidin-4-ylamino)-4,6-dihydro-6,6-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-36-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-6,6-dimethyl-3-[(2-methyl-4-quinazolinyl)amino]-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-37-6 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-6,6-dimethyl-N-
 [(1R,2S)-2-phenylcyclopropyl]-3-(4-quinazolinylamino)-, rel- (9CI) (CA
 INDEX NAME)


Relative stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-38-7 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(2-cyclopropyl-4-
 quinazolinyl)amino]-4,6-dihydro-6,6-dimethyl-N-[(1R,2S)-2-
 phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT 898044-44-5P, 3-Amino-6,6-dimethyl-N-(trans-2-phenylcyclopropyl)-
 4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide
 RL: PEP (Physical, engineering or chemical process); PYP (Physical
 process); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
 PROC (Process); RACT (Reactant or reagent)
 (intermediate; preparation of pyrrolopyrazoles as PAK4 inhibitors)

RN 898044-44-5 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-amino-4,6-dihydro-6,6-dimethyl-
 N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 898044-39-8P, N-(6,6-Dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)thieno[3,2-d]pyrimidin-4-amine 898044-40-1P, tert-Butyl 3-[(2-chlorothieno[3,2-d]pyrimidin-4-yl)amino]-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate 898044-41-2P 898044-46-7P 898044-54-7P, 3-Amino-N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide 898044-57-0P, (S)-2-(Dimethylamino)-1-phenylethyl 3-amino-6,6-dimethylpyrrolo[3,4-c]pyrazole-5(1H,4H,6H)-carboxylate 898044-60-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of pyrrolopyrazoles as PAK4 inhibitors)
 RN 898044-39-8 CAPLUS
 CN Thieno[3,2-d]pyrimidin-4-amine, N-(1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-40-1 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 3-[(2-chlorothieno[3,2-d]pyrimidin-4-yl)amino]-4,6-dihydro-6,6-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 898044-41-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, 1,4,5,6-tetrahydro-6,6-dimethyl-5-[[(2S)-4-methyl-2-(phenylmethyl)-1-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 898044-46-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-amino-4,6-dihydro-6,6-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 898044-54-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-amino-N-[(1S)-2-(dimethylamino)-1-phenylethyl]-4,6-dihydro-6,6-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 898044-57-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 3-amino-4,6-dihydro-6,6-dimethyl-, (1S)-2-(dimethylamino)-1-phenylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 898044-60-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, 5-[[[(3S,8aS)-hexahydro-3-methylpyrrolo[1,2-a]pyrazin-2(1H)-yl]carbonyl]-1,4,5,6-tetrahydro-6,6-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 398491-61-7, tert-Butyl 3-amino-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrrolopyrazoles as PAK4 inhibitors)

RN 398491-61-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 3-amino-4,6-dihydro-6,6-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 898044-47-8P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of pyrrolopyrazoles as PAK4 inhibitors)

RN 898044-47-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-amino-4,6-dihydro-6,6-dimethyl-N-[(1S,2R)-2-phenylcyclopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 40 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:440187 CAPLUS

DOCUMENT NUMBER: 144:468159

TITLE: Pyrrolopyridines as protein tyrosine kinase inhibitors, their preparation, pharmaceutical compositions, and use in therapy

INVENTOR(S): Dai, Yujia; Hartandi, Kresna; Michaelides, Michael M.

PATENT ASSIGNEE(S): Abbott Laboratories, USA
 SOURCE: PCT Int. Appl., 67 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006050109	A2	20060511	WO 2005-US38958	20051028
WO 2006050109	A3	20060803		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM US 2006178378 A1 20060810 US 2005-261814 20051028 PRIORITY APPLN. INFO.: US 2004-623175P P 20041029 OTHER SOURCE(S): MARPAT 144:468159 GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to pyrazolopyridines and related compds. of formula I, which are inhibitors of protein tyrosine kinases (PTK). In compds. I, Ar is selected from furyl, indazolyl, indolyl, Ph, pyrazinyl, pyridazinyl, pyridinyl, pyrimidinyl, and thienyl; W, X, and Y are independently selected from N and (un)substituted C; Z is O, S, or (un)substituted N; R1, R2, and R3 are independently selected from H, OH, halo, alkyl, alkoxy, haloalkyl, haloalkoxy, alkoxyalkoxy, and NR5R6, where R5 and R6 are independently selected from H, alkyl, and acyl; and R4 is H, OH, halo, alkyl, alkoxy, haloalkyl, haloalkoxy, alkoxyalkoxy, or LR7, where R7 is H, alkyl, aryl, cycloalkyl, heteroaryl, or heterocyclyl, and L is (CH2)m-N(R8)-C(O)-N(R9)-(CH2)n, where the left end is attached to Ar, m and n are independently 0 or 1, and R8 and R9 are independently selected from H and alkyl. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I in combination with a therapeutically acceptable carrier, as well as to the use of the compns. for the treatment of diseases and disorders resulting from aberrant or excessive PTK activity, such as proliferative disorders or immune system disorders. Amidation of 3,5-dichloroisonicotinic acid followed by dehydration and Suzuki coupling with pinacol 4-aminophenylboronate gave nitrile II, which underwent heterocyclization with hydrazine hydrate and addition to 1-fluoro-2-isocyanato-4-methylbenzene to give pyrazolopyridine III. The compds. of the invention, e.g., III, express IC50 values for KDR tyrosine kinase inhibition between 1 nM and 1 μM.

IT 886457-30-3P 886457-36-9P 886457-38-1P
 886457-40-5P 886457-42-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrazolopyridines as protein tyrosine kinase

inhibitors)


RN 886457-30-3 CAPLUS

CN Urea, N-[4-(3-amino-1H-pyrazolo[3,4-c]pyridin-4-yl)phenyl]-N'-(2-fluoro-5-methylphenyl)- (9CI) (CA INDEX NAME)




RN 886457-36-9 CAPLUS

CN Urea, N-[4-(3-amino-1H-pyrazolo[3,4-c]pyridin-4-yl)phenyl]-N'-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 886457-38-1 CAPLUS

CN Urea, N-[4-(3-amino-1H-pyrazolo[3,4-c]pyridin-4-yl)phenyl]-N'-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 886457-40-5 CAPLUS

CN Urea, N-[4-(3-amino-1H-pyrazolo[3,4-c]pyridin-4-yl)phenyl]-N'-(2-fluoro-5-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)




RN 886457-42-7 CAPLUS

CN Urea, N-[4-(3-amino-1H-pyrazolo[3,4-c]pyridin-4-yl)phenyl]-N'-(4-fluoro-3-methylphenyl)- (9CI) (CA INDEX NAME)



IT 886457-34-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (intermediate; preparation of pyrazolopyridines as protein tyrosine kinase
 inhibitors)
 RN 886457-34-7 CAPLUS
 CN 1H-Pyrazolo[3,4-c]pyridin-3-amine, 4-(4-aminophenyl)- (9CI) (CA INDEX
 NAME)



L4 ANSWER 6 OF 40 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2006:16521 CAPLUS
 DOCUMENT NUMBER: 144:274190
 TITLE: 3-Amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: A
 new class of CDK2 inhibitors
 AUTHOR(S): Pevarello, Paolo; Fancelli, Daniele; Vulpetti, Anna;
 Amici, Raffaella; Villa, Manuela; Pittala, Valeria;
 Vianello, Paola; Cameron, Alexander; Ciomei, Marina;
 Mercurio, Ciro; Bischoff, James R.; Roletto, Fulvia;
 Varasi, Mario; Brasca, Maria Gabriella
 CORPORATE SOURCE: Department of Chemistry, Nerviano Medical Science,
 BU-Oncology, Nerviano, 20014, Italy
 SOURCE: Bioorg. Med. Chem. Lett. (2006), 16(4), 1084-1090
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 144:274190


AB The authors have recently reported a new class of Aurora-A inhibitors based on a bicyclic tetrahydropyrrolo[3,4-c]pyrazole scaffold. Here, they describe the synthesis and early expansion of CDK2/cyclin A-E inhibitors belonging to the same chemical class. Synthesis of the compds. was accomplished using a solution-phase protocol amenable to rapid parallel expansion. Compds. with nanomolar activity in the biochem. assay and able to efficiently inhibit CDK2-mediated tumor cell proliferation have been obtained.

IT 398491-66-2P 398492-99-4P 398493-09-9P
398493-20-4P 398493-37-3P 398495-68-6P
398495-81-3P 398495-97-1P 398496-06-5P
398496-09-8P 398496-10-1P 398496-15-6P
398496-27-0P 398500-08-8P 398503-67-8P
877859-89-7P 877859-90-0P 877859-92-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of 3-amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles as CDK2 inhibitors)


RN 398491-66-2 CAPLUS

CN Benzeneacetamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 398492-99-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-butyl-4,6-dihydro-3-[[[4-(2-oxo-1-pyrrolidinyl)phenyl]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 398493-09-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-butyl-4,6-dihydro-3-[[[4-(1-pyrrolidinyl)phenyl]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 398493-20-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-butyl-4,6-dihydro-3-[(2-naphthalenylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398493-37-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-butyl-3-[[2-(2-fluorophenyl)acetyl]amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398495-68-6 CAPLUS

CN 1,3-Benzodioxole-5-carboxamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 398495-81-3 CAPLUS

CN Benzamide, 4-methyl-N-[1,4,5,6-tetrahydro-5-(8-quinolinylcarbonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398495-97-1 CAPLUS

CN Benzamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 398496-06-5 CAPLUS

CN Benzamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-4-methyl- (9CI) (CA INDEX NAME)




RN 398496-09-8 CAPLUS

CN Benzamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-3-fluoro- (9CI) (CA INDEX NAME)




RN 398496-10-1 CAPLUS

CN Benzamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-4-fluoro- (9CI) (CA INDEX NAME)




RN 398496-15-6 CAPLUS

CN Benzamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-4-cyano- (9CI) (CA INDEX NAME)




RN 398496-27-0 CAPLUS

CN Benzamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-4-methoxy- (9CI) (CA INDEX NAME)




RN 398500-08-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-N-phenyl-3-[(phenylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398503-67-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(phenylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 877859-89-7 CAPLUS

CN 1,3-Benzodioxole-5-carboxamide, N-[1,4,5,6-tetrahydro-5-(2-methyl-1-oxopropyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 877859-90-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(1,3-benzodioxol-5-ylcarbonyl)amino]-4,6-dihydro-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 877859-92-2 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-butyl-4,6-dihydro-3-[[(2S)-2-(2-naphthalenyl)-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 398491-59-3
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of 3-amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles as CDK2 inhibitors)
 RN 398491-59-3 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 3-amino-4,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 40 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1240986 CAPLUS

DOCUMENT NUMBER: 144:22906

TITLE: Preparation of fused heterocycle kinase inhibitors for treatment of protein tyrosine kinase-related diseases

INVENTOR(S): Cusack, Kevin; Salmeron-Garcia, Jose-Andres; Gordon, Thomas D.; Barberis, Claude E.; Allen, Hamish J.; Bischoff, Agnieszka K.; Ericsson, Anna M.; Friedman, Michael M.; George, Dawn M.; Roth, Gregory P.; Talanian, Robert V.; Thomas, Christine; Wallace, Grier A.; Wishart, Neil; Yu, Zhengtian

PATENT ASSIGNEE(S): Abbott Laboratories, USA

SOURCE: PCT Int. Appl., 362 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005110410	A2	20051124	WO 2005-US16903	20050513
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
 LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
 NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
 SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
 ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG

US 2006074102 A1 20060406 US 2005-129624 20050513
 PRIORITY APPLN. INFO.: US 2004-571281P P 20040514
 OTHER SOURCE(S): MARPAT 144:22906
 GI



AB The invention is related to the preparation of fused heterocycles of formula I [A, B = independently N, S, O, a bond, etc.; D = C, N, S, O, C:C; U, V, W = independently CH and derivs., N; Y = a bond, CONH2 and derivs., SO, etc.; Z = H, halo, CN, etc.; X1 = a bond, halo, O, SO, NHSO2, etc.; R1 = a bond, (un)substituted benzofuranyl, benzimidazolyl, pyrrolyl, etc.; when R1 is not a bond, then X2 = a bond, O, S, NHCO and derivs., aliphatic group, etc.; or when R1 = a bond, then X2 = a bond and R2 is not a bond; R2 = a bond or (un)substituted benzoxazolyl, Ph, etc.; with provisos; and with the exception of certain compds.], and their pharmaceutically acceptable salts as inhibitors of kinases, particularly COT or MK2 kinases. The invention is also related to the use of certain compds. I as inhibitors of angiogenic receptor tyrosine kinases. Thus, reacting 4-(3-aminophenyl)thieno[2,3-c]pyridine-2-carboxamide with cyclopropanecarboxaldehyde gave thienopyridine II. All compds. I significantly inhibit either COT or MK2 at concns. of 50 μ M or below.


IT 870244-33-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(COT kinase inhibitor; preparation of fused heterocycles as kinase inhibitors)

RN 870244-33-0 CAPLUS

CN 1H-Pyrazolo[3,4-c]pyridin-3-amine, 4-[1,1'-biphenyl]-3-yl- (9CI) (CA INDEX NAME)




IT 870244-35-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of fused heterocycles as kinase inhibitors)

RN 870244-35-2 CAPLUS

CN 1H-Pyrazolo[3,4-c]pyridin-3-amine, 4-bromo- (9CI) (CA INDEX NAME)



L4 ANSWER 8 OF 40 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:777811 CAPLUS

DOCUMENT NUMBER: 143:341691

TITLE: Structure-Based Approaches to Improve Selectivity: CDK2-GSK3 β Binding Site Analysis

AUTHOR(S): Vulpetti, Anna; Crivori, Patrizia; Cameron, Alexander; Bertrand, Jay; Brasca, Maria Gabriella; D'Alessio, Roberto; Pevarello, Paolo

CORPORATE SOURCE: Nerviano Medical Sciences, Nerviano, 20014, Italy

SOURCE: Journal of Chemical Information and Modeling (2005), 45(5), 1282-1290

CODEN: JCISD8; ISSN: 1549-9596

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB An evaluation and comparison of two different approaches, GRID/CPCA and GRIND/CPCA (CPCA = consensus principal component anal.; GRIND = GRid-INdependent Descriptors), suitable for visualizing the structural differences between related proteins is presented. Ten crystal structures of CDK2/cyclin A and GSK3 β solved inhouse with different inhibitors were compared with the aim of highlighting regions that could be potential sites for gaining selectivity for CDK2 vs. GSK3 β . The analyses pointed out remarkable differences in the backs of the CDK2-GSK3 β ATP binding pockets that guided the optimization toward a selective benzodipyrzole CDK2 inhibitor. The gain in selectivity can be associated with the two main differences in the ATP pocket between the enzymes. Phe80 of CDK2, the so-called gatekeeper residue often exploited for the design of kinase selective ligands, is replaced by a leucine in GSK3 β , and Ala144 is replaced by a cysteine. As a consequence of these mutations, CDK2 has a less elongated and less flat buried region at the back of the ATP pocket.

IT 398495-97-1D, complexes with CDK2/cyclin A


RL: BSU (Biological study, unclassified); PRP (Properties); BIOL

(Biological study)

(crystal structures of CDK2/cyclin A and GSK3 β with various inhibitors identify ATP binding pocket differences that promote selectivity of benzodipyrzole CDK2 inhibitor)

RN 398495-97-1 CAPLUS

CN Benzamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 40 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:395314 CAPLUS

DOCUMENT NUMBER: 142:447211

TITLE: Preparation of fused heterocyclic compounds as serotonin modulators

INVENTOR(S): Carruthers, Nicholas I.; Chai, Wenying; Deng, Xiaohu; Dvorak, Curt A.; Kwok, Annette K.; Liang, Jimmy T.; Mani, Neelakandha; Rudolph, Dale A.; Wong, Victoria D.

PATENT ASSIGNEE(S): Janssen Pharmaceutica, N. V., Belg.

SOURCE: PCT Int. Appl., 323 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent





LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005040169	A2	20050506	WO 2004-US30190	20040915
WO 2005040169	A3	20060330		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004283196	A1	20050506	AU 2004-283196	20040915
CA 2539426	AA	20050506	CA 2004-2539426	20040915
US 2005119295	A1	20050602	US 2004-941664	20040915
EP 1668014	A2	20060614	EP 2004-816874	20040915
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
BR 2004014541	A	20061107	BR 2004-14541	20040915
NO 2006001624	A	20060619	NO 2006-1624	20060410
PRIORITY APPLN. INFO.:			US 2003-504528P	P 20030917
			US 2004-552673P	P 20040311
			WO 2004-US30190	W 20040915

OTHER SOURCE(S): MARPAT 142:447211



AB The title compds. I-III [$m = 0-2$; $n = 1-3$; $p = 1-3$ (with the proviso that where $m = 1$, p is not 1); $m+n \leq 4$; $m+p \leq 4$; $q = 0-1$; $r = 0-5$; $R_3 =$ alkyl, allyl, propargyl, benzyl (each optionally substituted); $Ar =$ (un)substituted (hetero)aryl; $CYC = H$, (un)substituted carbocyclic, heterocyclic, (hetero)aryl; $R_1 = H$, alkyl, alkenyl, etc.; $R_2 = H$, alkyl, alkenyl, etc.; and their pharmaceutically acceptable salts] which are serotonin modulators useful in the treatment of serotonin-mediated diseases, were prepared Thus, reacting tert-Bu 4-oxopiperidine-1-carboxylate with benzylamine in PhMe followed by addition of silica gel, and 8 h later 1-nitro-4-(2-nitrovinyl)benzene, and subsequently, after cyclization is completed, deprotection of the resulting intermediate afforded IV which showed K_i of 120 nM against 5-HT₇ receptor binding.


IT 851376-80-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrrolopyridines and triazaazulenes for treating serotonin-mediated diseases)

RN 851376-80-2 CAPLUS

CN Pyrazolo[3,4-d]azepine-6(1H)-carboxylic acid, 2,3,4,5,7,8-hexahydro-3-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ACCESSION NUMBER: 2005:300452 CAPLUS
 DOCUMENT NUMBER: 142:349111
 TITLE: Pyrazolopyrrole derivatives as protein kinase inhibitors, and their therapeutic use
 INVENTOR(S): Binch, Hayley; Everitt, Simon; Mazzei, Francesca; Robinson, Daniel
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 72 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030776	A1	20050407	WO 2004-US31610	20040923
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004276341	A1	20050407	AU 2004-276341	20040923
CA 2539549	AA	20050407	CA 2004-2539549	20040923
US 2005101594	A1	20050512	US 2004-949714	20040923
EP 1668013	A1	20060614	EP 2004-785111	20040923
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
PRIORITY APPLN. INFO.:			US 2003-505236P	P 20030923
			WO 2004-US31610	W 20040923

OTHER SOURCE(S): MARPAT 142:349111

AB The invention provides pyrazolopyrrole derivs. which are inhibitors of a protein kinase, particularly inhibitors of AKT or PDK1 kinase, mammalian protein kinases involved in proliferative and neurodegenerative disorders. The invention also provides pharmaceutical compns. comprising these compds., processes for preparing the compds., and methods of using the compns. in the treatment of various disorders.


IT 398496-02-1 398496-61-2 849102-69-8
 849102-70-1 849102-71-2 849102-72-3
 849102-73-4 849102-74-5 849102-75-6
 849102-76-7 849102-77-8 849102-78-9
 849102-79-0 849102-80-3 849102-81-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pyrazolopyrrole derivative protein kinase inhibitors, and therapeutic use)


RN 398496-02-1 CAPLUS

CN 2-Thiophenecarboxamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)- (9CI) (CA INDEX NAME)



RN 398496-61-2 CAPLUS


CN 2-Thiophenecarboxamide, N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 849102-69-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, 1,4,5,6-tetrahydro-N-[2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-6-phenyl-4-pyrimidinyl]-5-(2-pyrimidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 849102-70-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, 5-benzoyl-1,4,5,6-tetrahydro-N-[2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-6-phenyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 849102-71-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, 1,4,5,6-tetrahydro-N-[2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-6-phenyl-4-pyrimidinyl]-5-(2-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 849102-72-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, 5-acetyl-1,4,5,6-tetrahydro-N-[2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-6-phenyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 849102-73-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, 1,4,5,6-tetrahydro-N-[2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-6-phenyl-4-pyrimidinyl]-5-(1-oxopropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 849102-74-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, 1,4,5,6-tetrahydro-N-[2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-6-phenyl-4-pyrimidinyl]-5-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 849102-75-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, 1,4,5,6-tetrahydro-N-[2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-6-phenyl-4-pyrimidinyl]-5-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 849102-76-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, 1,4,5,6-tetrahydro-N-[2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-6-phenyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 849102-77-8 CAPLUS

CN 2-Thiophenecarboxamide, N-[1,4,5,6-tetrahydro-5-(2-pyrimidinyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 849102-78-9 CAPLUS

CN 2-Thiophenecarboxamide, N-[1,4,5,6-tetrahydro-5-(2-pyridinyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 849102-79-0 CAPLUS

CN 2-Thiophenecarboxamide, N-[1,4,5,6-tetrahydro-5-(1-oxopropyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 849102-80-3 CAPLUS

CN 2-Thiophenecarboxamide, N-(5-benzoyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)- (9CI) (CA INDEX NAME)



RN 849102-81-4 CAPLUS

CN 2-Thiophenecarboxamide, N-[1,4,5,6-tetrahydro-5-(2-pyridinylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 40 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:208131 CAPLUS

DOCUMENT NUMBER: 142:430185

TITLE: Potent and selective Aurora inhibitors identified by the expansion of a Novel scaffold for protein kinase inhibition

AUTHOR(S): Fancelli, Daniele; Berta, Daniela; Bindi, Simona; Cameron, Alexander; Cappella, Paolo; Carpinelli, Patrizia; Catana, Cornel; Forte, Barbara; Giordano, Patrizia; Giorgini, Maria Laura; Mantegani, Sergio; Marsiglio, Aurelio; Meroni, Maurizio; Moll, Juergen; Pittala, Valeria; Roletto, Fulvia; Severino, Dino; Soncini, Chiara; Storici, Paola; Tonani, Roberto; Varasi, Mario; Vulpetti, Anna; Vianello, Paola

CORPORATE SOURCE: Nerviano Medical Sciences - Oncology, Milan, 20014, Italy

SOURCE: Journal of Medicinal Chemistry (2005), 48(8), 3080-3084

CODEN: JMCMAR; ISSN: 0022-2623


PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 142:430185

GI



AB Potent and selective Aurora kinase inhibitors were identified from the combinatorial expansion of the 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole bi-cycle, a versatile scaffold designed to target the ATP pocket of protein kinases. The most potent compound I had an IC₅₀ of 0.027 μ M in the enzymic assay for Aur-A inhibition and IC₅₀s between 0.05 μ M and 0.5 μ M for the inhibition of proliferation of different tumor cell lines.

IT 398491-86-6P 398491-97-9P 398492-11-0P
398493-74-8P 850997-38-5P 850997-39-6P
850997-40-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and Aurora kinase inhibition of aminotetrahydropyrrolopyrazoles

using solid-phase or solution-phase multistep procedures)


RN 398491-86-6 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-(phenylacetyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398491-97-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-(2,6-diethylphenyl)-3-[[4-(1,1-dimethylethyl)benzoyl]amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398492-11-0 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-(2-thienylacetyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-74-8 CAPLUS

CN Benzamide, 4-(4-methyl-1-piperazinyl)-N-[1,4,5,6-tetrahydro-5-(2-thienylacetyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 850997-38-5 CAPLUS


CN Benzamide, 4-(1,1-dimethylethyl)-N-[5-(2-furanylacetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 850997-39-6 CAPLUS
 CN Benzamide, N-[5-(2-furanylacetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 850997-40-9 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)



IT 398491-59-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and Aurora kinase inhibition of aminotetrahydropyrrolopyrazoles using solid-phase or solution-phase multistep procedures)
 RN 398491-59-3 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 3-amino-4,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 398493-79-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation, anticancer, and Aurora kinase inhibition of aminotetrahydropyrrolopyrazole using solid-phase or solution-phase multistep procedures)
 RN 398493-79-3 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-(2,6-diethylphenyl)-4,6-dihydro-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 40 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:58203 CAPLUS
 DOCUMENT NUMBER: 142:134624
 TITLE: Preparation of pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors
 INVENTOR(S): Fancelli, Daniele; Forte, Barbara; Moll, Jurgen; Varasi, Mario; Vianello, Paola
 PATENT ASSIGNEE(S): Pharmacia Italia S.P.A., Italy
 SOURCE: PCT Int. Appl., 38 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005005427	A1	20050120	WO 2004-EP7515	20040708
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005032839	A1	20050210	US 2004-882493	20040701
AU 2004255347	A1	20050120	AU 2004-255347	20040708
CA 2531759	AA	20050120	CA 2004-2531759	20040708
EP 1644376	A1	20060412	EP 2004-763132	20040708
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004011868	A	20060808	BR 2004-11868	20040708
CN 1820009	A	20060816	CN 2004-80019593	20040708
NO 2006000113	A	20060405	NO 2006-113	20060106
PRIORITY APPLN. INFO.:			US 2003-485814P	P 20030709
			WO 2004-EP7515	W 20040708
OTHER SOURCE(S):	MARPAT	142:134624		
GI				



I

AB Pyrrolo[3,4-c]pyrazole derivs. of formula (I) and pharmaceutically acceptable salts thereof [R = H, Me; R1 = OH, straight or branched C1-3 alkyl or alkoxy; R2 = H, halo; X = a divalent group selected from CH2 or CHF, or it is a heteroatom or heteroat. group selected from O or NR' (wherein R' = H, straight or branched C1-4 alkyl or C3-6 cycloalkyl)] are prepared These compds. are useful for treating cell proliferative disorders caused by/or associated with an altered protein kinase activity including cancer, Alzheimer's disease, viral infections, autoimmune diseases, and neurodegenerative disorders. Thus, 4-(4-methyl-1-piperazinyl)benzoic acid was converted into -methylpiperazinobenzoyl chloride dihydrochloride by treatment with oxalyl chloride in CH2Cl2 in the presence of DMF under reflux and condensed with 5-tert-Bu 1-Et 3-amino-4,6-dihydropyrrolo[3,4-c]pyrazole-1,5-dicarboxylate in the presence of diisopropylethylamine in THF at room temperature for 16 h and at 40° for 1 h to give 5-tert-Bu 1-Et 3-[[4-(4-methylpiperazin-1-yl)benzoyl]amino]-4,6-dihydropyrrolo[3,4-c]pyrazole-1,5-dicarboxylate (II). A solution of in CH2Cl2 II was treated with 4 N HCl/dioxane at room temperature for 24 h to give Et 3-[[4-(4-methylpiperazin-1-yl)benzoyl]amino]-5,6-dihydropyrrolo[3,4-c]pyrazole-1(4H)-carboxylate trihydrochloride which was condensed with (R)-(-)-α-methoxyphenylacetyl chloride in the presence of diisopropylethylamine in CH2Cl2 at room temperature for 20 h to give Et 5-((2R)-2-methoxy-2-phenylethanoyl)-3-[[4-(4-methylpiperazin-1-yl)benzoyl]amino]-5,6-dihydropyrrolo[3,4-c]pyrazole-1(4H)-carboxylate (III). III was stirred with Et3N in MeOH at room temperature for 16 h to give N-[5-((2R)-2-methoxy-2-phenylethanoyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide (IV). IV showed IC50 of 16 nM against aurora-2 kinase, inhibited the proliferation of human colon cancer cell line HCT-116 with IC50 of 31 nM, and blocked cell cycle and induced polyploidy.

IT 827318-97-8P, N-[5-((2R)-2-Methoxy-2-phenylethanoyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide
 827318-98-9P, N-[5-((2R)-2-Methoxy-2-phenylethanoyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-(4-ethylpiperazin-1-yl)benzamide
 827318-99-0P, N-[5-((2R)-2-Methoxy-2-phenylethanoyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-(4-isopropylpiperazin-1-yl)benzamide
 827319-00-6P, N-[5-((2R)-2-Methoxy-2-phenylethanoyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-(4-cyclopropylpiperazin-1-yl)benzamide
 827319-01-7P
 827319-02-8P, N-[5-((2R)-2-Methoxy-2-phenylethanoyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-(piperidin-1-yl)benzamide
 827319-03-9P, 4-(4-Fluoropiperidin-1-yl)-N-[5-((2R)-2-methoxy-2-phenylethanoyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]benzamide


827319-04-0P, N-[5-((2R)-2-Methoxy-2-phenylethanoyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-(morpholin-4-yl)benzamide
 827319-05-1P, 4-(4-tert-Butylpiperazin-1-yl)-N-[5-((2R)-2-methoxy-2-phenylethanoyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]benzamide
 827319-06-2P, N-[5-((2R)-2-Hydroxy-2-phenylethanoyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide
 827319-07-3P, N-[5-((2R)-2-Methyl-2-phenylethanoyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide
 827319-08-4P, N-[5-((2R)-2-Methyl-2-phenylethanoyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-(4-ethylpiperazin-1-yl)benzamide
 827319-09-5P, N-[5-((2R)-2-Methyl-2-phenylethanoyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-(4-isopropylpiperazin-1-yl)benzamide
 827319-10-8P, N-[5-((2R)-2-Methyl-2-phenylethanoyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-(4-cyclopropylpiperazin-1-yl)benzamide
 827319-11-9P 827319-12-0P, N-[5-((2R)-2-Phenylpropanoyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-(piperidin-1-yl)benzamide
 827319-13-1P, 4-(4-Fluoropiperidin-1-yl)-N-[5-((2R)-2-methyl-2-phenylethanoyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]benzamide
 827319-14-2P, N-[5-((2R)-2-Methyl-2-phenylethanoyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-(morpholin-4-yl)benzamide
 827319-15-3P, 4-(4-tert-Butylpiperazin-1-yl)-N-[5-((2R)-2-phenylpropanoyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]benzamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolo[3,4-c]pyrazole derivs. active as kinase inhibitors for treating cell proliferative disorders)

RN 827318-97-8 CAPLUS

CN Benzamide, 4-(4-methyl-1-piperazinyl)-N-[1,4,5,6-tetrahydro-5-[(2R)-methoxyphenylacetyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827318-98-9 CAPLUS

CN Benzamide, 4-(4-ethyl-1-piperazinyl)-N-[1,4,5,6-tetrahydro-5-[(2R)-methoxyphenylacetyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827318-99-0 CAPLUS

CN Benzamide, 4-[4-(1-methylethyl)-1-piperazinyl]-N-[1,4,5,6-tetrahydro-5-[(2R)-methoxyphenylacetyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827319-00-6 CAPLUS

CN Benzamide, 4-(4-cyclopropyl-1-piperazinyl)-N-[1,4,5,6-tetrahydro-5-[(2R)-methoxyphenylacetyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827319-01-7 CAPLUS

CN Benzamide, 4-(3,4-dimethyl-1-piperazinyl)-N-[1,4,5,6-tetrahydro-5-[(2R)-methoxyphenylacetyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827319-02-8 CAPLUS

CN Benzamide, 4-(1-piperidiny1)-N-[1,4,5,6-tetrahydro-5-[(2R)-methoxyphenylacetyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827319-03-9 CAPLUS

CN Benzamide, 4-(4-fluoro-1-piperidiny1)-N-[1,4,5,6-tetrahydro-5-[(2R)-methoxyphenylacetyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827319-04-0 CAPLUS

CN Benzamide, 4-(4-morpholinyl)-N-[1,4,5,6-tetrahydro-5-[(2R)-

methoxyphenylacetyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827319-05-1 CAPLUS

CN Benzamide, 4-[4-(1,1-dimethylethyl)-1-piperazinyl]-N-[1,4,5,6-tetrahydro-5-[(2R)-methoxyphenylacetyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827319-06-2 CAPLUS

CN Benzamide, 4-(4-methyl-1-piperazinyl)-N-[1,4,5,6-tetrahydro-5-[(2R)-hydroxyphenylacetyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827319-07-3 CAPLUS

CN Benzamide, 4-(4-methyl-1-piperazinyl)-N-[1,4,5,6-tetrahydro-5-[(2R)-1-oxo-

2-phenylpropyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827319-08-4 CAPLUS

CN Benzamide, 4-(4-ethyl-1-piperazinyl)-N-[1,4,5,6-tetrahydro-5-[(2R)-1-oxo-2-phenylpropyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827319-09-5 CAPLUS

CN Benzamide, 4-[4-(1-methylethyl)-1-piperazinyl]-N-[1,4,5,6-tetrahydro-5-[(2R)-1-oxo-2-phenylpropyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827319-10-8 CAPLUS

CN Benzamide, 4-(4-cyclopropyl-1-piperazinyl)-N-[1,4,5,6-tetrahydro-5-[(2R)-1-oxo-2-phenylpropyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827319-11-9 CAPLUS

CN Benzamide, 4-(3,4-dimethyl-1-piperazinyl)-N-[1,4,5,6-tetrahydro-5-[(2R)-1-oxo-2-phenylpropyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827319-12-0 CAPLUS

CN Benzamide, 4-(1-piperidinyl)-N-[1,4,5,6-tetrahydro-5-[(2R)-1-oxo-2-phenylpropyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827319-13-1 CAPLUS

CN Benzamide, 4-(4-fluoro-1-piperidiny1)-N-[1,4,5,6-tetrahydro-5-[(2R)-1-oxo-2-phenylpropyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827319-14-2 CAPLUS

CN Benzamide, 4-(4-morpholinyl)-N-[1,4,5,6-tetrahydro-5-[(2R)-1-oxo-2-phenylpropyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 827319-15-3 CAPLUS

CN Benzamide, 4-[4-(1,1-dimethylethyl)-1-piperazinyl]-N-[1,4,5,6-tetrahydro-5-[(2R)-1-oxo-2-phenylpropyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 398491-59-3, tert-Butyl 3-amino-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reactant; preparation of pyrrolo[3,4-c]pyrazole derivs. active as kinase inhibitors for treating cell proliferative disorders)
 RN 398491-59-3 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 3-amino-4,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 40 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:780535 CAPLUS
 DOCUMENT NUMBER: 141:296039
 TITLE: Preparation of bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
 INVENTOR(S): Abrate, Francesca; Fancelli, Daniele; Varasi, Mario; Villa, Manuela
 PATENT ASSIGNEE(S): Pharmacia Italia S.p.A., Italy
 SOURCE: PCT Int. Appl., 68 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004080457	A1	20040923	WO 2004-EP50237	20040302
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2518395	AA	20040923	CA 2004-2518395	20040302
EP 1608364	A1	20051228	EP 2004-716253	20040302
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004008486	A	20060404	BR 2004-8486	20040302
JP 2006519816	T2	20060831	JP 2006-505439	20040302
PRIORITY APPLN. INFO.:			US 2003-453885P	P 20030311
			WO 2004-EP50237	W 20040302
OTHER SOURCE(S):			MARPAT 141:296039	
GI				



AB Pyrrolo-pyrazole derivs. (I) and pharmaceutically acceptable salts thereof [wherein R = H, COR', CO₂R', CONHR', -C(:NH)NHR', SO₂R', SO₂NR'R"; R1 = optionally substituted and optionally benzocondensed 5 or 6 membered heterocyclic group with from 1 to 3 heteroatoms or heteroat. groups selected from N, NR', O or S; R2 = H, R', COR', CO₂R', CONR'R", S(O)qR'; R3 and R4 are both H or Me or, together with the carbon atom to which they are attached, form a cyclopropyl group; R', R'' are, the same or different and independently in each of the above occasions, H or an optionally substituted group selected from straight or branched C1-6 alkyl, C3-6 cycloalkyl, aryl, aryl C1-6 alkyl, heterocyclyl or heterocyclyl-C1-6 alkyl; m, n = 0 or 1, provided that they are not both 1; q = 0 or an integer from 1 to 2] are prepared Also disclosed are the process for their preparation and pharmaceutical compns. thereof. These compds. or compns. are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders. Two representative I compds., 3-(4-tert-butylbenzamido)-5-[(2-propylamino)pyrimidin-4-yl]-4,6-dihydropyrrolo[3,4-c]pyrazole and 3-(4-tert-butylbenzamido)-5-[2-(N-morpholino)pyrimidin-4-yl]-4,6-dihydropyrrolo[3,4-c]pyrazole showed IC₅₀ of 0.221 and 0.341 μM against Cdk2/Cyclin A kinase. Their inhibitory activity resulted to be markedly superior than that of the prior art compds. of WO 02/12242 (reference compds.), e.g.

N-[5-(pyridine-4-carbonyl)-4,6-dihydropyrrolo[3,4-c]pyrazol-3-yl]-4-tert-butylbenzamide (IC₅₀ >10 μM).

IT 398491-64-OP, 3-Amino-5-tert-butyloxycarbonyl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridine 761443-77-ODP, 3-[(4-tert-Butylbenzoyl)amino]-5-[2-(methanesulfonyl)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole, resin-bound 761443-78-1DP, 3-[(4-tert-Butylbenzoyl)amino]-5-[2-(propylamino)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole, resin-bound 761443-79-2DP, 3-[(4-tert-Butylbenzoyl)amino]-5-[2-(phenylamino)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole, resin-bound 761443-80-5DP, 3-[(4-tert-Butylbenzoyl)amino]-5-(2-ethoxypyrimidin-4-yl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole, resin-bound 761444-39-7DP, resin-bound 761444-40-ODP, resin-bound 761444-41-1DP, resin-bound 761444-42-2DP, 3-[(4-tert-Butylbenzoyl)amino]-5-[2-(methanesulfonyl)pyrimidin-4-yl]-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridine, resin-bound 761444-43-3DP, 3-[(4-tert-Butylbenzoyl)amino]-5-[2-(propylamino)pyrimidin-4-yl]-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridine, resin-bound


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of bicyclo-pyrazole derivs. active as kinase inhibitors for treating cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and

neurodegenerative disorders)


RN 398491-64-0 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 3-amino-1,4,6,7-tetrahydro-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 761443-77-0 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-[2-(methylsulfonyl)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761443-78-1 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-[2-(propylamino)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761443-79-2 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-[2-(phenylamino)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761443-80-5 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[5-(2-ethoxy-4-pyrimidinyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-39-7 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[4,5,6,7-tetrahydro-5-[2-(methylthio)-4-pyrimidinyl]-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-40-0 CAPLUS

CN Benzamide, 4-fluoro-N-[4,5,6,7-tetrahydro-5-[2-(methylthio)-4-pyrimidinyl]-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-41-1 CAPLUS

CN Benzamide, 3-phenoxy-N-[4,5,6,7-tetrahydro-5-[2-(methylthio)-4-pyrimidinyl]-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-42-2 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[4,5,6,7-tetrahydro-5-[2-(methylsulfonyl)-4-pyrimidinyl]-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 761444-43-3 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[4,5,6,7-tetrahydro-5-[2-(propylamino)-4-pyrimidinyl]-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)



IT 761443-74-7P, 3-(4-tert-Butylbenzoylamino)-5-[2-(methylthio)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole
761443-75-8P, 3-(4-Fluorobenzoylamino)-5-[2-(methylthio)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761443-76-9P,
3-(3-Phenoxybenzoylamino)-5-[2-(methylthio)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761443-78-1P 761443-79-2P
761443-80-5P 761443-81-6P, 3-[(4-Fluorobenzoyl)amino]-5-[2-(propylamino)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole
761443-82-7P, 3-[(3-Phenoxybenzoyl)amino]-5-[2-(propylamino)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole
761443-83-8P, 3-[(4-tert-Butylbenzoyl)amino]-5-[2-(benzylamino)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole
761443-84-9P, 3-[(4-Fluorobenzoyl)amino]-5-[2-(benzylamino)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole
761443-85-0P, 3-[(3-Phenoxybenzoyl)amino]-5-[2-(benzylamino)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole
761443-86-1P, 3-[(4-tert-Butylbenzoyl)amino]-5-[2-(morpholino)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole
761443-87-2P, 3-[(4-Fluorobenzoyl)amino]-5-[2-(morpholino)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole
761443-88-3P, 3-[(3-Phenoxybenzoyl)amino]-5-[2-(morpholino)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole
761443-89-4P, 3-[(3-Phenoxybenzoyl)amino]-5-[2-(cyclopropylamino)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole
761443-90-7P, 3-[(4-Fluorobenzoyl)amino]-5-[2-(phenylamino)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole
761443-91-8P, 3-[(3-Phenoxybenzoyl)amino]-5-[2-ethoxypyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761443-92-9P,
3-[(Thien-2-yl)carbonyl]amino]-5-[2-(4-methylpiperazin-1-yl)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761443-94-1P,
3-(Cyclobutylcarbonylamino)-5-[2-(4-methylpiperazin-1-yl)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761443-95-2P,
3-(Cyclobutylcarbonylamino)-5-[2-(morpholin-4-yl)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761443-96-3P,
3-(Cyclobutylcarbonylamino)-5-[2-(N-phenylmethylamino)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761443-97-4P,
3-(Cyclobutylcarbonylamino)-5-[2-(propylamino)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761443-98-5P, 3-(Cyclobutylcarbonylamino)-5-(2-cyclopropylaminopyrimidin-4-yl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761443-99-6P, 3-(Cyclobutylcarbonylamino)-5-(2-allylaminopyrimidin-4-yl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761444-00-2P, 3-[(Thien-2-yl)carbonyl]amino]-5-[2-(morpholin-4-yl)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761444-01-3P, 3-[(Thien-2-yl)carbonyl]amino]-5-[2-(N-phenylmethylamino)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761444-02-4P, 3-[(Thien-2-yl)carbonyl]amino]-5-(2-propylaminopyrimidin-4-yl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761444-03-5P, 3-[(Thien-2-yl)carbonyl]amino]-5-(2-cyclopropylaminopyrimidin-4-yl)-4,6-dihydro-1H-

pyrrolo[3,4-c]pyrazole 761444-04-6P, 3-(4-Methoxybenzoylamino)-5-[2-(4-methylpiperazin-1-yl)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761444-05-7P, 3-(4-Methoxybenzoylamino)-5-[2-(morpholin-4-yl)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761444-06-8P, 3-(4-Methoxybenzoylamino)-5-[2-(N-phenylmethylamino)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761444-07-9P, 3-(4-Methoxybenzoylamino)-5-[2-n-propylaminopyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761444-08-0P, 3-(4-Methoxybenzoylamino)-5-[2-cyclopropylaminopyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761444-09-1P, 3-[[4-(4-Methylpiperazin-1-yl)benzoyl]amino]-5-[2-(4-methylpiperazin-1-yl)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761444-10-4P, 3-[[4-(4-Methylpiperazin-1-yl)benzoyl]amino]-5-[2-(morpholin-4-yl)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761444-11-5P, 3-[[4-(4-Methylpiperazin-1-yl)benzoyl]amino]-5-[2-(N-phenylmethylamino)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761444-12-6P, 3-[[4-(4-Methylpiperazin-1-yl)benzoyl]amino]-5-(2-n-propylaminopyrimidin-4-yl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761444-13-7P, 3-[[4-(4-Methylpiperazin-1-yl)benzoyl]amino]-5-(2-cyclopropylaminopyrimidin-4-yl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761444-14-8P, 3-[[4-(Morpholin-4-yl)benzoyl]amino]-5-[2-(4-methylpiperazin-1-yl)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761444-15-9P, 3-[[4-(Morpholin-4-yl)benzoyl]amino]-5-[2-(morpholin-4-yl)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761444-16-0P, 3-[[4-(Morpholin-4-yl)benzoyl]amino]-5-[2-(N-phenylmethylamino)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761444-17-1P, 3-[[4-(Morpholin-4-yl)benzoyl]amino]-5-(2-n-propylaminopyrimidin-4-yl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761444-18-2P, 3-[[4-(Morpholin-4-yl)benzoyl]amino]-5-(2-cyclopropylaminopyrimidin-4-yl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761444-19-3P, 3-[(4-Fluorobenzoyl)amino]-5-[2-(4-methylpiperazin-1-yl)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761444-20-6P, 3-[(4-Fluorobenzoyl)amino]-5-[2-[N-methyl-N-[2-(dimethylamino)ethyl]amino]pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761444-21-7P, 3-[(4-Fluorobenzoyl)amino]-5-[2-[N-(2-dimethylaminoethyl)amino]pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761444-22-8P, 3-[(4-tert-Butylbenzoyl)amino]-5-(pyrimidin-2-yl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761444-26-2P, 3-(2-Naphthalenylacetamido)-5-(pyrimidin-2-yl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761444-27-3P, 3-[(4-Fluorobenzoyl)amino]-5-[2-(4-methylpiperidin-1-yl)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761444-28-4P, 3-[(4-Fluorobenzoyl)amino]-5-[2-(4-hydroxymethylpiperidin-1-yl)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761444-29-5P, 3-[(4-Fluorobenzoyl)amino]-5-[2-[4-(2-hydroxyethyl)piperazin-1-yl]pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761444-30-8P, 3-[(4-Fluorobenzoyl)amino]-5-(thiazol-2-yl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761444-32-0P, 3-[(4-Fluorobenzoyl)amino]-5-(6-chloropyrimidin-4-yl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole 761444-40-0P, 3-[(4-Fluorobenzoyl)amino]-5-[2-(methylthio)pyrimidin-4-yl]-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridine 761444-41-1P, 3-[(3-Phenoxybenzoyl)amino]-5-[2-(methylthio)pyrimidin-4-yl]-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridine 761444-43-3P 761444-44-4P, 3-[(4-Fluorobenzoyl)amino]-5-[2-(propylamino)pyrimidin-4-yl]-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridine 761444-45-5P, 3-[(3-Phenoxybenzoyl)amino]-5-[2-(propylamino)pyrimidin-4-yl]-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridine 761444-46-6P, 3-[(4-Fluorobenzoyl)amino]-5-[2-(morpholino)pyrimidin-4-yl]-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridine 761444-47-7P, 3-[(3-Phenoxybenzoyl)amino]-5-[2-(morpholino)pyrimidin-4-yl]-4,6,4,5,6,7-tetrahydropyrazolo[4,3-c]pyridine 761444-48-8P, 3-[(4-tert-Butylbenzoyl)amino]-5-[2-(benzylamino)pyrimidin-4-yl]-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridine


761444-49-9P, 3-[(4-Fluorobenzoyl)amino]-5-[2-(benzylamino)pyrimidin-4-yl]-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridine
 761444-50-2P, 3-[(3-Phenoxybenzoyl)amino]-5-[2-(benzylamino)pyrimidin-4-yl]-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridine
 761444-51-3P, 3-[(4-tert-Butylbenzoyl)amino]-5-[2-(4-methylpiperazin-1-yl)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole
 761444-52-4P, 3-[(3-Phenoxybenzoyl)amino]-5-[2-(4-methylpiperazin-1-yl)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole
 761444-53-5P, 3-[(4-tert-Butylbenzoyl)amino]-5-[2-(4-methylpiperidin-1-yl)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole
 761444-54-6P, 3-[(3-Phenoxybenzoyl)amino]-5-[2-(4-methylpiperidin-1-yl)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole
 761444-55-7P, 3-[(4-tert-Butylbenzoyl)amino]-5-[2-[(2-dimethylaminoethyl)amino]pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole
 761444-56-8P, 3-[(3-Phenoxybenzoyl)amino]-5-[2-[(2-dimethylaminoethyl)amino]pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole
 761444-57-9P, 3-[(4-tert-Butylbenzoyl)amino]-5-[2-[N-methyl(2-dimethylaminoethyl)amino]pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole
 761444-58-0P, 3-[(3-Phenoxybenzoyl)amino]-5-[2-[N-methyl(2-dimethylaminoethyl)amino]pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole
 761444-59-1P, 3-[(4-tert-Butylbenzoyl)amino]-5-[2-(4-hydroxymethylpiperidin-1-yl)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole
 761444-60-4P, 3-[(3-Phenoxybenzoyl)amino]-5-[2-(4-hydroxymethylpiperidin-1-yl)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole
 761444-61-5P, 3-[(4-tert-Butylbenzoyl)amino]-5-[2-[4-(2-hydroxyethyl)piperazin-1-yl]pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole
 761444-62-6P, 3-[(3-Phenoxybenzoyl)amino]-5-[2-[4-(2-hydroxyethyl)piperazin-1-yl]pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole
 761444-63-7P, 3-[(4-Fluorobenzoyl)amino]-5-[2-(cyclopropylamino)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole
 761444-64-8P, 3-[(4-tert-Butylbenzoyl)amino]-5-[2-(cyclopropylamino)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole
 761444-65-9P, 3-[(3-Phenoxybenzoyl)amino]-5-[2-(phenylamino)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole
 761444-66-0P, 3-[(4-Fluorobenzoyl)amino]-5-(2-ethoxypyrimidin-4-yl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole
 761444-67-1P, 3-[(4-Fluorobenzoyl)amino]-5-[2-[(1-methylpiperidin-4-yl)oxy]pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole
 761444-68-2P, 3-[(4-tert-Butylbenzoyl)amino]-5-[2-(1-methylpiperidin-4-yloxy)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole
 761444-69-3P, 3-[(3-Phenoxybenzoyl)amino]-5-[2-(1-methylpiperidin-4-yloxy)pyrimidin-4-yl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole
 761444-70-6P, 3-[(4-Fluorobenzoyl)amino]-5-(benzothiazol-2-yl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole
 761444-71-7P, 3-[(4-tert-Butylbenzoyl)amino]-5-(2-morpholinopyrimidin-4-yl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of bicyclo-pyrazole derivs. active as kinase inhibitors for treating cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders)


RN 761443-74-7 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-[2-(methylthio)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761443-75-8 CAPLUS

CN Benzamide, 4-fluoro-N-[1,4,5,6-tetrahydro-5-[2-(methylthio)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761443-76-9 CAPLUS

CN Benzamide, 3-phenoxy-N-[1,4,5,6-tetrahydro-5-[2-(methylthio)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761443-78-1 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-[2-(propylamino)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761443-79-2 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-[2-(phenylamino)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761443-80-5 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[5-(2-ethoxy-4-pyrimidinyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761443-81-6 CAPLUS

CN Benzamide, 4-fluoro-N-[1,4,5,6-tetrahydro-5-[2-(propylamino)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761443-82-7 CAPLUS

CN Benzamide, 3-phenoxy-N-[1,4,5,6-tetrahydro-5-[2-(propylamino)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761443-83-8 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-[2-[(phenylmethyl)amino]-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761443-84-9 CAPLUS

CN Benzamide, 4-fluoro-N-[1,4,5,6-tetrahydro-5-[2-[(phenylmethyl)amino]-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761443-85-0 CAPLUS

CN Benzamide, 3-phenoxy-N-[1,4,5,6-tetrahydro-5-[2-[(phenylmethyl)amino]-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761443-86-1 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-[2-(4-morpholinyl)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761443-87-2 CAPLUS

CN Benzamide, 4-fluoro-N-[1,4,5,6-tetrahydro-5-[2-(4-morpholinyl)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761443-88-3 CAPLUS

CN Benzamide, 3-phenoxy-N-[1,4,5,6-tetrahydro-5-[2-(4-morpholinyl)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761443-89-4 CAPLUS

CN Benzamide, N-[5-[2-(cyclopropylamino)-4-pyrimidinyl]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-3-phenoxy- (9CI) (CA INDEX NAME)




RN 761443-90-7 CAPLUS

CN Benzamide, 4-fluoro-N-[1,4,5,6-tetrahydro-5-[2-(phenylamino)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761443-91-8 CAPLUS

CN Benzamide, N-[5-(2-ethoxy-4-pyrimidinyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-3-phenoxy- (9CI) (CA INDEX NAME)




RN 761443-92-9 CAPLUS

CN 2-Thiophenecarboxamide, N-[1,4,5,6-tetrahydro-5-[2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761443-94-1 CAPLUS

CN Cyclobutanecarboxamide, N-[1,4,5,6-tetrahydro-5-[2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761443-95-2 CAPLUS

CN Cyclobutanecarboxamide, N-[1,4,5,6-tetrahydro-5-[2-(4-morpholinyl)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761443-96-3 CAPLUS

CN Cyclobutanecarboxamide, N-[1,4,5,6-tetrahydro-5-[2-(methylphenylamino)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761443-97-4 CAPLUS

CN Cyclobutanecarboxamide, N-[1,4,5,6-tetrahydro-5-[2-(propylamino)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761443-98-5 CAPLUS

CN Cyclobutanecarboxamide, N-[5-[2-(cyclopropylamino)-4-pyrimidinyl]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761443-99-6 CAPLUS

CN Cyclobutanecarboxamide, N-[1,4,5,6-tetrahydro-5-[2-(2-propenylamino)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-00-2 CAPLUS

CN 2-Thiophenecarboxamide, N-[1,4,5,6-tetrahydro-5-[2-(4-morpholinyl)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-01-3 CAPLUS

CN 2-Thiophenecarboxamide, N-[1,4,5,6-tetrahydro-5-[2-(methylphenylamino)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-02-4 CAPLUS

CN 2-Thiophenecarboxamide, N-[1,4,5,6-tetrahydro-5-[2-(propylamino)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-03-5 CAPLUS

CN 2-Thiophenecarboxamide, N-[5-[2-(cyclopropylamino)-4-pyrimidinyl]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-04-6 CAPLUS

CN Benzamide, 4-methoxy-N-[1,4,5,6-tetrahydro-5-[2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-05-7 CAPLUS

CN Benzamide, 4-methoxy-N-[1,4,5,6-tetrahydro-5-[2-(4-morpholinyl)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-06-8 CAPLUS

CN Benzamide, 4-methoxy-N-[1,4,5,6-tetrahydro-5-[2-(methylphenylamino)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-07-9 CAPLUS

CN Benzamide, 4-methoxy-N-[1,4,5,6-tetrahydro-5-[2-(propylamino)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-08-0 CAPLUS

CN Benzamide, N-[5-[2-(cyclopropylamino)-4-pyrimidinyl]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 761444-09-1 CAPLUS

CN Benzamide, 4-(4-methyl-1-piperazinyl)-N-[1,4,5,6-tetrahydro-5-[2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-10-4 CAPLUS

CN Benzamide, 4-(4-methyl-1-piperazinyl)-N-[1,4,5,6-tetrahydro-5-[2-(4-morpholinyl)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-11-5 CAPLUS

CN Benzamide, 4-(4-methyl-1-piperazinyl)-N-[1,4,5,6-tetrahydro-5-[2-(methylphenylamino)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-12-6 CAPLUS

CN Benzamide, 4-(4-methyl-1-piperazinyl)-N-[1,4,5,6-tetrahydro-5-[2-(propylamino)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-13-7 CAPLUS

CN Benzamide, N-[5-[2-(cyclopropylamino)-4-pyrimidinyl]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 761444-14-8 CAPLUS

CN Benzamide, 4-(4-morpholinyl)-N-[1,4,5,6-tetrahydro-5-[2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-15-9 CAPLUS

CN Benzamide, 4-(4-morpholinyl)-N-[1,4,5,6-tetrahydro-5-[2-(4-morpholinyl)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-16-0 CAPLUS

CN Benzamide, 4-(4-morpholinyl)-N-[1,4,5,6-tetrahydro-5-[2-(methylphenylamino)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 761444-17-1 CAPLUS


CN Benzamide, 4-(4-morpholinyl)-N-[1,4,5,6-tetrahydro-5-[2-(propylamino)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 761444-18-2 CAPLUS


CN Benzamide, N-[5-[2-(cyclopropylamino)-4-pyrimidinyl]-1,4,5,6-

tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 761444-19-3 CAPLUS

CN Benzamide, 4-fluoro-N-[1,4,5,6-tetrahydro-5-[2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-20-6 CAPLUS

CN Benzamide, N-[5-[2-[[2-(dimethylamino)ethyl]methylamino]-4-pyrimidinyl]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 761444-21-7 CAPLUS

CN Benzamide, N-[5-[2-[[2-(dimethylamino)ethyl]amino]-4-pyrimidinyl]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 761444-22-8 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-(2-pyrimidinyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-26-2 CAPLUS

CN 1-Naphthaleneacetamide, N-[1,4,5,6-tetrahydro-5-(2-pyrimidinyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-27-3 CAPLUS

CN Benzamide, 4-fluoro-N-[1,4,5,6-tetrahydro-5-[2-(4-methyl-1-piperidiny)]-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-28-4 CAPLUS

CN Benzamide, 4-fluoro-N-[1,4,5,6-tetrahydro-5-[2-[4-(hydroxymethyl)-1-piperidiny]]-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-29-5 CAPLUS

CN Benzamide, 4-fluoro-N-[1,4,5,6-tetrahydro-5-[2-[4-(2-hydroxyethyl)-1-piperaziny]]-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-30-8 CAPLUS

CN Benzamide, 4-fluoro-N-[1,4,5,6-tetrahydro-5-(2-thiazolyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-32-0 CAPLUS

CN Benzamide, N-[5-(6-chloro-4-pyrimidinyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 761444-40-0 CAPLUS

CN Benzamide, 4-fluoro-N-[4,5,6,7-tetrahydro-5-[2-(methylthio)-4-pyrimidinyl]-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-41-1 CAPLUS

CN Benzamide, 3-phenoxy-N-[4,5,6,7-tetrahydro-5-[2-(methylthio)-4-pyrimidinyl]-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-43-3 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[4,5,6,7-tetrahydro-5-[2-(propylamino)-4-pyrimidinyl]-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-44-4 CAPLUS


CN Benzamide, 4-fluoro-N-[4,5,6,7-tetrahydro-5-[2-(propylamino)-4-pyrimidinyl]-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-45-5 CAPLUS
 CN Benzamide, 3-phenoxy-N-[4,5,6,7-tetrahydro-5-[2-(propylamino)-4-pyrimidinyl]-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 761444-46-6 CAPLUS
 CN Benzamide, 4-fluoro-N-[4,5,6,7-tetrahydro-5-[2-(4-morpholinyl)-4-pyrimidinyl]-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-47-7 CAPLUS
 CN Benzamide, 3-phenoxy-N-[4,5,6,7-tetrahydro-5-[2-(4-morpholinyl)-4-pyrimidinyl]-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-48-8 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[4,5,6,7-tetrahydro-5-[2-[(phenylmethyl)amino]-4-pyrimidinyl]-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-49-9 CAPLUS

CN Benzamide, 4-fluoro-N-[4,5,6,7-tetrahydro-5-[2-[(phenylmethyl)amino]-4-pyrimidinyl]-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-50-2 CAPLUS

CN Benzamide, 3-phenoxy-N-[4,5,6,7-tetrahydro-5-[2-[(phenylmethyl)amino]-4-pyrimidinyl]-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-51-3 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-[2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-52-4 CAPLUS

CN Benzamide, 3-phenoxy-N-[1,4,5,6-tetrahydro-5-[2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-53-5 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-[2-(4-methyl-1-piperidinyl)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-54-6 CAPLUS

CN Benzamide, 3-phenoxy-N-[1,4,5,6-tetrahydro-5-[2-(4-methyl-1-piperidinyl)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-55-7 CAPLUS

CN Benzamide, N-[5-[2-[[2-(dimethylamino)ethyl]amino]-4-pyrimidinyl]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 761444-56-8 CAPLUS

CN Benzamide, N-[5-[2-[[2-(dimethylamino)ethyl]amino]-4-pyrimidinyl]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-3-phenoxy- (9CI) (CA INDEX NAME)




RN 761444-57-9 CAPLUS

CN Benzamide, N-[5-[2-[[2-(dimethylamino)ethyl]methylamino]-4-pyrimidinyl]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 761444-58-0 CAPLUS

CN Benzamide, N-[5-[2-[[2-(dimethylamino)ethyl]methylamino]-4-pyrimidinyl]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-3-phenoxy- (9CI) (CA INDEX NAME)




RN 761444-59-1 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-[2-[4-(hydroxymethyl)-1-piperidinyl]-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-60-4 CAPLUS

CN Benzamide, 3-phenoxy-N-[1,4,5,6-tetrahydro-5-[2-[4-(hydroxymethyl)-1-piperidinyl]-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-61-5 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-[2-[4-(2-hydroxyethyl)-1-piperazinyl]-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-62-6 CAPLUS

CN Benzamide, 3-phenoxy-N-[1,4,5,6-tetrahydro-5-[2-[4-(2-hydroxyethyl)-1-piperazinyl]-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-63-7 CAPLUS

CN Benzamide, N-[5-[2-(cyclopropylamino)-4-pyrimidinyl]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 761444-64-8 CAPLUS

CN Benzamide, N-[5-[2-(cyclopropylamino)-4-pyrimidinyl]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 761444-65-9 CAPLUS

CN Benzamide, 3-phenoxy-N-[1,4,5,6-tetrahydro-5-[2-(phenylamino)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-66-0 CAPLUS

CN Benzamide, N-[5-(2-ethoxy-4-pyrimidinyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 761444-67-1 CAPLUS

CN Benzamide, 4-fluoro-N-[1,4,5,6-tetrahydro-5-[2-[(1-methyl-4-piperidinyl)oxy]-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-68-2 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-[2-[(1-methyl-4-piperidinyl)oxy]-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-69-3 CAPLUS

CN Benzamide, 3-phenoxy-N-[1,4,5,6-tetrahydro-5-[2-[(1-methyl-4-piperidinyl)oxy]-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 761444-70-6 CAPLUS

CN Benzamide, N-[5-(2-benzothiazolyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 761444-71-7 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[4,5,6,7-tetrahydro-5-[2-(4-morpholinyl)-4-pyrimidinyl]-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




IT 761443-74-7DP, resin-bound

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of bicyclo-pyrazole derivs. active as kinase inhibitors for treating cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders)

RN 761443-74-7 CAPLUS


CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-[2-(methylthio)-4-pyrimidinyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




IT 761444-39-7P, 3-[(4-tert-Butylbenzoyl)amino]-5-[2-(methylthio)pyrimidin-4-yl]-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridine
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (reactant; preparation of bicyclo-pyrazole derivs. active as kinase inhibitors for treating cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders)
 RN 761444-39-7 CAPLUS
 CN Benzamide, 4-(1,1-dimethylethyl)-N-[4,5,6,7-tetrahydro-5-[2-(methylthio)-4-pyrimidinyl]-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)



IT 398491-59-3, 3-Amino-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carboxylic acid tert-butyl ester 761443-93-0,
 3-[[(Thien-2-yl)carbonyl]amino]-5-(2-chloropyrimidin-4-yl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reactant; preparation of bicyclo-pyrazole derivs. active as kinase inhibitors for treating cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders)
 RN 398491-59-3 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 3-amino-4,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 761443-93-0 CAPLUS
 CN 2-Thiophenecarboxamide, N-[5-(2-chloro-4-pyrimidinyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2004:756698 CAPLUS
 DOCUMENT NUMBER: 141:277632
 TITLE: Preparation of quinazolines as modulators of ion channels
 INVENTOR(S): Gonzales, Jesus E., III; Wilson, Dean Mitchell; Termin, Andreas Peter; Grootenhuis, Peter Diederik Jan; Zhang, Yulian; Petzoldt, Benjamin John; Fanning, Lev Tyler Dewey; Neubert, Timothy Donald; Tung, Roger D.; Martinborough, Esther; Zimmermann, Nicole
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
 SOURCE: PCT Int. Appl., 565 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004078733	A1	20040916	WO 2004-US6451	20040303
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004217891	A1	20040916	AU 2004-217891	20040303
CA 2517844	AA	20040916	CA 2004-2517844	20040303
EP 1608632	A1	20051228	EP 2004-716887	20040303
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004008026	A	20060207	BR 2004-8026	20040303
CN 1784391	A	20060607	CN 2004-80011981	20040303
JP 2006522119	T2	20060928	JP 2006-509028	20040303
NO 2005004546	A	20051125	NO 2005-4546	20051003
PRIORITY APPLN. INFO.:			US 2003-451458P	P 20030303
			US 2003-463797P	P 20030418
			WO 2004-US6451	A 20040303
OTHER SOURCE(S):		MARPAT 141:277632		
GI				



AB The title compds. [I; NR¹R² = (un)substituted 3-12 membered monocyclic or

bicyclic (un)saturated ring having 0-3 heteroatoms selected from N, S or O; ring A = (un)substituted 5-7 membered aryl or 8-10 membered bicyclic aryl having 0-3 heteroatoms selected from N, S or O; x = 0-4; R3 = QR (wherein Q = a bond, alkylidene wherein up to two non-adjacent methylene units are optionally replaced by S, O, CS, etc.; R = halo, NO2, CN, etc.)), useful as inhibitors of voltage-gated sodium channels and calcium channels, were prepared. Thus, reacting 2-(4-chloro-7-methylquinazolin-2-yl)phenol with 4-aminopiperidine in the presence of Et3N in CH2Cl2 afforded 89% II. Representative compds. I were found to possess desired N-type calcium channel modulation activity and selectivity (no specific data given). Also, representative compds. I were found to possess desired voltage gated sodium channel activity and selectivity (no specific data given). The invention also provides pharmaceutically acceptable compns. comprising the compds. I and methods of using the compns. in the treatment of various disorders.


IT 757982-54-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinazolines as modulators of ion channels)

RN 757982-54-0 CAPLUS

CN 3H-Pyrazolo[3,4-c]pyridin-3-one, 6-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-1,2,4,5,6,7-hexahydro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 40 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:589550 CAPLUS

DOCUMENT NUMBER: 141:140435

TITLE: Preparation of pyrazolopyridines and related compounds as aggrecanase inhibitors

INVENTOR(S): Shiozaki, Makoto; Suma, Akira; Yasue, Katsutaka; Sakai, Atsushi; Matsuo, Takafumi; Tanaka, Masahiro; Shinozaki, Yuichi

PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan

SOURCE: PCT Int. Appl., 202 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 2004060892 A1 20040722 WO 2003-JP17067 20031226
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2003292724 A1 20040729 AU 2003-292724 20031226
JP 2004217654 A2 20040805 JP 2003-435749 20031226
PRIORITY APPLN. INFO.: JP 2002-382573 A 20021227
WO 2003-JP17067 W 20031226
OTHER SOURCE(S): MARPAT 141:140435
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1, R2 = H, halo, etc.; R3, R4 = H, alkyl, etc.; R5, R6 = complete X together, further details on R5 and R6 given; R8, R9 = H, alkyl, etc.; R10, R11 = H, alkyl, etc.; R7 = OH, etc.; R21 = H, alkyl, etc.; A = alkylene, etc.; B = (un)substituted heterocycle, etc.; m = 1-3; n = 0-3] were prepared In MMP-13 (matrix metalloproteinase-13) inhibition assays, the IC50 value of compound II was <0.1 μ M. Compds. I are claimed useful for the treatment of arthritis deformans, chronic articular rheumatism.
IT 725258-44-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyridines and related compds. as aggrecanase inhibitors for treatment of arthrorheumatism, chronic articular rheumatism)
RN 725258-44-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]pyridine-4-carboxamide, 2,3,4,5,6,7-hexahydro-N-hydroxy-3-oxo-5-[[4-(phenylmethoxy)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 16 OF 40 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:589247 CAPLUS
DOCUMENT NUMBER: 141:140463
TITLE: Preparation of heterocyclic compounds as selective phosphodiesterase V inhibitors
INVENTOR(S): Yamada, Koichiro; Matsuki, Kenji; Omori, Kenji; Kikkawa, Kohei
PATENT ASSIGNEE(S): Japan
SOURCE: U.S. Pat. Appl. Publ., 116 pp., Cont.-in-part of U.S.

Ser. No. 258,545.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 3


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004142930	A1	20040722	US 2003-699804	20031104
JP 2002012587	A2	20020115	JP 2000-277652	20000913
JP 3637961	B2	20050413		
WO 2001083460	A1	20011108	WO 2001-JP2034	20010315
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2003229089	A1	20031211	US 2002-258545	20021025
PRIORITY APPLN. INFO.:			JP 2000-130371	A 20000428
			JP 2000-277652	A 20000913
			WO 2001-JP2034	W 20010315
			US 2002-258545	A2 20021025
			JP 1999-261852	A 19990916

OTHER SOURCE(S):

MARPAT 141:140463

GI



AB The title compds. (I) [X = CH, N; Y = NH, NR, S, O, CH:N, N:CH, N:N, CH:CHC(:R5)N, CH:C(R5), N:C(R7)]; R1 = each (un)substituted lower alkoxy, amino, heterocyclyl containing N atom(s), HO, or heterocyclyloxy containing N atom(s), cyano; R2 = lower alkylamino or lower alkoxy each optionally substituted by an (un)substituted aryl, lower alkoxy group substituted by an aromatic heterocyclic ring containing N atom(s), lower alkylamino group substituted by a (un)substituted heterocyclic ring, (un)substituted arylamino; R3 = each (un)substituted aryl, heterocyclyl containing N atom(s), lower alkyl, lower alkoxy, lower cycloalkoxy, heterocyclyloxy containing N atom(s), or NH2; R4-R7 = each (un)substituted aryl, heterocyclyl containing N atom(s), lower alkoxy, or NH2; R4, R5, R6 or R7 may combine with R3 to form a lactone ring Q or Q1; when X = N, Y = CH:N, or N:CH, R2 = an amino group monosubstituted by an (un)substituted arylmethyl, and R3 = (un)substituted lower alkyl, amino monosubstituted by an (un)substituted heterocyclyl-lower alkyl containing N atom(s) in the ring, heterocyclylamino containing N atom(s) in the ring, or (un)substituted lower cycloalkylamino, R1 = each (un)substituted lower alkoxy, amino, heterocyclyloxy containing N atom(s) in the ring, or cyano group] or pharmacol. acceptable salts thereof are prepared These compds. have excellent selective PDE V inhibitory activity and therefore, are useful as therapeutic or

prophylactic drugs for treating various diseases due to functional disorders on cGMP-signaling, such as erectile dysfunction, pulmonary hypertension, and diabetic gastroparesis. Thus, 2-(hydroxymethyl)pyridine was treated with NaH in THF and etherified with 2-chloro-5-(3,4,5-trimethoxyphenylcarbonyl)-4-(3-chloro-4-methoxybenzylamino)pyrimidine to give 2-(2-pyridylmethoxy)-5-(3,4,5-trimethoxyphenylcarbonyl)-4-(3-chloro-4-methoxybenzylamino)pyrimidine.


IT 372113-78-5P 372114-34-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic compds. as selective phosphodiesterase V inhibitors for treating various diseases due to functional disorders on cGMP-signaling)


RN 372113-78-5 CAPLUS

CN 3H-Pyrazolo[4,3-c]pyridin-3-one, 5-[4-[(3-chloro-4-methoxyphenyl)methyl]amino]-5-(3,4,5-trimethoxybenzoyl)-2-pyrimidinyl]-1,2,4,5,6,7-hexahydro- (9CI) (CA INDEX NAME)



RN 372114-34-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(octahydro-3-oxo-5H-pyrazolo[4,3-c]pyridin-5-yl)-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 17 OF 40 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:550958 CAPLUS



DOCUMENT NUMBER: 141:106465

TITLE: Preparation of substituted pyrrolo-pyrazole derivatives as kinase inhibitors

INVENTOR(S): Brasca, Maria Gabriella; Amici, Raffaella; Fancelli, Daniele; Nesi, Marcella; Orsini, Paolo; Orzi, Fabrizio; Roussel, Patrick; Vulpetti, Anna; Pevarello,

PATENT ASSIGNEE(S): Paolo
 SOURCE: Pharmacia Italia S.p.A., Italy
 PCT Int. Appl., 116 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056827	A2	20040708	WO 2003-EP50942	20031204
WO 2004056827	A3	20041028		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2508069	AA	20040708	CA 2003-2508069	20031204
AU 2003300255	A1	20040714	AU 2003-300255	20031204
EP 1575954	A2	20050921	EP 2003-799536	20031204
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017455	A	20051116	BR 2003-17455	20031204
CN 1726217	A	20060125	CN 2003-80106447	20031204
JP 2006514026	T2	20060427	JP 2004-561484	20031204
ZA 2005004298	A	20060222	ZA 2005-4298	20050526
NO 2005002805	A	20050714	NO 2005-2805	20050609
PRIORITY APPLN. INFO.:			US 2002-434952P	P 20021219
			WO 2003-EP50942	W 20031204
OTHER SOURCE(S):		MARPAT 141:106465		
GI				



AB Title compds. I [R = acyl, carboxamido, etc.; R1 = alkyl, cycloalkyl, 2-thienyl, etc.; R2 = Me or together form a spiro-fused 3-membered ring.] are prepared For instance, tert-Bu 4-cyano-3-hydroxy-2,2-dimethyl-2,5-dihydro-1H-pyrrole-1-carboxylate (preparation given) is treated with hydrazine (EtOH, HOAc, 60°, 48 h) to give the corresponding pyrrolo[3,4-c]pyrazole. This intermediate is acylated with ClCO2Et (THF, LDA, 0°) and the pyrazole regioisomers isolated. The resulting dicarboxylate is reacted with 3-fluorophenylisocyanate (THF, room temperature), treated with 4M HCl in dioxane, acylated with pivaloyl chloride (CH2Cl2, i-Pr2NEt) and finally reacted with MeOH, TEA to give II. II has IC50 =

0.030 μ M for Cdk2-cyclin A kinase. I are useful in the treatment of cell cycle proliferative disorders, e.g. cancer, associated with an altered cell cycle dependent kinase activity.


IT 718631-66-4P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of substituted pyrrolo-pyrazole derivs. as inhibitors of Cdk2-cyclin A kinase)

RN 718631-66-4 CAPLUS

CN Benzamide, 4-chloro-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[[4-(1-pyrrolidinylmethyl)-1-piperidinyl]carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



IT 718629-68-6P 718629-70-0P 718629-71-1P
 718629-72-2P 718629-73-3P 718629-74-4P
 718629-75-5P 718629-76-6P 718629-77-7P
 718629-78-8P 718629-79-9P 718629-80-2P
 718629-81-3P 718629-82-4P 718629-83-5P
 718629-84-6P 718629-85-7P 718629-86-8P
 718629-87-9P 718629-88-0P 718629-89-1P
 718629-90-4P 718629-91-5P 718629-92-6P
 718629-93-7P 718629-94-8P 718630-08-1P
 718630-09-2P 718630-10-5P 718630-11-6P
 718630-12-7P 718630-13-8P 718630-14-9P
 718630-15-0P 718630-16-1P 718630-18-3P
 718630-19-4P 718630-20-7P 718630-21-8P
 718630-22-9P 718630-23-0P 718630-24-1P
 718630-25-2P 718630-26-3P 718630-27-4P
 718630-28-5P 718630-29-6P 718630-30-9P
 718630-31-0P 718630-32-1P 718630-33-2P
 718630-34-3P 718630-35-4P 718630-36-5P
 718630-37-6P 718630-38-7P 718630-39-8P
 718630-40-1P 718630-43-4P 718630-44-5P
 718630-45-6P 718630-46-7P 718630-49-0P
 718630-50-3P 718630-51-4P 718630-52-5P
 718630-53-6P 718630-54-7P 718630-55-8P
 718630-56-9P 718630-57-0P 718630-58-1P
 718630-59-2P 718630-60-5P 718630-61-6P
 718630-62-7P 718630-63-8P 718630-64-9P
 718630-65-0P 718630-66-1P 718630-67-2P
 718630-68-3P 718630-69-4P 718630-70-7P
 718630-71-8P 718630-72-9P 718630-73-0P
 718630-75-2P 718630-76-3P 718630-77-4P
 718630-78-5P 718630-79-6P 718630-80-9P
 718630-81-0P 718630-82-1P 718630-83-2P
 718630-84-3P 718630-85-4P 718630-86-5P
 718630-87-6P 718630-88-7P 718630-89-8P
 718630-90-1P 718630-91-2P 718630-92-3P
 718630-93-4P 718630-94-5P 718630-95-6P
 718630-96-7P 718630-97-8P 718630-98-9P
 718630-99-0P 718631-00-6P 718631-01-7P
 718631-02-8P 718631-03-9P 718631-04-0P
 718631-05-1P 718631-06-2P 718631-07-3P


718631-08-4P 718631-10-8P 718631-11-9P
 718631-13-1P 718631-14-2P 718631-15-3P
 718631-16-4P 718631-17-5P 718631-18-6P
 718631-19-7P 718631-20-0P 718631-22-2P
 718631-23-3P 718631-24-4P 718631-25-5P
 718631-26-6P 718631-27-7P 718631-28-8P
 718631-29-9P 718631-31-3P 718631-32-4P
 718631-65-3P 718631-67-5P 718631-68-6P
 718631-69-7P 718631-70-0P 718631-72-2P
 718631-73-3P 718631-74-4P 718631-75-5P
 718631-76-6P 718631-77-7P 718631-78-8P
 718631-79-9P 718631-80-2P 718631-81-3P
 718631-82-4P 718631-83-5P 718631-84-6P
 718631-85-7P 718631-86-8P 718631-87-9P
 718631-88-0P 718631-89-1P 718631-90-4P
 718631-91-5P 718631-92-6P 718632-07-6P
 718632-08-7P 718632-09-8P 718632-11-2P
 718632-12-3P 718632-13-4P 718632-14-5P
 718632-15-6P 718632-16-7P 718632-17-8P
 718632-18-9P 718632-19-0P 718632-20-3P
 718632-21-4P 718632-22-5P 718632-23-6P
 718632-24-7P 718632-25-8P 718632-27-0P
 718632-29-2P 718632-30-5P 718632-33-8P
 718632-34-9P 718632-36-1P 718633-93-3P
 718633-95-5P 718633-97-7P 718633-98-8P
 718634-00-5P 718634-02-7P 718634-03-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted pyrrolo-pyrazole derivs. as inhibitors of Cdk2-cyclin A kinase)

RN 718629-68-6 CAPLUS


CN Benzamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 718629-70-0 CAPLUS

CN Benzamide, 4-fluoro-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[[(2R)-tetrahydro-2-furanyl]carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 718629-71-1 CAPLUS


CN Benzamide, 4-fluoro-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[[(2S)-tetrahydro-2-furanyl]carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 718629-72-2 CAPLUS

CN Benzamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 718629-73-3 CAPLUS

CN Benzamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-3,4-difluoro- (9CI) (CA INDEX NAME)




RN 718629-74-4 CAPLUS

CN Benzamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-2,4-difluoro- (9CI) (CA INDEX NAME)




RN 718629-75-5 CAPLUS

CN Benzamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-3,5-difluoro- (9CI) (CA INDEX NAME)




RN 718629-76-6 CAPLUS

CN Benzamide, 4-chloro-N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718629-77-7 CAPLUS

CN Benzamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 718629-78-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718629-79-9 CAPLUS

CN 4-Pyridinecarboxamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718629-80-2 CAPLUS

CN 2-Thiophenecarboxamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718629-81-3 CAPLUS

CN 3-Thiophenecarboxamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718629-82-4 CAPLUS

CN Butanamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 718629-83-5 CAPLUS

CN Cyclobutanecarboxamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718629-84-6 CAPLUS

CN Cyclopropanecarboxamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718629-85-7 CAPLUS

CN Propanamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 718629-86-8 CAPLUS

CN Benzamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 718629-87-9 CAPLUS

CN 2-Furancarboxamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718629-88-0 CAPLUS

CN 4-Piperidinecarboxamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718629-89-1 CAPLUS

CN 1-Naphthalenecarboxamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718629-90-4 CAPLUS

CN 2-Naphthalenecarboxamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718629-91-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, 5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethyl-N-[[[(2-methylphenyl)methyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 718629-92-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, 5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethyl-N-[(phenylmethyl)amino]carbonyl- (9CI) (CA INDEX NAME)




RN 718629-93-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718629-94-8 CAPLUS

CN Acetamide, 2-(dimethylamino)-N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718630-08-1 CAPLUS

CN Benzamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718630-09-2 CAPLUS

CN Benzamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-4-[(1-methyl-4-piperidinyl)oxy]- (9CI)
(CA INDEX NAME)



RN 718630-10-5 CAPLUS


CN Benzamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-3-[(1-methyl-4-piperidinyl)oxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 718630-11-6 CAPLUS


CN Benzamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-4-[(4-methyl-1-piperazinyl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 718630-12-7 CAPLUS


CN Benzamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-4-(4-fluoro-1-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 718630-13-8 CAPLUS

CN Benzamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 718630-14-9 CAPLUS

CN Benzamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-4-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 718630-15-0 CAPLUS


CN Benzamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-4-(2-oxo-3-oxazolidinyl)- (9CI) (CA INDEX NAME)



RN 718630-16-1 CAPLUS


CN Benzamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-

dimethylpyrrolo[3,4-c]pyrazol-3-yl]-3,4-dimethoxy- (9CI) (CA INDEX NAME)




RN 718630-18-3 CAPLUS

CN 1,4-Benzenedicarboxamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718630-19-4 CAPLUS

CN Benzamide, 4-cyano-N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718630-20-7 CAPLUS

CN Benzamide, 3-cyano-N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718630-21-8 CAPLUS

CN Benzamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 718630-22-9 CAPLUS

CN Benzamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 718630-23-0 CAPLUS

CN Benzamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 718630-24-1 CAPLUS

CN Benzamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 718630-25-2 CAPLUS

CN Benzeneacetamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718630-26-3 CAPLUS

CN 2-Naphthaleneacetamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718630-27-4 CAPLUS

CN Cyclopentanecarboxamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718630-28-5 CAPLUS

CN Cyclohexanecarboxamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718630-29-6 CAPLUS

CN 2-Furancarboxamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]tetrahydro- (9CI) (CA INDEX NAME)



RN 718630-30-9 CAPLUS


CN 4-Piperidinecarboxamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 718630-31-0 CAPLUS

CN 4-Piperidinecarboxamide, 1-acetyl-N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718630-32-1 CAPLUS

CN Benzamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 718630-33-2 CAPLUS

CN Benzamide, 4-fluoro-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(tetrahydro-2-furanyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 718630-34-3 CAPLUS


CN 2-Naphthaleneacetamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(tetrahydro-2-furanyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 718630-35-4 CAPLUS

CN Benzamide, 3,4-difluoro-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[[(2R)-tetrahydro-2-furanyl]carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 718630-36-5 CAPLUS

CN Butanamide, 3-methyl-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[[(2R)-tetrahydro-2-furanyl]carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 718630-37-6 CAPLUS

CN Cyclobutanecarboxamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[[(2R)-

tetrahydro-2-furanyl]carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 718630-38-7 CAPLUS

CN Benzamide, 3-[(1-methyl-4-piperidinyl)oxy]-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(2R)-tetrahydro-2-furanyl]carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




● HCl

RN 718630-39-8 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(2R)-tetrahydro-2-furanyl]carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




● 2 HCl

RN 718630-40-1 CAPLUS

CN Benzamide, 4-[(1-methyl-4-piperidinyl)oxy]-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[[(2R)-tetrahydro-2-furanyl]carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl


RN 718630-43-4 CAPLUS

CN Formic acid, compd. with 3-methyl-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(1,4-dimethyl-4-piperidinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]butanamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 718630-42-3

CMF C20 H33 N5 O2



CM 2


CRN 64-18-6

CMF C H2 O2

O=CH-OH

RN 718630-44-5 CAPLUS


CN Benzamide, N-[5-[(1,4-dimethyl-4-piperidinyl)carbonyl]-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-4-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 718630-45-6 CAPLUS


CN Benzamide, N-[5-(1-azabicyclo[2.2.2]oct-4-ylcarbonyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-4-fluoro-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl


RN 718630-46-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 4,6-dihydro-6,6-dimethyl-3-[(2-naphthalenylacetyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 718630-49-0 CAPLUS

CN Benzamide, 4-fluoro-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(1-methyl-4-piperidinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]-, monohydrochloride (9CI)
(CA INDEX NAME)




● HCl

RN 718630-50-3 CAPLUS
 CN Benzamide, 3-fluoro-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(1-methyl-4-piperidinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]-, monohydrochloride (9CI)
 (CA INDEX NAME)




● HCl

RN 718630-51-4 CAPLUS
 CN Benzamide, 3,4-difluoro-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(1-methyl-4-piperidinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]-, monohydrochloride (9CI)
 (CA INDEX NAME)




● HCl

RN 718630-52-5 CAPLUS
 CN Benzamide, 2,4-difluoro-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(1-methyl-4-piperidinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 718630-53-6 CAPLUS


CN Benzamide, 3,5-difluoro-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(1-methyl-4-piperidiny)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl

RN 718630-54-7 CAPLUS


CN Benzamide, 4-chloro-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(1-methyl-4-piperidiny)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl

RN 718630-55-8 CAPLUS


CN Benzamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(1-methyl-4-piperidiny)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]-4-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 718630-56-9 CAPLUS

CN 4-Pyridinecarboxamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(1-methyl-4-piperidiny)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]-, dihydrochloride (9CI)
(CA INDEX NAME)




● 2 HCl

RN 718630-57-0 CAPLUS
 CN 2-Thiophenecarboxamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(1-methyl-4-piperidinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]-, monohydrochloride (9CI)
 (CA INDEX NAME)




● HCl

RN 718630-58-1 CAPLUS
 CN 3-Thiophenecarboxamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(1-methyl-4-piperidinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]-, monohydrochloride (9CI)
 (CA INDEX NAME)




● HCl

RN 718630-59-2 CAPLUS
 CN Butanamide, 3-methyl-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(1-methyl-4-piperidinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 718630-60-5 CAPLUS


CN Butanamide, 3-methyl-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(1-methyl-4-piperidinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl


RN 718630-61-6 CAPLUS

CN Cyclobutanecarboxamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(1-methyl-4-piperidinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 718630-62-7 CAPLUS

CN Cyclobutanecarboxamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(1-methyl-4-piperidinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl


RN 718630-63-8 CAPLUS

CN Cyclobutanecarboxamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(1-methyl-4-piperidinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 718630-61-6


CMF C19 H29 N5 O2



CM 2


CRN 75-75-2

CMF C H4 O3 S




RN 718630-64-9 CAPLUS


CN Cyclopropanecarboxamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(1-methyl-4-piperidinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718630-65-0 CAPLUS
 CN Benzamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(1-methyl-4-piperidinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]-4-(trifluoromethoxy)-(9CI) (CA INDEX NAME)



RN 718630-66-1 CAPLUS
 CN Benzamide, 3-phenoxy-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(1-methyl-4-piperidinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718630-67-2 CAPLUS
 CN 2-Furancarboxamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(1-methyl-4-piperidinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 718630-68-3 CAPLUS
 CN Benzamide, 4-(1H-pyrazol-1-yl)-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(1-methyl-4-piperidinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718630-69-4 CAPLUS
 CN 1-Naphthalenecarboxamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(1-methyl-

4-piperidinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718630-70-7 CAPLUS

CN 2-Naphthalenecarboxamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(1-methyl-4-piperidinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718630-71-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, 1,4,5,6-tetrahydro-6,6-dimethyl-N-[[[(2-methylphenyl)methyl]amino]carbonyl]-5-[(1-methyl-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 718630-72-9 CAPLUS

CN Benzamide, 3-fluoro-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(1-methyl-4-piperidinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718630-73-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, 1,4,5,6-tetrahydro-6,6-dimethyl-5-[(1-methyl-4-piperidinyl)carbonyl]-N-[(propylamino)carbonyl]- (9CI) (CA INDEX NAME)



RN 718630-75-2 CAPLUS


CN 1-Piperidinecarboxamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(1-methyl-4-piperidinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl


RN 718630-76-3 CAPLUS

CN Benzamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(1-methyl-4-piperidinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 718630-77-4 CAPLUS

CN Benzamide, N-[5-[(1-ethyl-4-piperidinyl)carbonyl]-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-4-fluoro-, monohydrochloride (9CI)
(CA INDEX NAME)




● HCl

RN 718630-78-5 CAPLUS

CN Benzamide, N-[5-[(1-ethyl-4-piperidinyl)carbonyl]-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-3,4-difluoro-, monohydrochloride (9CI)


(CA INDEX NAME)



● HCl

RN 718630-79-6 CAPLUS


CN Butanamide, N-[5-[(1-ethyl-4-piperidinyl)carbonyl]-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-3-methyl-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl

RN 718630-80-9 CAPLUS


CN Cyclobutanecarboxamide, N-[5-[(1-ethyl-4-piperidinyl)carbonyl]-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl

RN 718630-81-0 CAPLUS


CN Pyrrolo[3,4-c]pyrazol-3-amine, 5-[(1-ethyl-4-piperidinyl)carbonyl]-N-[[[(3-fluorophenyl)amino]carbonyl]-1,4,5,6-tetrahydro-6,6-dimethyl-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl


RN 718630-82-1 CAPLUS

CN Benzamide, N-[5-[(1-cyclopropyl-4-piperidinyl)carbonyl]-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 718630-83-2 CAPLUS


CN Benzamide, N-[5-[(1-cyclopropyl-4-piperidinyl)carbonyl]-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-3,4-difluoro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 718630-84-3 CAPLUS


CN Butanamide, N-[5-[(1-cyclopropyl-4-piperidinyl)carbonyl]-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 718630-85-4 CAPLUS


CN Cyclobutanecarboxamide, N-[5-[(1-cyclopropyl-4-piperidiny)carbonyl]-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 718630-86-5 CAPLUS


CN Pyrrolo[3,4-c]pyrazol-3-amine, 5-[(1-cyclopropyl-4-piperidiny)carbonyl]-N-[[(3-fluorophenyl)amino]carbonyl]-1,4,5,6-tetrahydro-6,6-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 718630-87-6 CAPLUS


CN Benzamide, 4-fluoro-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-(4-piperidiny)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 718630-88-7 CAPLUS


CN Benzamide, 3,4-difluoro-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-(4-piperidiny)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 718630-89-8 CAPLUS

CN Benzamide, 2,4-difluoro-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(3-methyl-2-thienyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718630-90-1 CAPLUS

CN Butanamide, 3-methyl-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(3-methyl-2-thienyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718630-91-2 CAPLUS

CN Cyclobutanecarboxamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(3-methyl-2-thienyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718630-92-3 CAPLUS

CN Cyclopropanecarboxamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(3-methyl-2-thienyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718630-93-4 CAPLUS

CN Benzamide, 4-(1H-pyrazol-1-yl)-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(3-methyl-2-thienyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718630-94-5 CAPLUS

CN 2-Naphthalenecarboxamide, N-[(3-methyl-2-thienyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718630-95-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, 1,4,5,6-tetrahydro-6,6-dimethyl-5-[(3-methyl-2-thienyl)carbonyl]-N-[(phenylmethyl)amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 718630-96-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, N-[(3-fluorophenyl)amino]carbonyl]-1,4,5,6-tetrahydro-6,6-dimethyl-5-[(3-methyl-2-thienyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 718630-97-8 CAPLUS

CN Benzamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(3-methyl-2-thienyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718630-98-9 CAPLUS

CN 2-Naphthaleneacetamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(3-methyl-2-thienyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718630-99-0 CAPLUS

CN 4-Piperidinecarboxamide, 1-acetyl-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(3-methyl-2-thienyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 718631-00-6 CAPLUS


CN Benzamide, 4-[(1-methyl-4-piperidinyl)oxy]-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(2-thienylcarbonyl)pyrrolo[3,4-c]pyrazol-3-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 718631-01-7 CAPLUS


CN Benzamide, 4-[(1-methyl-4-piperidinyloxy)-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(tetrahydro-2H-pyran-4-yl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 718631-02-8 CAPLUS


CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(tetrahydro-2H-pyran-4-yl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 718631-03-9 CAPLUS

CN Butanamide, N-[5-(cyclopropylacetyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 718631-04-0 CAPLUS

CN Cyclobutanecarboxamide, N-[5-(cyclopropylacetyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718631-05-1 CAPLUS

CN Cyclopropanecarboxamide, N-[5-(cyclopropylacetyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718631-06-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, 5-(cyclopropylacetyl)-1,4,5,6-tetrahydro-6,6-dimethyl-N-[(phenylmethyl)amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 718631-07-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, 5-(cyclopropylacetyl)-1,4,5,6-tetrahydro-6,6-dimethyl-N-[(propylamino)carbonyl]- (9CI) (CA INDEX NAME)




RN 718631-08-4 CAPLUS

CN Benzamide, N-[5-(cyclopropylacetyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718631-10-8 CAPLUS

CN Benzamide, 2,4-difluoro-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(2-methylcyclopropyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718631-11-9 CAPLUS

CN Benzamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(2-methylcyclopropyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718631-13-1 CAPLUS

CN Benzamide, N-[5-[4-[(dimethylamino)methyl]benzoyl]-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 718631-14-2 CAPLUS


CN 2-Naphthaleneacetamide, N-[5-[4-[(dimethylamino)methyl]benzoyl]-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718631-15-3 CAPLUS

CN 2-Naphthaleneacetamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[4-[(4-methyl-1-piperazinyl)methyl]benzoyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 718631-16-4 CAPLUS

CN Benzamide, 4-fluoro-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-(1-oxobutyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718631-17-5 CAPLUS

CN Benzamide, 2,4-difluoro-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-(1-oxobutyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718631-18-6 CAPLUS

CN Cyclobutanecarboxamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-(1-oxobutyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718631-19-7 CAPLUS

CN Cyclopropanecarboxamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-(1-oxobutyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718631-20-0 CAPLUS

CN Benzamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-(1-oxobutyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718631-22-2 CAPLUS

CN Benzamide, 2,4-difluoro-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(tetrahydro-3-furanyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718631-23-3 CAPLUS

CN Butanamide, 3-methyl-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(tetrahydro-3-furanyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718631-24-4 CAPLUS

CN Cyclobutanecarboxamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(tetrahydro-3-furanyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718631-25-5 CAPLUS

CN Cyclopropanecarboxamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(tetrahydro-3-furanyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718631-26-6 CAPLUS


CN Benzamide, N-(5-benzoyl-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl)-4-fluoro- (9CI) (CA INDEX NAME)




RN 718631-27-7 CAPLUS
 CN Benzamide, N-[5-(2,6-difluorobenzoyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 718631-28-8 CAPLUS
 CN Benzamide, N-[5-(2,6-difluorobenzoyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-2,4-difluoro- (9CI) (CA INDEX NAME)



RN 718631-29-9 CAPLUS
 CN 2-Naphthaleneacetamide, N-[5-(2,6-difluorobenzoyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718631-31-3 CAPLUS
 CN Benzamide, N-[5-[4-(aminosulfonyl)benzoyl]-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 718631-32-4 CAPLUS

CN 2-Naphthaleneacetamide, N-[5-[4-(aminosulfonyl)benzoyl]-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 718631-65-3 CAPLUS


CN Benzamide, 4-chloro-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[[4-(1-pyrrolidinylmethyl)-1-piperidinyl]carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 718631-67-5 CAPLUS

CN Benzamide, 3,4-difluoro-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(4-methyl-1-piperazinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 718631-68-6 CAPLUS
 CN Benzamide, 2,4-difluoro-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(4-methyl-1-piperazinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718631-69-7 CAPLUS
 CN Benzamide, 4-chloro-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(4-methyl-1-piperazinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718631-70-0 CAPLUS
 CN Benzamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(4-methyl-1-piperazinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 718631-72-2 CAPLUS
 CN Butanamide, 3-methyl-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(4-methyl-1-piperazinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718631-73-3 CAPLUS
 CN Cyclobutanecarboxamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(4-methyl-1-piperazinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718631-74-4 CAPLUS

CN Cyclopropanecarboxamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(4-methyl-1-piperazinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718631-75-5 CAPLUS

CN Benzamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(4-methyl-1-piperazinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 718631-76-6 CAPLUS

CN Benzamide, 3-phenoxy-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(4-methyl-1-piperazinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718631-77-7 CAPLUS

CN Benzamide, 3-(phenylthio)-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(4-methyl-1-piperazinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718631-78-8 CAPLUS

CN Benzamide, 4-(1H-pyrazol-1-yl)-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(4-methyl-1-piperazinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718631-79-9 CAPLUS

CN 1-Naphthalenecarboxamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(4-methyl-1-piperazinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718631-80-2 CAPLUS

CN 2-Naphthalenecarboxamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(4-methyl-1-piperazinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718631-81-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, 1,4,5,6-tetrahydro-6,6-dimethyl-N-[[[(2-methylphenyl)methyl]amino]carbonyl]-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 718631-82-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, 1,4,5,6-tetrahydro-6,6-dimethyl-5-[(4-methyl-1-piperazinyl)carbonyl]-N-[[[(phenylmethyl)amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 718631-83-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, 1,4,5,6-tetrahydro-6,6-dimethyl-5-[(4-methyl-1-piperazinyl)carbonyl]-N-[(propylamino)carbonyl]- (9CI) (CA INDEX NAME)




RN 718631-84-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, N-[[[(3-fluorophenyl)amino]carbonyl]-1,4,5,6-tetrahydro-6,6-dimethyl-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 718631-85-7 CAPLUS

CN Benzamide, 4-fluoro-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-(1-piperidinylcarbonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718631-86-8 CAPLUS

CN Benzamide, 4-chloro-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-(1-piperidinylcarbonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718631-87-9 CAPLUS

CN Benzamide, 4-fluoro-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-(4-morpholinylcarbonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718631-88-0 CAPLUS

CN Benzamide, 4-fluoro-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(4-methyl-1-piperidinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718631-89-1 CAPLUS

CN Cyclobutanecarboxamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(4-methyl-1-piperidinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718631-90-4 CAPLUS

CN Cyclopropanecarboxamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(4-methyl-1-piperidinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718631-91-5 CAPLUS

CN Cyclopropanecarboxamide, N-[1,4,5,6-tetrahydro-5-[[4-(hydroxymethyl)-1-piperidinyl]carbonyl]-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718631-92-6 CAPLUS

CN Benzamide, 4-fluoro-N-[1,4,5,6-tetrahydro-5-[[4-(2-hydroxyethyl)-1-piperidinyl]carbonyl]-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718632-07-6 CAPLUS

CN 2-Naphthaleneacetamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(4-methyl-1-piperazinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718632-08-7 CAPLUS

CN Benzamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(4-methyl-1-piperazinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718632-09-8 CAPLUS

CN Benzamide, 3,4-dimethoxy-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(4-methyl-1-piperazinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718632-11-2 CAPLUS

CN Benzamide, 2,4-difluoro-N-[1,4,5,6-tetrahydro-5-[[4-(hydroxymethyl)-1-piperidinyl]carbonyl]-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718632-12-3 CAPLUS

CN 2-Naphthaleneacetamide, N-[1,4,5,6-tetrahydro-5-[[4-(2-hydroxyethyl)-1-piperidinyl]carbonyl]-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718632-13-4 CAPLUS

CN Benzamide, N-[1,4,5,6-tetrahydro-5-[[4-(2-hydroxyethyl)-1-piperidinyl]carbonyl]-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718632-14-5 CAPLUS

CN 2-Naphthalenecarboxamide, N-[1,4,5,6-tetrahydro-5-[[4-(2-hydroxyethyl)-1-piperidinyl]carbonyl]-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718632-15-6 CAPLUS

CN Cyclopropanecarboxamide, N-[1,4,5,6-tetrahydro-5-[[4-(2-hydroxyethyl)-1-piperidinyl]carbonyl]-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718632-16-7 CAPLUS

CN Benzamide, 2,4-difluoro-N-[1,4,5,6-tetrahydro-5-[[4-(2-hydroxyethyl)-1-piperidinyl]carbonyl]-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME).




RN 718632-17-8 CAPLUS

CN Benzamide, N-[1,4,5,6-tetrahydro-5-[[4-(2-hydroxyethyl)-1-piperidinyl]carbonyl]-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 718632-18-9 CAPLUS

CN 1-Naphthalenecarboxamide, N-[1,4,5,6-tetrahydro-5-[[4-(2-hydroxyethyl)-1-piperidinyl]carbonyl]-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718632-19-0 CAPLUS

CN Cyclobutanecarboxamide, N-[1,4,5,6-tetrahydro-5-[[4-(2-hydroxyethyl)-1-piperidinyl]carbonyl]-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718632-20-3 CAPLUS

CN Benzamide, 4-(1H-pyrazol-1-yl)-N-[1,4,5,6-tetrahydro-5-[[4-(2-hydroxyethyl)-1-piperidinyl]carbonyl]-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718632-21-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, 1,4,5,6-tetrahydro-5-[[4-(2-hydroxyethyl)-1-piperidinyl]carbonyl]-6,6-dimethyl-N-[(phenylmethyl)amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 718632-22-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, N-[(3-fluorophenyl)amino]carbonyl]-1,4,5,6-tetrahydro-5-[[4-(2-hydroxyethyl)-1-piperidinyl]carbonyl]-6,6-dimethyl- (9CI) (CA INDEX NAME)




RN 718632-23-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, 1,4,5,6-tetrahydro-5-[[4-(2-hydroxyethyl)-1-piperidinyl]carbonyl]-6,6-dimethyl-N-[[[(2-methylphenyl)methyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 718632-24-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, 1,4,5,6-tetrahydro-5-[[4-(2-hydroxyethyl)-1-piperidinyl]carbonyl]-6,6-dimethyl-N-[(propylamino)carbonyl]- (9CI) (CA INDEX NAME)




RN 718632-25-8 CAPLUS

CN Butanamide, 3-methyl-N-[1,4,5,6-tetrahydro-5-[[4-(2-hydroxyethyl)-1-piperidinyl]carbonyl]-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 718632-27-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-butyl-3-[(4-fluorobenzoyl)amino]-4,6-dihydro-6,6-dimethyl- (9CI) (CA INDEX NAME)




RN 718632-29-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-3-[(4-fluorobenzoyl)amino]-4,6-dihydro-6,6-dimethyl- (9CI) (CA INDEX NAME)




RN 718632-30-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-6,6-dimethyl-3-[[2-(2-naphthalenyl)-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)




RN 718632-33-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(4-fluorobenzoyl)amino]-4,6-dihydro-6,6-dimethyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 718632-34-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-6,6-dimethyl-N-(1-methylethyl)-3-[(2-naphthalenylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 718632-36-1 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[3-[(4-fluorobenzoyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 718633-93-3 CAPLUS

CN Benzamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(3-methyl-2-thienyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 718633-95-5 CAPLUS

CN Benzamide, N-[5-(cyclopropylacetyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 718633-97-7 CAPLUS

CN Benzamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(2-methylcyclopropyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 718633-98-8 CAPLUS

CN Benzamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-(1-oxobutyl)pyrrolo[3,4-c]pyrazol-3-yl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 718634-00-5 CAPLUS

CN Benzamide, N-[5-(2,6-difluorobenzoyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 718634-02-7 CAPLUS

CN Benzamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(4-methyl-1-piperazinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 718634-03-8 CAPLUS

CN Benzamide, N-[1,4,5,6-tetrahydro-5-[[4-(2-hydroxyethyl)-1-piperidinyl]carbonyl]-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 18 OF 40 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:867247 CAPLUS

DOCUMENT NUMBER: 140:156715

TITLE: Aza-THIP and related analogues of THIP as GABAC antagonists

AUTHOR(S): Krehan, Dorte; Frolund, Bente; Ebert, Bjarke; Nielsen, Birgitte; Krosgaard-Larsen, Povl; Johnston, Graham A. R.; Chebib, Mary

CORPORATE SOURCE: Department of Medicinal Chemistry, Centre for Drug Design and Transport, The Danish University of Pharmaceutical Sciences, Copenhagen, DK 2100, Den.

SOURCE: Bioorganic & Medicinal Chemistry (2003), 11(23), 4891-4896

CODEN: BMECEP; ISSN: 0968-0896

PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 140:156715

AB The potency of a series of eight compds. structurally related with 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol (THIP), a potent GABAA partial agonist exhibiting GABAC $\rho 1$ antagonist effect ($K_i=25 \mu\text{M}$), was determined electrophysiol. using homomeric human GABAC $\rho 1$ receptors expressed in *Xenopus* oocytes. Protolytic properties (pK_a values for the acidic bioisosteric groups) and the presence of steric bulk in the mols. appear to be structural parameters of importance for blockade of the GABAC $\rho 1$ receptor. Within this series of moderately potent GABAC antagonists, only 4,5,6,7-tetrahydropyrazolo[5,4-c]pyridin-3-ol (Aza-THIP) does not interact detectably with GABAA receptors, and Aza-THIP has the potential of being a useful tool for mol. and behavioral pharmacol. studies.


IT 654666-65-6

RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)

(Aza-THIP and related analogs of THIP as GABAC $\rho 1$ antagonists)

RN 654666-65-6 CAPLUS

CN 3H-Pyrazolo[3,4-c]pyridin-3-one, 1,2,4,5,6,7-hexahydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 40 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:900736 CAPLUS

DOCUMENT NUMBER: 138:4612

TITLE: Preparation of 2-heterocyclyl-4-aminopyrimidine-5-carboxamide and 5-heterocyclyl-3-aminopyrazine-2-carboxamide derivatives as selective inhibitors of phosphodiesterase IV

INVENTOR(S): Yamada, Koichiro; Matsumoto, Kenji; Omori, Kenji; Yoshikawa, Kohei

PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 53 pp.
CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002338466	A2	20021127	JP 2002-61580	20020307
PRIORITY APPLN. INFO.:			JP 2001-73385	A 20010315
OTHER SOURCE(S):	MARPAT 138:4612			

GI



AB Disclosed is a pharmaceutical composition containing the title compound [I; the ring

A = (un)substituted N-containing heterocyclyl; R1 = (un)substituted lower alkyl, NH-Q-R3, NH-R4; wherein R3 = (un)substituted N-containing heterocyclyl; Q = a single bond, lower alkylene; R4 = (un)substituted cycloalkyl; R2 = (un)substituted aryl; one of Y and Z is CH and the other is N] or pharmacol. acceptable salt thereof as the active ingredient for the prevention and/or treatment of impotence, pulmonary hypertension, or diabetic stomach failure or paralysis. Thus, a solution of 2.057 g 2-methylthio-4-(3-chloro-4-methoxybenzylamino)-5-formylpyrimidine was treated with 1.468 g m-chloroperbenzoic acid (80%) at 0° for 30 min, followed by successively adding 0.901 g L-prolinol and 1.33 mL Et3N, and the resulting mixture was allowed to react at 0° for 1 h to give 2.00 g (S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-formylpyrimidine (II). A solution of 91.0 mg II in 20 mL THF was reacted with 1.1 mL 1.10 M MeLi/Et2O at -78° for 10 min to give, after treatment with aqueous NaHCO3 and extraction with EtOAc, an

EtOAc solution of crude (S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-(1-hydroxyethyl)pyrimidine which was stirred with 0.5 g MnO2 at room temperature overnight and then at refluxing temperature for 5 h to give (S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-acetylpyrimidine (III). III and inhibitors N-(2-pyridylmethyl)-2-(1,2,3,4-tetrahydroisoquinolin-2-yl)-4-(3-chloro-4-methoxybenzylamino)pyrimidine-5-carboxamide showed IC50 of 5.18 and 0.0859 μM, resp., against PDE IV isolated from a dog lung. III in vitro exhibited the relaxant activity on rabbit corpus cavernosum with ED50 of 1 nM.

IT 330784-63-9P 330784-77-5P 330784-84-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclpyrimidinecarboxamide and heterocyclpyrazinecarboxamide derivs. as selective inhibitors of phosphodiesterase IV for prevention and/or treatment of diseases)

RN 330784-63-9 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(1,2,3,4,6,7-hexahydro-3-oxo-5H-pyrazolo[4,3-c]pyridin-5-yl)-N-(trans-4-hydroxycyclohexyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 330784-77-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(1,2,3,4,6,7-hexahydro-3-oxo-5H-pyrazolo[4,3-c]pyridin-5-yl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 330784-84-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(1,2,3,4,6,7-hexahydro-3-oxo-5H-pyrazolo[4,3-c]pyridin-5-yl)-N-(2-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 20 OF 40 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:800320 CAPLUS
 DOCUMENT NUMBER: 138:255162
 TITLE: Ene Synthesis of Bicyclic Arylmethylenedihydropyrazoles Using 4-Phenyl-4,5-dihydro-3H-1,2,4-triazole-3,5-dione
 AUTHOR(S): Martinez, M. G.; Klimova-Berestneva, T.; Damian-Zea, K.; Meleshonkova, N. N.; Klimova, E. I.
 CORPORATE SOURCE: Institute of Chemistry, National Autonomous University of Mexico, Mexico City, Mex.
 SOURCE: Russian Journal of General Chemistry (Translation of Zhurnal Obshchei Khimii) (2002), 72(7), 1132-1140
 CODEN: RJGCEK; ISSN: 1070-3632
 PUBLISHER: MAIK Nauka/Interperiodica Publishing
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 138:255162
 AB 8-Acetyl-7-aryl-2-arylmethylene-8,9-diaza- and 4,8,9-triazabicyclo[4.3.0]non-9-enes react with 4-phenyl-4,5-dihydro-3H-1,2,4-triazole-3,5-dione, following the ene addition pattern. Under similar conditions 7-aryl-2-arylmethylene-8-methyl-8,9-diazabicyclo[4.3.0]non-9-enes give rise to both mono- and polyaddn. products. The product structures were studied by ¹H and ¹³C NMR, IR, and UV spectroscopy and single crystal X-ray diffraction.
 IT 503026-14-0P, 7-(p-Methoxyphenyl)-2-(p-methoxyphenylmethylene)-4-methyl-4,8,9-triazabicyclo[4.3.0]non-9-ene
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (precursor; ene synthesis of bicyclic arylmethylenedihydropyrazoles using 4-phenyl-4,5-dihydro-3H-1,2,4-triazole-3,5-dione)
 RN 503026-14-0 CAPLUS
 CN 1H-Pyrazolo[4,3-c]pyridine, octahydro-3-(4-methoxyphenyl)-7-[(4-methoxyphenyl)methylene]-5-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 21 OF 40 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:220579 CAPLUS

DOCUMENT NUMBER: 136:247580

TITLE: Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease

INVENTOR(S): Davies, Robert; Li, Pan; Golec, Julian; Bebbington, David

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 406 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 14

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022603	A1	20020321	WO 2001-US28738	20010914
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2422367	AA	20020321	CA 2001-2422367	20010914
AU 2001090912	A5	20020326	AU 2001-90912	20010914
US 2003055044	A1	20030320	US 2001-953505	20010914
US 6638926	B2	20031028		
US 2003064981	A1	20030403	US 2001-952836	20010914
US 6613776	B2	20030902		
US 2003064982	A1	20030403	US 2001-952875	20010914
US 2003073687	A1	20030417	US 2001-952671	20010914
US 6660731	B2	20031209		
US 2003078166	A1	20030424	US 2001-955601	20010914
US 6696452	B2	20040224		
US 2003083327	A1	20030501	US 2001-952833	20010914
US 6610677	B2	20030826		
EP 1317447	A1	20030611	EP 2001-970969	20010914
EP 1317447	B1	20060517		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003001701	A	20040301	ZA 2003-1701	20010914
ZA 2003001703	A	20040302	ZA 2003-1703	20010914
US 2004097501	A1	20040520	US 2001-953471	20010914
US 7115739	B2	20061003		
JP 2004525075	T2	20040819	JP 2002-526856	20010914
US 2005004110	A1	20050106	US 2001-952878	20010914
US 7098330	B2	20060829		
ES 2242771	T3	20051116	ES 2001-1971006	20010914
AT 326458	E	20060615	AT 2001-970969	20010914
AT 327990	E	20060615	AT 2001-970971	20010914
AT 327992	E	20060615	AT 2001-971082	20010914
AT 327991	E	20060615	AT 2001-973050	20010914
AT 326459	E	20060615	AT 2001-977779	20010914
EP 1698627	A1	20060906	EP 2006-10798	20010914
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CA 2432303	AA	20020829	CA 2001-2432303	20011219
CA 2432223	AA	20020906	CA 2001-2432223	20011219
EP 1345922	A1	20030924	EP 2001-271061	20011219
EP 1345922	B1	20060531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1355905	A1	20031029	EP 2001-273861	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 526472	A	20040430	NZ 2001-526472	20011219
JP 2004518743	T2	20040624	JP 2002-565976	20011219
JP 2004519479	T2	20040702	JP 2002-567928	20011219
HU 200400842	A2	20040728	HU 2004-842	20011219
NZ 526473	A	20050624	NZ 2001-526473	20011219
EP 1702920	A1	20060920	EP 2006-11799	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003001697	A	20040301	ZA 2003-1697	20030228
ZA 2003001699	A	20040301	ZA 2003-1699	20030228
ZA 2003001700	A	20040301	ZA 2003-1700	20030228
ZA 2003001702	A	20040301	ZA 2003-1702	20030228
ZA 2003001704	A	20040301	ZA 2003-1704	20030228
ZA 2003001698	A	20040302	ZA 2003-1698	20030228
ZA 2003004468	A	20040624	ZA 2003-4468	20030609
ZA 2003004469	A	20040624	ZA 2003-4469	20030609
ZA 2003004470	A	20040624	ZA 2003-4470	20030609
ZA 2003004471	A	20040624	ZA 2003-4471	20030609
ZA 2003004473	A	20040624	ZA 2003-4473	20030609
ZA 2003004475	A	20040624	ZA 2003-4475	20030609
ZA 2003004472	A	20040625	ZA 2003-4472	20030609
ZA 2003004474	A	20040625	ZA 2003-4474	20030609
NO 2003002704	A	20030821	NO 2003-2704	20030613
US 2004224944	A1	20041111	US 2003-624800	20030722
US 7008948	B2	20060307		
US 2004116454	A1	20040617	US 2003-692355	20031023
US 2004157893	A1	20040812	US 2003-722374	20031125
US 2004132781	A1	20040708	US 2003-736426	20031215
US 7087603	B2	20060808		
US 2004167141	A1	20040826	US 2004-775699	20040210
JP 2005097322	A2	20050414	JP 2004-366925	20041217
AU 2006201228	A1	20060413	AU 2006-201228	20060321
AU 2006201229	A1	20060413	AU 2006-201229	20060321
AU 2006201230	A1	20060413	AU 2006-201230	20060321
AU 2006201262	A1	20060427	AU 2006-201262	20060321
AU 2006201263	A1	20060427	AU 2006-201263	20060321
AU 2006201264	A1	20060427	AU 2006-201264	20060321

AU 2006201265	A1	20060427	AU 2006-201265	20060321
AU 2006201391	A1	20060427	AU 2006-201391	20060404
AU 2006201396	A1	20060504	AU 2006-201396	20060404
US 2006258658	A1	20061116	US 2006-492450	20060725
PRIORITY APPLN. INFO.:			US 2000-232795P	P 20000915
			US 2000-257887P	P 20001221
			US 2001-286949P	P 20010427
			AU 2001-90944	A3 20010914
			AU 2001-91013	A3 20010914
			AU 2001-94558	A3 20010914
			AU 2001-96871	A3 20010914
			AU 2001-96875	A3 20010914
			EP 2001-971082	A3 20010914
			US 2001-952671	A3 20010914
			US 2001-953471	A3 20010914
			US 2001-955601	A3 20010914
			WO 2001-US28738	W 20010914
			EP 2001-273861	A 20011219
			EP 2001-994323	A3 20011219
			JP 2002-557938	A3 20011219
			US 2001-26966	A1 20011219
			WO 2001-US49139	W 20011219
			WO 2001-US50312	W 20011219
			US 2001-34019	A3 20011220
			US 2001-34683	A1 20011220
OTHER SOURCE(S):	MARPAT	136:247580		
GI				



AB Title compds. I [wherein G = Ring C or Ring D; Ring C = (un)substituted Ph, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl; Ring D = (un)substituted monocyclic or bicyclic ring selected from aryl, heteroaryl, heterocyclyl, or carbocyclyl; Z1 = N or CR9; Z2 = N or CH; Z3 = N or CRx; Z4 = N or CRy; Rx and Ry = independently TR3, or taken together with their intervening atoms form an (un)saturated fused ring having 1-3 ring heteroatoms; R2 and R2a = independently R, TWR6; or C2R2R2a = (un)substituted fused ring containing 0-3 heteroatoms; T = a bond or alkylidene chain; W = C(R6)2O, C(R6)2SO-2, C(R6)2NR6, CO, CO2, CR6OCO, CR6OCONR6, C(R6)2NR6CO, C(R6)2NR6CO2, CR6:NNR6, CR6:NO, C(R6)2NR6NR6, C(R6)2NR6SO2NR6, C(R6)2NR6CONR6, or CONR6; R = H or (un)substituted aliphatic, (hetero)aryl, or heterocyclyl ring; R3 = R, halo, O, OR, COR, CO2R, COCOR, COCH2COR, NO2, CN, SO0-2R, N(R4)2, CON(R4)2, SO2N(R4)2, OCOR, NR4COR, NR4CO2(aliphatic), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO2N(R4)2, NR4SO2R, or OCON(R4)2; R4 = R7, COR7, CO2(aliphatic), CON(R7)2, or SO2R7; or N(R4)2 = heterocyclyl or heteroaryl; R6 and R7 = independently H or (un)substituted aliphatic group; or N(R6)2 = heterocyclyl or heteroaryl; or N(R7)2 = heterocyclyl or heteroaryl; R9 = R, halo, OR,

as COR, CO2R, COCOR, etc.] were prepared as protein kinase inhibitors, especially

inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes, and Alzheimer's disease. Claims cover (triazinyl)pyrazolamines and indazolamines I [wherein Z1, Z2, and Z3 = N; Z4 = CRy]. Examples include data for approx. 300 invention compds. prepared by a variety of synthetic methods and bioassay results for the inhibition of GSK- β 3, Aurora-2, ERK, and Src. For instance, the N-(4-pyrimidinyl)-3-pyrazolamine II was prepared and exhibited Ki values of < 0.1 μ M for glycogen synthetase kinase 3 β (GSK-3 β) and 0.1-1.0 μ M for Aurora-2.


IT 404874-74-4P 404874-77-7P 404874-80-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404874-74-4 CAPLUS


CN 1H-Pyrazolo[3,4-c]pyridin-3-amine, N-[4-(2-chlorophenyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404874-77-7 CAPLUS


CN 1H-Pyrazolo[3,4-c]pyridin-3-amine, N-[4-[2-(trifluoromethyl)phenyl]-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 404874-80-2 CAPLUS

CN 1H-Pyrazolo[3,4-c]pyridin-3-amine, N-[4-[3-(methylamino)phenyl]-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE



REFERENCE COUNT:

3


THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 22 OF 40 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:123007 CAPLUS
 DOCUMENT NUMBER: 136:183816
 TITLE: Combinatorial preparation of bicyclo pyrazoles as
 kinase inhibitors for treatment of cancer and other
 proliferative disorders
 INVENTOR(S): Fancelli, Daniele; Pittala, Valeria; Varasi, Mario
 PATENT ASSIGNEE(S): Pharmacia & Upjohn S.p.A., Italy
 SOURCE: PCT Int. Appl., 331 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002012242	A2	20020214	WO 2001-EP8639	20010725
WO 2002012242	A3	20020606		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2416527	AA	20020214	CA 2001-2416527	20010725
AU 2001087654	A5	20020218	AU 2001-87654	20010725
BR 2001013176	A	20030617	BR 2001-13176	20010725
EP 1320531	A2	20030625	EP 2001-967223	20010725
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 200300741	A2	20031128	HU 2003-741	20010725
JP 2004505977	T2	20040226	JP 2002-518217	20010725
ZA 2003001813	A	20040622	ZA 2003-1813	20010725
NZ 524475	A	20041126	NZ 2001-524475	20010725
EE 200300054	A	20041215	EE 2003-54	20010725
NO 2003000381	A	20030224	NO 2003-381	20030124
US 2003171357	A1	20030911	US 2003-344480	20030210
PRIORITY APPLN. INFO.:			US 2000-635914	A 20000810
			WO 2001-EP8639	W 20010725
OTHER SOURCE(S):		MARPAT 136:183816		
GI				




- AB Title compds. I [wherein R and R1 = independently H or (un)substituted R', COR', CONHR', CONR'R'', NHC(:NH)NHR', C(:NH)NHR', SO2R', SO2NHR', or SO2NR'R''; R' and R'' = independently H or (un)substituted (cyclo)alkyl, or aryl(alkyl); or R'R'' = alkylene chain; Ra, Rb, Rc, and Rd = independently H or (un)substituted alkyl, aryl(alkyl), or CH2OR'; or Ra and Rb and/or Rc and Rd taken together with the C to which they are bonded = (un)substituted cycloalkyl; m and n = independently 0-2, provided that m + n ≤ 2; and pharmaceutically acceptable salts thereof] were prepared, primarily by solid phase combinatorial methods, as protein kinase inhibitors (no data). For example, cycloaddn. of H2NNH2•HCl to tert-Bu 3-cyano-4-oxo-1-pyrrolidinecarboxylate (preparation given) afforded 3-amino-5-(tert-butoxycarbonyl)-4,6-dihydropyrrolo[3,4-c]pyrazole (31%). The pyrrolopyrazole was dissolved in anhydrous CH2Cl2 and linked to methylisocyanate polystyrene resin to give the polymer-bound urea. The resin-supported urea was partitioned into 96 batches and reacted with acyl chlorides. A second partition of one of the lots, followed by reaction with carboxylic acids, sulfonyl chlorides, and isocyanates and hydrolytic cleavage from the resin, afforded combinatorial libraries of functionalized derivs., including II. I are useful for treating diseases linked to dysregulated protein kinases, such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, autoimmune disease, and neurodegenerative disorders (no data).
- IT 398491-59-3P 398491-60-6P 398491-61-7P,
3-Amino-5-(tert-butoxycarbonyl)-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole 398491-62-8P, 3-Amino-5-(tert-butoxycarbonyl)-6-benzoxymethyl-4,6-dihydropyrrolo[3,4-c]pyrazole 398491-63-9P
398491-64-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; combinatorial preparation of bicyclo pyrazoles as kinase inhibitors for treatment of cancer and other proliferative disorders)
- RN 398491-59-3 CAPLUS
- CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 3-amino-4,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



- RN 398491-60-6 CAPLUS
- CN Pyrrolo[3,4-c]pyrazol-3-amine, 5-acetyl-1,4,5,6-tetrahydro- (9CI) (CA INDEX NAME)




- RN 398491-61-7 CAPLUS
- CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 3-amino-4,6-dihydro-6,6-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 398491-62-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 3-amino-4,6-dihydro-6-[(phenylmethoxy)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 398491-63-9 CAPLUS

CN 6H-Pyrazolo[3,4-c]pyridine-6-carboxylic acid, 3-amino-1,4,5,7-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 398491-64-0 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 3-amino-1,4,6,7-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 398491-65-1P 398491-66-2P 398491-67-3P
398491-68-4P 398491-69-5P 398491-70-8P
398491-71-9P 398492-80-3P 398492-81-4P
398495-42-6P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)

(kinase inhibitor; combinatorial preparation of bicyclo pyrazoles as kinase inhibitors for treatment of cancer and other proliferative disorders)


RN 398491-65-1 CAPLUS

CN Benzeneacetamide, N-[1,4,5,6-tetrahydro-5-(phenylacetyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398491-66-2 CAPLUS

CN Benzeneacetamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 398491-67-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(phenylacetyl)amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398491-68-4 CAPLUS

CN Benzeneacetamide, N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398491-69-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[(phenylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398491-70-8 CAPLUS

CN [1,1'-Biphenyl]-4-acetamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 398491-71-9 CAPLUS

CN 2-Naphthaleneacetamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 398492-80-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-N,N-dimethyl-3-[[2-(2-naphthalenyl)-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)




RN 398492-81-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[2-(2-naphthalenyl)-1-oxopropyl]amino]-N-1-piperidinyl- (9CI) (CA INDEX NAME)



RN 398495-42-6 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1,4,6,7-tetrahydro-N,N-dimethyl-3-[[(2-phenyl-4-thiazolyl)acetyl]amino]- (9CI) (CA INDEX NAME)



IT 398491-72-0P 398491-73-1P 398491-74-2P
 398491-75-3P 398491-76-4P 398491-77-5P
 398491-78-6P 398491-79-7P 398491-80-0P
 398491-81-1P 398491-82-2P 398491-83-3P
 398491-84-4P 398491-85-5P 398491-86-6P
 398491-87-7P 398491-88-8P 398491-89-9P
 398491-90-2P 398491-91-3P 398491-92-4P
 398491-93-5P 398491-94-6P 398491-95-7P
 398491-96-8P 398491-97-9P 398491-98-0P
 398491-99-1P 398492-00-7P 398492-01-8P
 398492-02-9P 398492-03-0P 398492-04-1P
 398492-05-2P 398492-06-3P 398492-07-4P
 398492-08-5P 398492-09-6P 398492-10-9P
 398492-11-0P 398492-12-1P 398492-13-2P
 398492-14-3P 398492-15-4P 398492-16-5P
 398492-17-6P 398492-18-7P 398492-19-8P
 398492-20-1P 398492-21-2P 398492-22-3P
 398492-23-4P 398492-24-5P 398492-25-6P
 398492-26-7P 398492-27-8P 398492-28-9P
 398492-29-0P 398492-30-3P 398492-31-4P
 398492-32-5P 398492-33-6P 398492-34-7P
 398492-35-8P 398492-36-9P 398492-37-0P
 398492-38-1P 398492-39-2P 398492-40-5P
 398492-42-7P 398492-44-9P 398492-45-0P
 398492-46-1P 398492-47-2P 398492-48-3P
 398492-49-4P 398492-50-7P 398492-51-8P
 398492-52-9P 398492-53-0P 398492-54-1P
 398492-55-2P 398492-56-3P 398492-57-4P
 398492-58-5P 398492-59-6P 398492-60-9P
 398492-61-0P 398492-62-1P 398492-63-2P
 398492-64-3P 398492-65-4P 398492-66-5P
 398492-67-6P 398492-68-7P 398492-69-8P
 398492-70-1P 398492-71-2P 398492-72-3P
 398492-73-4P 398492-74-5P 398492-75-6P
 398492-76-7P 398492-77-8P 398492-78-9P
 398492-79-0P 398492-82-5P 398492-83-6P
 398492-84-7P 398492-85-8P 398492-86-9P
 398492-87-0P 398492-88-1P 398492-89-2P


398492-90-5P 398492-91-6P 398492-92-7P
 398492-93-8P 398492-94-9P 398492-95-0P
 398492-96-1P 398492-97-2P 398492-98-3P
 398492-99-4P 398493-00-0P 398493-01-1P
 398493-02-2P 398493-03-3P 398493-04-4P
 398493-05-5P 398493-06-6P 398493-07-7P
 398493-08-8P 398493-09-9P 398493-10-2P
 398493-11-3P 398493-12-4P 398493-13-5P
 398493-14-6P 398493-15-7P 398493-16-8P
 398493-17-9P 398493-18-0P 398493-19-1P
 398493-20-4P 398493-21-5P 398493-22-6P
 398493-23-7P 398493-24-8P 398493-25-9P
 398493-26-0P 398493-27-1P 398493-28-2P
 398493-29-3P 398493-30-6P 398493-31-7P
 398493-32-8P 398493-33-9P 398493-34-0P
 398493-35-1P 398493-36-2P 398493-37-3P
 398493-38-4P 398493-39-5P 398493-40-8P
 398493-41-9P 398493-42-0P 398493-43-1P
 398493-44-2P 398493-45-3P 398493-46-4P
 398493-47-5P 398493-48-6P 398493-49-7P
 398493-50-0P 398493-51-1P 398493-52-2P
 398493-53-3P 398493-54-4P 398493-55-5P
 398493-56-6P 398493-57-7P 398493-58-8P
 398493-59-9P 398493-60-2P 398493-61-3P
 398493-62-4P 398493-63-5P 398493-64-6P
 398493-65-7P 398493-66-8P 398493-67-9P
 398493-68-0P 398493-69-1P 398493-70-4P
 398493-71-5P 398493-72-6P 398493-73-7P
 398493-74-8P 398493-75-9P 398493-76-0P
 398493-77-1P 398493-78-2P 398493-79-3P
 398493-80-6P 398493-81-7P 398493-82-8P
 398493-83-9P 398493-84-0P 398493-85-1P
 398493-86-2P 398493-87-3P 398493-88-4P
 398493-89-5P 398493-90-8P 398493-91-9P
 398493-92-0P 398493-93-1P 398493-94-2P
 398493-95-3P 398493-96-4P 398493-97-5P
 398493-98-6P 398493-99-7P 398494-00-3P
 398494-01-4P 398494-02-5P 398494-03-6P
 398494-04-7P 398494-05-8P 398494-06-9P
 398494-07-0P 398494-08-1P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU
 (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study);
 PREP (Preparation); USES (Uses)

(kinase inhibitor; combinatorial preparation of bicyclo pyrazoles as kinase
 inhibitors for treatment of cancer and other proliferative disorders)


RN 398491-72-0 CAPLUS

CN 2-Furancarboxamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-
 yl)- (9CI) (CA INDEX NAME)




RN 398491-73-1 CAPLUS

CN 2-Thiophenecarboxamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-
 c]pyrazol-3-yl)-5-chloro- (9CI) (CA INDEX NAME)




RN 398491-74-2 CAPLUS

CN 3-Pyridinecarboxamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-6-chloro- (9CI) (CA INDEX NAME)




RN 398491-75-3 CAPLUS

CN 2-Benzofurancarboxamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 398491-76-4 CAPLUS

CN Benzamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-4-phenoxy- (9CI) (CA INDEX NAME)




RN 398491-77-5 CAPLUS

CN Benzamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-4-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 398491-78-6 CAPLUS

CN 3-Furancarboxamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-2-methyl-5-phenyl- (9CI) (CA INDEX NAME)




RN 398491-79-7 CAPLUS

CN 6-Quinolinecarboxamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 398491-80-0 CAPLUS

CN 2-Furancarboxamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-5-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 398491-81-1 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398491-82-2 CAPLUS


CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-(phenylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398491-83-3 CAPLUS


CN Benzamide, N-(5-benzoyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-4-

(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 398491-84-4 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-(1-naphthalenylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398491-85-5 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-(1-naphthalenylcarbonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398491-86-6 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-(phenylacetyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398491-87-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[4-(1,1-dimethylethyl)benzoyl]amino]-4,6-dihydro-N-phenyl- (9CI) (CA INDEX NAME)




RN 398491-88-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[4-(1,1-dimethylethyl)benzoyl]amino]-4,6-dihydro-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 398491-89-9 CAPLUS

CN Benzamide, 4-phenoxy-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398491-90-2 CAPLUS

CN Benzamide, N-(5-benzoyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-4-phenoxy- (9CI) (CA INDEX NAME)




RN 398491-91-3 CAPLUS

CN Benzamide, 4-phenoxy-N-[1,4,5,6-tetrahydro-5-(1-naphthalenylcarbonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398491-92-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-N-(1-methylethyl)-3-
[(4-phenoxybenzoyl)amino]- (9CI) (CA INDEX NAME)




RN 398491-93-5 CAPLUS

CN 2-Naphthaleneacetamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-
c]pyrazol-3-yl)- α -methyl- (9CI) (CA INDEX NAME)




RN 398491-94-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(1,3-benzodioxol-5-
ylacetyl)amino]-4,6-dihydro-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 398491-95-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-cyclohexyl-3-[[4-(1,1-
dimethylethyl)benzoyl]amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398491-96-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[4-(1,1-
dimethylethyl)benzoyl]amino]-N-ethyl-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398491-97-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-(2,6-diethylphenyl)-3-[[4-(1,1-dimethylethyl)benzoyl]amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398491-98-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-cyclohexyl-3-[(2-ethyl-1-oxobutyl)amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398491-99-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(1,3-benzodioxol-5-ylacetyl)amino]-N-(2,6-diethylphenyl)-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398492-00-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-N-(2-methoxyphenyl)-3-[[2-(2-naphthalenyl)-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)




RN 398492-01-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[2-(2-naphthalenyl)-1-oxopropyl]amino]-N-(1-phenylethyl)- (9CI) (CA INDEX NAME)




RN 398492-02-9 CAPLUS

CN 2-Naphthaleneacetamide, α -methyl-N-[1,4,5,6-tetrahydro-5-(phenylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-03-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[4-(1,1-dimethylethyl)benzoyl]amino]-N-(2,5-dimethylphenyl)-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398492-04-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-(2,5-dimethylphenyl)-3-[(2-ethyl-1-oxobutyl)amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398492-05-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(2-ethyl-1-oxobutyl)amino]-N-[(4-fluorophenyl)methyl]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398492-06-3 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-07-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-(2-chlorophenyl)-4,6-dihydro-3-[[2-(2-naphthalenyl)-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)




RN 398492-08-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[2-(2-naphthalenyl)-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)




RN 398492-09-6 CAPLUS

CN Benzamide, 4-phenoxy-N-[1,4,5,6-tetrahydro-5-(3-methyl-1-oxobutyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-10-9 CAPLUS

CN Benzamide, 4-phenoxy-N-[1,4,5,6-tetrahydro-5-[(2-phenyl-4-thiazolyl)acetyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-11-0 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-(2-thienylacetyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-12-1 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-(3-pyridinylacetyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-13-2 CAPLUS

CN Benzamide, 4-phenoxy-N-[1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-14-3 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-(3-methyl-1-oxobutyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-15-4 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-[(2-phenyl-4-thiazolyl)acetyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-16-5 CAPLUS

CN Benzamide, 4-phenoxy-N-[1,4,5,6-tetrahydro-5-(2-thienylacetyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-17-6 CAPLUS

CN Cyclopropanecarboxamide, N-[1,4,5,6-tetrahydro-5-(1-naphthalenylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398492-18-7 CAPLUS


CN 2-Naphthaleneacetamide, alpha-methyl-N-[1,4,5,6-tetrahydro-5-(2-methoxyphenyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398492-19-8 CAPLUS


CN 2-Naphthaleneacetamide, N-[5-(2-furanylcarbonyl)-1,4,5,6-tetrahydro-5-(2-methoxyphenyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)

tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- α -methyl- (9CI) (CA INDEX NAME)



RN 398492-20-1 CAPLUS


CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-[[5-(4-morpholinylmethyl)-2-furanyl]carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-21-2 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]acetyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 398492-22-3 CAPLUS

CN Benzamide, N-[5-(1H-benzotriazol-5-ylcarbonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 398492-23-4 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-(1H-pyrrol-3-ylcarbonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-24-5 CAPLUS

CN Benzamide, 4-phenoxy-N-[1,4,5,6-tetrahydro-5-[[4-[2-oxo-2-(1-pyrrolidinyl)ethoxy]phenyl]acetyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 1-B




RN 398492-25-6 CAPLUS

CN Benzamide, 4-phenoxy-N-[1,4,5,6-tetrahydro-5-[[4-[(methylsulfonyl)amino]phenyl]acetyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-26-7 CAPLUS

CN Benzamide, 4-phenoxy-N-[1,4,5,6-tetrahydro-5-[(6-oxo-1(6H)-pyridazinyl)acetyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-27-8 CAPLUS

CN Benzamide, N-[5-[[3-(2-amino-2-oxoethoxy)phenyl]acetyl]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-phenoxy- (9CI) (CA INDEX NAME)




RN 398492-28-9 CAPLUS

CN Benzamide, N-[5-[[4-(2-amino-2-oxoethoxy)phenyl]acetyl]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-phenoxy- (9CI) (CA INDEX NAME)




RN 398492-29-0 CAPLUS

CN Benzamide, 4-phenoxy-N-[1,4,5,6-tetrahydro-5-[[4-(1-pyrrolidinyl)phenyl]acetyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398492-30-3 CAPLUS


CN Benzamide, N-[5-[[[(aminocarbonyl)oxy]acetyl]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-phenoxy- (9CI) (CA INDEX NAME)




RN 398492-31-4 CAPLUS

CN Benzamide, 4-phenoxy-N-[1,4,5,6-tetrahydro-5-[[4-[2-(4-methyl-2-piperazinyl)ethoxy]phenyl]acetyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 398492-32-5 CAPLUS

CN Benzamide, 4-phenoxy-N-[1,4,5,6-tetrahydro-5-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]acetyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 398492-33-6 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-[[4-[2-oxo-2-(1-pyrrolidinyl)ethoxy]phenyl]acetyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)


PAGE 1-A






RN 398492-34-7 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-[[4-[(methylsulfonyl)amino]phenyl]acetyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI)
(CA INDEX NAME)




RN 398492-35-8 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-(3-pyridinylcarbonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-36-9 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-(4-pyridinylcarbonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398492-37-0 CAPLUS


CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-[(2-methyl-3-pyridinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398492-38-1 CAPLUS


CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-[[2-

(mercaptomethyl)-3-pyridinyl]carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI)
(CA INDEX NAME)




RN 398492-39-2 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-(pyrazinylcarbonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-40-5 CAPLUS

CN Benzamide, N-[5-(3-furanylcarbonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-phenoxy- (9CI) (CA INDEX NAME)




RN 398492-42-7 CAPLUS

CN Benzamide, 4-phenoxy-N-[1,4,5,6-tetrahydro-5-(2-thienylcarbonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398492-44-9 CAPLUS


CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-[(7-methoxy-2-benzofuranyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398492-45-0 CAPLUS


CN Benzamide, N-[5-(2-benzofuranylcarbonyl)-1,4,5,6-tetrahydropyrrolo[3,4-

c]pyrazol-3-yl]-4-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 398492-46-1 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[5-(2-furanylcarbonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-47-2 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[5-(3-furanylcarbonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-48-3 CAPLUS

CN Benzamide, N-[5-(2-furanylcarbonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-phenoxy- (9CI) (CA INDEX NAME)




RN 398492-49-4 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-(3-thienylcarbonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-50-7 CAPLUS

CN Benzamide, 4-phenoxy-N-[1,4,5,6-tetrahydro-5-(2-quinoxalinylylcarbonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-51-8 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-(6-quinolinylcarbonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-52-9 CAPLUS

CN Benzamide, 4-phenoxy-N-[1,4,5,6-tetrahydro-5-(pyrazinylcarbonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-53-0 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-[(6-oxo-1(6H)-pyridazinyl)acetyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-54-1 CAPLUS

CN Benzamide, N-[5-[[4-(2-amino-2-oxoethoxy)phenyl]acetyl]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 398492-55-2 CAPLUS


CN Benzamide, N-[5-[[(aminocarbonyl)oxy]acetyl]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 398492-56-3 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-[[4-[2-(4-methyl-2-piperazinyl)ethoxy]phenyl]acetyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 398492-57-4 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-[[2-[(methylsulfonyl)amino]-4-thiazolyl]carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-58-5 CAPLUS


CN Benzamide, N-[5-(2-benzofuranylcarbonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-phenoxy- (9CI) (CA INDEX NAME)




RN 398492-59-6 CAPLUS
 CN Benzamide, 4-phenoxy-N-[1,4,5,6-tetrahydro-5-(2-pyridinylcarbonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-60-9 CAPLUS
 CN Benzamide, 4-phenoxy-N-[1,4,5,6-tetrahydro-5-[(2-methyl-3-pyridinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-61-0 CAPLUS
 CN Benzamide, 4-phenoxy-N-[1,4,5,6-tetrahydro-5-(4-quinolinylcarbonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398492-62-1 CAPLUS
 CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-[4-(2-oxo-1-pyrrolidinyl)benzoyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-63-2 CAPLUS
 CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-64-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-butyl-4,6-dihydro-3-[[2-(2-naphthalenyl)-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)




RN 398492-65-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-N-(1-methylethyl)-3-[[2-(2-naphthalenyl)-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)




RN 398492-66-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[[2-(2-naphthalenyl)-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)




RN 398492-67-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 4,6-dihydro-3-[[2-(2-naphthalenyl)-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 398492-68-7 CAPLUS

CN 2-Naphthaleneacetamide, α-methyl-N-[1,4,5,6-tetrahydro-5-(3-methyl-1-oxobutyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-69-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-acetamide, 4,6-dihydro-3-[[2-(2-naphthalenyl)-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)




RN 398492-70-1 CAPLUS

CN 2-Naphthaleneacetamide, α-methyl-N-[1,4,5,6-tetrahydro-5-(1H-pyrrol-3-ylcarbonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-71-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 3-[[4-(1,1-dimethylethyl)benzoyl]amino]-4,6-dihydro-, ethyl ester (9CI) (CA INDEX NAME)




RN 398492-72-3 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-(3-methylbutyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-73-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-butyl-3-[[4-(1,1-dimethylethyl)benzoyl]amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398492-74-5 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-(1H-indol-2-ylcarbonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-75-6 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-[(1-methyl-1H-indol-3-yl)acetyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-76-7 CAPLUS

CN Benzamide, 4-phenoxy-N-[1,4,5,6-tetrahydro-5-[4-(1H-imidazol-1-ylmethyl)benzoyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-77-8 CAPLUS

CN Benzamide, 4-phenoxy-N-[1,4,5,6-tetrahydro-5-[4-(2-oxo-1-pyrrolidinyl)benzoyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-78-9 CAPLUS

CN Benzamide, 4-phenoxy-N-[1,4,5,6-tetrahydro-5-[[5-(4-morpholinylmethyl)-2-furanyl]carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-79-0 CAPLUS

CN 2-Naphthaleneacetamide, N-[5-[[5-(acetylamino)-2-furanyl]carbonyl]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-α-methyl- (9CI) (CA INDEX NAME)




RN 398492-82-5 CAPLUS

CN 2-Naphthaleneacetamide, α-methyl-N-[1,4,5,6-tetrahydro-5-[(4-methyl-1-piperazinyl)acetyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-83-6 CAPLUS

CN 2-Naphthaleneacetamide, α-methyl-N-[1,4,5,6-tetrahydro-5-(1-piperidinylacetyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-84-7 CAPLUS

CN 2-Naphthaleneacetamide, α-methyl-N-[1,4,5,6-tetrahydro-5-[2-oxo-2-(1-pyrrolidinyl)ethyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-85-8 CAPLUS

CN Benzeneacetamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 398492-86-9 CAPLUS

CN Benzeneacetamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-α-methyl-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 398492-87-0 CAPLUS

CN Benzeneacetamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-4-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 398492-88-1 CAPLUS

CN Benzeneacetamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)- α -methyl-4-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 398492-89-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-N-(2-methoxyphenyl)-3-[[1-oxo-2-[4-(2-oxo-1-pyrrolidinyl)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)




RN 398492-90-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-(2,4-difluorophenyl)-4,6-dihydro-3-[[1-oxo-2-[4-(2-oxo-1-pyrrolidinyl)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)




RN 398492-91-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[1-oxo-2-[4-(2-oxo-1-pyrrolidinyl)phenyl]propyl]amino]-N-(1-phenylethyl)- (9CI) (CA INDEX NAME)




RN 398492-92-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-N-(2-methoxyphenyl)-3-[[1-oxo-2-[4-(1-pyrrolidinyl)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)




RN 398492-93-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-(2,4-difluorophenyl)-4,6-dihydro-3-[[1-oxo-2-[4-(1-pyrrolidinyl)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)




RN 398492-94-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[1-oxo-2-[4-(1-pyrrolidinyl)phenyl]propyl]amino]-N-(1-phenylethyl)- (9CI) (CA INDEX NAME)




RN 398492-95-0 CAPLUS

CN Benzeneacetamide, α-methyl-4-(1-pyrrolidinyl)-N-[1,4,5,6-tetrahydro-5-(phenylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398492-96-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-N-(2-methoxyphenyl)-3-[[[4-(2-oxo-1-pyrrolidinyl)phenyl]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 398492-97-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-(2-chlorophenyl)-4,6-dihydro-3-[[[4-(2-oxo-1-pyrrolidinyl)phenyl]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 398492-98-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[[4-(2-oxo-1-pyrrolidinyl)phenyl]acetyl]amino]-N-(1-phenylethyl)- (9CI) (CA INDEX NAME)




RN 398492-99-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-butyl-4,6-dihydro-3-[[[4-(2-oxo-1-pyrrolidinyl)phenyl]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 398493-00-0 CAPLUS

CN Benzeneacetamide, 4-(2-oxo-1-pyrrolidinyl)-N-[1,4,5,6-tetrahydro-5-(phenylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-01-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-butyl-4,6-dihydro-3-[[[1-oxo-2-[4-(2-oxo-1-pyrrolidinyl)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)




RN 398493-02-2 CAPLUS

CN Benzeneacetamide, α -methyl-4-(2-oxo-1-pyrrolidinyl)-N-[1,4,5,6-tetrahydro-5-(phenylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-03-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[[4-(2-oxo-1-pyrrolidinyl)phenyl]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 398493-04-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-butyl-4,6-dihydro-3-[[[1-oxo-2-[4-(1-pyrrolidinyl)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)




RN 398493-05-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[1-oxo-2-[4-(1-pyrrolidinyl)phenyl]propyl]amino]- (9CI) (CA INDEX NAME)




RN 398493-06-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-N-(2-methoxyphenyl)-3-[[[4-(1-pyrrolidinyl)phenyl]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 398493-07-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-(2-chlorophenyl)-4,6-dihydro-3-[[[4-(1-pyrrolidinyl)phenyl]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 398493-08-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-N-(1-phenylethyl)-3-[[[4-(1-pyrrolidinyl)phenyl]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 398493-09-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-butyl-4,6-dihydro-3-[[[4-(1-pyrrolidinyl)phenyl]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 398493-10-2 CAPLUS

CN Benzeneacetamide, 4-(1-pyrrolidinyl)-N-[1,4,5,6-tetrahydro-5-(phenylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-11-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[[[4-(2-oxo-1-pyrrolidinyl)phenyl]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 398493-12-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-N-(1-methylethyl)-3-[[[4-(2-oxo-1-pyrrolidinyl)phenyl]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 398493-13-5 CAPLUS

CN Benzeneacetamide, N-[5-(2-furanylcarbonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 398493-14-6 CAPLUS

CN Benzeneacetamide, 4-(2-oxo-1-pyrrolidinyl)-N-[1,4,5,6-tetrahydro-5-(2-methoxyphenyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-15-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-acetamide, 4,6-dihydro-3-[[[4-(2-oxo-1-pyrrolidinyl)phenyl]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 398493-16-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-N-(1-methylethyl)-3-[[[4-(1-pyrrolidinyl)phenyl]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 398493-17-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[[[4-(1-pyrrolidinyl)phenyl]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 398493-18-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-acetamide, 4,6-dihydro-3-[[[4-(1-pyrrolidinyl)phenyl]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 398493-19-1 CAPLUS

CN Benzeneacetamide, 4-(2-oxo-1-pyrrolidinyl)-N-[1,4,5,6-tetrahydro-5-(3-methyl-1-oxobutyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-20-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-butyl-4,6-dihydro-3-[(2-naphthalenylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398493-21-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-butyl-4,6-dihydro-3-[[3-methylphenyl]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 398493-22-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-butyl-3-[[3-fluorophenyl]acetyl]amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398493-23-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-butyl-4,6-dihydro-3-[(3-pyridinylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398493-24-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(bicyclo[4.2.0]octa-1,3,5-trien-7-ylcarbonyl)amino]-N-butyl-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398493-25-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-butyl-4,6-dihydro-3-[(phenoxycarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 398493-26-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-butyl-4,6-dihydro-3-[[4-methylphenyl]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 398493-27-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-butyl-3-[[4-fluorophenyl]acetyl]amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398493-28-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-butyl-3-[[4-(4-fluorophenyl)acetyl]amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398493-29-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-butyl-4,6-dihydro-3-[[4-(trifluoromethoxy)phenyl]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 398493-30-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-butyl-4,6-dihydro-3-[[4-(2-methylphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)



RN 398493-31-7 CAPLUS


CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[4-(2-bromophenyl)acetyl]amino]-N-butyl-4,6-dihydro- (9CI) (CA INDEX NAME)



RN 398493-32-8 CAPLUS


CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-butyl-3-[[4-(2,5-

difluorophenyl)acetyl]amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398493-33-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-butyl-4,6-dihydro-3-[[[4-(2-oxo-2-(1-pyrrolidinyl)ethoxy)phenyl]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 398493-34-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[[3-(2-amino-2-oxoethoxy)phenyl]acetyl]amino]-N-butyl-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398493-35-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-butyl-4,6-dihydro-3-[(4-pyridinylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398493-36-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-butyl-4,6-dihydro-3-[[[4-(4-morpholinyl)phenyl]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 398493-37-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-butyl-3-[[2-fluorophenyl)acetyl]amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398493-38-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-butyl-3-[[3,5-difluorophenyl)acetyl]amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398493-39-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-butyl-4,6-dihydro-3-[[2-oxo-1(2H)-pyrazinyl)acetyl]amino]- (9CI) (CA INDEX NAME)




RN 398493-40-8 CAPLUS

CN Benzeneacetamide, 4-(2-oxo-3-oxazolidinyl)-N-[1,4,5,6-tetrahydro-5-(2-pyridinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-41-9 CAPLUS

CN Benzeneacetamide, 4-(2-oxo-3-oxazolidinyl)-N-[1,4,5,6-tetrahydro-5-(2-thienylacetyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-42-0 CAPLUS

CN Benzeneacetamide, N-[5-(2-furanylcarbonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-(2-oxo-3-oxazolidinyl)- (9CI) (CA INDEX NAME)




RN 398493-43-1 CAPLUS

CN Benzeneacetamide, N-[5-(ethoxyacetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-(2-oxo-3-oxazolidinyl)- (9CI) (CA INDEX NAME)




RN 398493-44-2 CAPLUS

CN Benzeneacetamide, 4-(2-oxo-3-oxazolidinyl)-N-[1,4,5,6-tetrahydro-5-(3-methyl-1-oxobutyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-45-3 CAPLUS

CN Benzeneacetamide, 4-(2-oxo-3-oxazolidinyl)-N-[1,4,5,6-tetrahydro-5-(1-oxobutyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-46-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-N-(1-methylethyl)-3-[[[4-(2-oxo-3-oxazolidinyl)phenyl]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 398493-47-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-butyl-4,6-dihydro-3-[[[4-(2-oxo-3-oxazolidinyl)phenyl]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 398493-48-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 4,6-dihydro-3-[[[4-(2-oxo-3-oxazolidinyl)phenyl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 398493-49-7 CAPLUS

CN 2H-1,4-Benzoxazine-6-acetamide, 3,4,4a,8a-tetrahydro-3-oxo-N-[1,4,5,6-tetrahydro-5-[(1-methylethyl)amino]carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-50-0 CAPLUS


CN 2-Naphthaleneacetamide, N-[5-(4-chloro-2,5-difluorobenzoyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-51-1 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 4,6-dihydro-3-[(2-naphthalenylacetyl)amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 398493-52-2 CAPLUS
 CN 2-Naphthaleneacetamide, N-[1,4,5,6-tetrahydro-5-[(1-methylcyclopropyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398493-53-3 CAPLUS
 CN 2-Naphthaleneacetamide, N-[5-(cyclobutylcarbonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-54-4 CAPLUS
 CN 2-Naphthaleneacetamide, N-[5-(2-fluorobenzoyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-55-5 CAPLUS

CN 2-Naphthaleneacetamide, N-[1,4,5,6-tetrahydro-5-(3-pyridinylcarbonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-56-6 CAPLUS

CN 2-Naphthaleneacetamide, N-[1,4,5,6-tetrahydro-5-[(2,2,3,3-tetramethylcyclopropyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-57-7 CAPLUS

CN 2-Naphthaleneacetamide, N-[1,4,5,6-tetrahydro-5-(2,4,5-trifluorobenzoyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-58-8 CAPLUS

CN 2-Naphthaleneacetamide, N-[1,4,5,6-tetrahydro-5-(2-methyl-1-oxo-4-pentenyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-59-9 CAPLUS

CN 2-Naphthaleneacetamide, N-[5-(cyclopropylacetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-60-2 CAPLUS

CN 2-Naphthaleneacetamide, N-[5-(5-fluoro-2-methylbenzoyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-61-3 CAPLUS

CN 2-Naphthaleneacetamide, N-[5-[2-fluoro-5-(trifluoromethyl)benzoyl]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-62-4 CAPLUS

CN 2-Naphthaleneacetamide, N-[1,4,5,6-tetrahydro-5-[(3-methoxycyclohexyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-63-5 CAPLUS

CN 2-Naphthaleneacetamide, N-[5-(2,4-dichloro-5-fluorobenzoyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-64-6 CAPLUS

CN 2-Naphthaleneacetamide, N-[5-(2-chloro-4,5-difluorobenzoyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-65-7 CAPLUS

CN 2-Naphthaleneacetamide, N-[1,4,5,6-tetrahydro-5-[4-(1H-imidazol-1-yl)benzoyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-66-8 CAPLUS

CN 2-Naphthaleneacetamide, N-[5-[4-(aminosulfonyl)-1-oxobutyl]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-67-9 CAPLUS

CN 2-Naphthaleneacetamide, N-[1,4,5,6-tetrahydro-5-[(5,6,7,8-tetrahydro-8-oxo-2-naphthalenyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-68-0 CAPLUS

CN 2-Naphthaleneacetamide, N-[5-(2,2-dimethyl-1-oxopropyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-69-1 CAPLUS

CN 2-Naphthaleneacetamide, N-[1,4,5,6-tetrahydro-5-(1-oxo-2-butynyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-70-4 CAPLUS

CN 2-Naphthaleneacetamide, N-[1,4,5,6-tetrahydro-5-(3-iodo-4-methylbenzoyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-71-5 CAPLUS

CN 2-Naphthaleneacetamide, N-[1,4,5,6-tetrahydro-5-[(phenylmethoxy)acetyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-72-6 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[5-(fluorophenylacetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-73-7 CAPLUS

CN Benzamide, N-[5-(fluorophenylacetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-phenoxy- (9CI) (CA INDEX NAME)




RN 398493-74-8 CAPLUS

CN Benzamide, 4-(4-methyl-1-piperazinyl)-N-[1,4,5,6-tetrahydro-5-(2-thienylacetyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-75-9 CAPLUS

CN Benzamide, 4-(4-methyl-1-piperazinyl)-N-[1,4,5,6-tetrahydro-5-(3-methyl-1-oxobutyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-76-0 CAPLUS

CN Benzamide, N-[5-(2-furanylcarbonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 398493-77-1 CAPLUS

CN Benzamide, 4-(4-methyl-1-piperazinyl)-N-[1,4,5,6-tetrahydro-5-(phenylacetyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-78-2 CAPLUS


CN Benzamide, 4-(4-methyl-1-piperazinyl)-N-[1,4,5,6-tetrahydro-5-(phenylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-79-3 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-(2,6-diethylphenyl)-4,6-dihydro-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]- (9CI) (CA INDEX NAME)




RN 398493-80-6 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]- (9CI) (CA INDEX NAME)




RN 398493-81-7 CAPLUS
 CN Benzamide, N-[5-(fluorophenylacetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-(2-oxo-1-pyrrolidiny)- (9CI) (CA INDEX NAME)



RN 398493-82-8 CAPLUS
 CN 1,3-Benzodioxole-5-carboxamide, N-[1,4,5,6-tetrahydro-5-(2-thienylacetyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-83-9 CAPLUS
 CN 1,3-Benzodioxole-5-carboxamide, N-[1,4,5,6-tetrahydro-5-(3-methyl-1-oxobutyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-84-0 CAPLUS

CN 1,3-Benzodioxole-5-carboxamide, N-[5-(2-furanylacetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-85-1 CAPLUS

CN 1,3-Benzodioxole-5-carboxamide, N-[1,4,5,6-tetrahydro-5-(phenylacetyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-86-2 CAPLUS

CN 1,3-Benzodioxole-5-carboxamide, N-[1,4,5,6-tetrahydro-5-(phenylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-87-3 CAPLUS

CN 1,3-Benzodioxole-5-carboxamide, N-[1,4,5,6-tetrahydro-5-[[2-(trifluoromethyl)phenyl]sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-88-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(1,3-benzodioxol-5-ylcarbonyl)amino]-N-ethyl-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398493-89-5 CAPLUS

CN Benzamide, 4-fluoro-N-[4,5,6,7-tetrahydro-5-(phenylsulfonyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-90-8 CAPLUS

CN Benzamide, N-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)







RN 398493-91-9 CAPLUS


CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-(benzoylamino)-1,4,6,7-tetrahydro-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 398493-92-0 CAPLUS


CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1,4,6,7-tetrahydro-N-(1-methylethyl)-3-[(phenylacetyl)amino]- (9CI) (CA INDEX NAME)






RN 398493-97-5 CAPLUS

CN Benzamide, 4-phenoxy-N-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398493-98-6 CAPLUS

CN Benzamide, N-(5-benzoyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-4-phenoxy- (9CI) (CA INDEX NAME)




RN 398493-99-7 CAPLUS

CN Benzamide, 4-phenoxy-N-[4,5,6,7-tetrahydro-5-(phenylacetyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-00-3 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-[(4-fluorobenzoyl)amino]-1,4,6,7-tetrahydro-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 398494-01-4 CAPLUS

CN Benzamide, 4-fluoro-N-[5-(4-fluorobenzoyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-02-5 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-[[4-(1,1-dimethylethyl)benzoyl]amino]-1,4,6,7-tetrahydro-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 398494-03-6 CAPLUS

CN Benzamide, 4-fluoro-N-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-04-7 CAPLUS

CN Benzamide, 4-phenoxy-N-[4,5,6,7-tetrahydro-5-(phenylsulfonyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-05-8 CAPLUS

CN Benzamide, 4-phenoxy-N-[4,5,6,7-tetrahydro-5-[(phenylmethyl)sulfonyl]-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-06-9 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1,4,6,7-tetrahydro-3-[(4-phenoxybenzoyl)amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 398494-07-0 CAPLUS

CN Benzamide, 4-phenoxy-N-[4,5,6,7-tetrahydro-5-(8-quinolinylsulfonyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 398494-08-1 CAPLUS
 CN Benzamide, 4-phenoxy-N-[4,5,6,7-tetrahydro-5-(2-thienylacetyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)



IT 398494-09-2P 398494-10-5P 398494-11-6P
 398494-12-7P 398494-13-8P 398494-14-9P
 398494-15-0P 398494-16-1P 398494-17-2P
 398494-18-3P 398494-19-4P 398494-20-7P
 398494-21-8P 398494-22-9P 398494-23-0P
 398494-24-1P 398494-25-2P 398494-26-3P
 398494-27-4P 398494-28-5P 398494-29-6P
 398494-30-9P 398494-31-0P 398494-32-1P
 398494-33-2P 398494-34-3P 398494-36-5P
 398494-37-6P 398494-38-7P 398494-39-8P
 398494-40-1P 398494-41-2P 398494-42-3P
 398494-43-4P 398494-44-5P 398494-45-6P
 398494-46-7P 398494-47-8P 398494-48-9P
 398494-49-0P 398494-50-3P 398494-51-4P
 398494-52-5P 398494-53-6P, N-(5-Acetyl-4,5,6,7-
 tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-fluorobenzamide
 398494-54-7P 398494-55-8P 398494-56-9P
 398494-57-0P 398494-58-1P 398494-59-2P
 398494-60-5P 398494-61-6P 398494-62-7P
 398494-63-8P 398494-64-9P 398494-65-0P
 398494-66-1P 398494-67-2P 398494-68-3P
 398494-69-4P 398494-70-7P 398494-71-8P
 398494-72-9P 398494-73-0P 398494-74-1P
 398494-75-2P 398494-76-3P 398494-77-4P
 398494-78-5P 398494-79-6P 398494-80-9P
 398494-81-0P 398494-82-1P 398494-83-2P
 398494-84-3P 398494-85-4P 398494-86-5P
 398494-87-6P 398494-89-8P 398494-90-1P
 398494-91-2P 398494-92-3P 398494-93-4P
 398494-94-5P 398494-95-6P 398494-96-7P
 398494-97-8P 398494-98-9P 398494-99-0P
 398495-00-6P 398495-01-7P 398495-02-8P
 398495-03-9P 398495-04-0P 398495-05-1P
 398495-06-2P 398495-07-3P 398495-08-4P
 398495-09-5P 398495-10-8P 398495-11-9P
 398495-12-0P 398495-13-1P 398495-14-2P
 398495-15-3P 398495-16-4P 398495-17-5P
 398495-18-6P 398495-20-0P 398495-22-2P
 398495-23-3P 398495-24-4P 398495-25-5P
 398495-26-6P 398495-27-7P 398495-28-8P
 398495-29-9P 398495-30-2P 398495-31-3P

398495-32-4P 398495-33-5P 398495-34-6P
398495-35-7P 398495-36-8P 398495-37-9P
398495-38-0P 398495-39-1P 398495-40-4P
398495-41-5P 398495-43-7P 398495-45-9P
398495-46-0P 398495-47-1P 398495-48-2P
398495-49-3P 398495-50-6P 398495-51-7P
398495-52-8P 398495-53-9P 398495-54-0P
398495-55-1P 398495-56-2P 398495-57-3P
398495-58-4P 398495-59-5P 398495-60-8P
398495-61-9P 398495-62-0P 398495-63-1P
398495-64-2P 398495-68-6P 398495-69-7P
398495-70-0P 398495-71-1P 398495-72-2P
398495-73-3P 398495-74-4P 398495-75-5P
398495-77-7P 398495-79-9P 398495-80-2P
398495-81-3P 398495-82-4P 398495-83-5P
398495-84-6P 398495-85-7P 398495-86-8P
398495-88-0P 398495-89-1P, N-(5-Acetyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-phenoxybenzamide 398495-91-5P
398495-92-6P 398495-93-7P 398495-94-8P,
N-(5-Acetyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)cyclopropanecarboxamide 398495-95-9P, N-(5-Acetyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)isobutyramide 398495-96-0P,
N-(5-Acetyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)cyclopentanecarboxamide 398495-97-1P, N-(5-Acetyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)benzamide 398495-98-2P
398495-99-3P 398496-00-9P 398496-01-0P,
N-(5-Acetyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-methyl-2-furoic amide 398496-02-1P, N-(5-Acetyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-2-carboxamide 398496-03-2P,
N-(5-Acetyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-3-carboxamide 398496-04-3P 398496-05-4P
398496-06-5P 398496-07-6P 398496-08-7P,
N-(5-Acetyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-fluorobenzamide 398496-09-8P, N-(5-Acetyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-fluorobenzamide 398496-10-1P, N-(5-Acetyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-fluorobenzamide 398496-11-2P,
N-(5-Acetyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-2-acetamide 398496-12-3P, N-(5-Acetyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-3-acetamide 398496-13-4P
398496-14-5P, N-(5-Acetyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-cyanobenzamide 398496-15-6P, N-(5-Acetyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-cyanobenzamide 398496-16-7P
398496-17-8P 398496-18-9P 398496-20-3P
398496-21-4P, N-(5-Acetyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-phenylpropionamide 398496-22-5P 398496-23-6P
398496-24-7P 398496-25-8P 398496-26-9P,
N-(5-Acetyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-methoxybenzamide 398496-27-0P 398496-28-1P 398496-29-2P,
N-(5-Acetyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-fluorophenylacetamide 398496-30-5P, N-(5-Acetyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-fluorophenylacetamide 398496-31-6P
, N-(5-Acetyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-fluorophenylacetamide 398496-32-7P 398496-33-8P
398496-34-9P, N-(5-Acetyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-(2-thienyl)propanoic amide 398496-35-0P,
N-(5-Acetyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-chlorobenzamide 398496-36-1P, N-(5-Acetyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-chlorobenzamide 398496-37-2P, N-(5-Acetyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-chlorobenzamide 398496-38-3P
398496-39-4P, N-(5-Acetyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-acetylbenzamide 398496-40-7P, N-(5-Acetyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-acetylbenzamide 398496-41-8P,
N-(5-Acetyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-1-naphthoic amide


398496-42-9P, N-(5-Acetyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-naphthoic amide 398496-43-0P 398496-44-1P
 398496-45-2P, N-(5-Acetyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2,5-dimethoxybenzamide 398496-46-3P, N-(5-Acetyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2,6-dimethoxybenzamide 398496-47-4P
 , N-(5-Acetyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3,4-dimethoxybenzamide 398496-48-5P, N-(5-Acetyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3,5-dimethoxybenzamide 398496-49-6P
 398496-50-9P 398496-51-0P, N-(5-Acetyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-phenylbenzamide 398496-52-1P,
 N-(5-Benzyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)acetamide 398496-53-2P, N-(5-Benzyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)cyclopropanecarboxamide 398496-54-3P, N-(5-Benzyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)isobutyramide 398496-55-4P,
 N-(5-Benzyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)cyclopentanecarboxamide

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)

(kinase inhibitor; combinatorial preparation of bicyclo pyrazoles as kinase inhibitors for treatment of cancer and other proliferative disorders)


RN 398494-09-2 CAPLUS

CN Benzamide, 4-fluoro-N-[4,5,6,7-tetrahydro-5-(2-methyl-1-oxopropyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-10-5 CAPLUS

CN Benzamide, N-(5-benzoyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-4-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 398494-11-6 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[4,5,6,7-tetrahydro-5-(phenylsulfonyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-12-7 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-[[4-(1,1-dimethylethyl)benzoyl]amino]-1,4,6,7-tetrahydro-N-phenyl- (9CI) (CA INDEX NAME)




RN 398494-13-8 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[4,5,6,7-tetrahydro-5-(8-quinolinylsulfonyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-14-9 CAPLUS

CN Cyclopropanecarboxamide, N-[4,5,6,7-tetrahydro-5-[(phenylmethyl)sulfonyl]-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-15-0 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-[(cyclopropylcarbonyl)amino]-1,4,6,7-tetrahydro-N-phenyl- (9CI) (CA INDEX NAME)




RN 398494-16-1 CAPLUS

CN Cyclopropanecarboxamide, N-[4,5,6,7-tetrahydro-5-(2-thienylacetyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-17-2 CAPLUS

CN Cyclopropanecarboxamide, N-[4,5,6,7-tetrahydro-5-(8-quinolinylsulfonyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-18-3 CAPLUS

CN Benzamide, N-(5-acetyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-
(9CI) (CA INDEX NAME)




RN 398494-19-4 CAPLUS

CN Benzamide, N-(5-benzoyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-
(9CI) (CA INDEX NAME)




RN 398494-20-7 CAPLUS

CN Benzamide, N-[4,5,6,7-tetrahydro-5-(phenylacetyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-21-8 CAPLUS

CN Benzamide, N-[4,5,6,7-tetrahydro-5-(phenylsulfonyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-22-9 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-(benzoylamino)-N-butyl-1,4,6,7-tetrahydro- (9CI) (CA INDEX NAME)




RN 398494-23-0 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-(benzoylamino)-N-ethyl-1,4,6,7-tetrahydro- (9CI) (CA INDEX NAME)




RN 398494-24-1 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[5-(2-furanylcarbonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-25-2 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[4,5,6,7-tetrahydro-5-(2-thienylacetyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-26-3 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-(acetylamino)-1,4,6,7-tetrahydro-N-phenyl- (9CI) (CA INDEX NAME)




RN 398494-27-4 CAPLUS

CN Acetamide, N-[4,5,6,7-tetrahydro-5-(phenylacetyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-28-5 CAPLUS

CN Acetamide, N-[4,5,6,7-tetrahydro-5-(phenylsulfonyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-29-6 CAPLUS

CN Acetamide, N-[4,5,6,7-tetrahydro-5-[(phenylmethyl)sulfonyl]-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-30-9 CAPLUS

CN Acetamide, N-(5-benzoyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-
(9CI) (CA INDEX NAME)




RN 398494-31-0 CAPLUS

CN Acetamide, N-[4,5,6,7-tetrahydro-5-(8-quinolinylsulfonyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-32-1 CAPLUS

CN Benzamide, 4-fluoro-N-[4,5,6,7-tetrahydro-5-(8-quinolinylsulfonyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-33-2 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[4,5,6,7-tetrahydro-5-(phenylacetyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-34-3 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[4,5,6,7-tetrahydro-5-[(phenylmethyl)sulfonyl]-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-36-5 CAPLUS

CN Acetamide, N-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-37-6 CAPLUS

CN Acetamide, N-(5-acetyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 398494-38-7 CAPLUS

CN Acetamide, N-[4,5,6,7-tetrahydro-5-(2-thienylacetyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-39-8 CAPLUS

CN Benzamide, N-(5-benzoyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-4-fluoro- (9CI) (CA INDEX NAME)




RN 398494-40-1 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-41-2 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[4,5,6,7-tetrahydro-5-(1-naphthalenylcarbonyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-42-3 CAPLUS

CN Benzamide, 4-fluoro-N-[4,5,6,7-tetrahydro-5-[(phenylmethyl)sulfonyl]-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-43-4 CAPLUS

CN Benzamide, 4-fluoro-N-[4,5,6,7-tetrahydro-5-(phenylacetyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-44-5 CAPLUS

CN Benzamide, 3-methoxy-N-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-45-6 CAPLUS

CN Benzamide, 3-methoxy-N-[4,5,6,7-tetrahydro-5-(8-quinolinylsulfonyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-46-7 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-(benzoylamino)-1,4,6,7-tetrahydro-N-phenyl- (9CI) (CA INDEX NAME)




RN 398494-47-8 CAPLUS

CN Benzeneacetamide, N-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-48-9 CAPLUS

CN Benzamide, N-[4,5,6,7-tetrahydro-5-(2-thienylacetyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 398494-49-0 CAPLUS


CN Benzamide, N-[4,5,6,7-tetrahydro-5-(8-quinolinylsulfonyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 398494-50-3 CAPLUS


CN Benzamide, 3-fluoro-N-[4,5,6,7-tetrahydro-5-(methylsulfonyl)-1H-

pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-51-4 CAPLUS

CN Benzamide, 3-fluoro-N-[4,5,6,7-tetrahydro-5-[(phenylmethyl)sulfonyl]-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-52-5 CAPLUS

CN Benzamide, 3-fluoro-N-[4,5,6,7-tetrahydro-5-(phenylacetyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-53-6 CAPLUS

CN Benzamide, N-(5-acetyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-fluoro- (9CI) (CA INDEX NAME)




RN 398494-54-7 CAPLUS

CN Benzamide, N-(5-benzoyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-fluoro- (9CI) (CA INDEX NAME)




RN 398494-55-8 CAPLUS

CN Benzamide, 3-fluoro-N-[4,5,6,7-tetrahydro-5-(phenylsulfonyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-56-9 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-[(3-fluorobenzoyl)amino]-1,4,6,7-tetrahydro-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 398494-57-0 CAPLUS

CN Benzamide, 3-phenoxy-N-[4,5,6,7-tetrahydro-5-(phenylsulfonyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-58-1 CAPLUS

CN Benzamide, N-(5-benzoyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-phenoxy- (9CI) (CA INDEX NAME)




RN 398494-59-2 CAPLUS

CN Benzamide, 3-phenoxy-N-[4,5,6,7-tetrahydro-5-[(phenylmethyl)sulfonyl]-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-60-5 CAPLUS

CN Benzamide, 3-phenoxy-N-[4,5,6,7-tetrahydro-5-(1-naphthalenylcarbonyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 398494-61-6 CAPLUS


CN Benzamide, 3-phenoxy-N-[4,5,6,7-tetrahydro-5-(phenylacetyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 398494-62-7 CAPLUS


CN Benzamide, 3-phenoxy-N-[4,5,6,7-tetrahydro-5-(2-thienylacetyl)-1H-

pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-63-8 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[4,5,6,7-tetrahydro-5-(2-quinoxalinylylcarbonyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 398494-64-9 CAPLUS


CN Benzamide, 3-phenoxy-N-[4,5,6,7-tetrahydro-5-(2-quinoxalinylylcarbonyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 398494-65-0 CAPLUS


CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1,4,6,7-tetrahydro-3-[(3-

phenoxybenzoyl)amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 398494-66-1 CAPLUS

CN Benzeneacetamide, N-(5-benzoyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 398494-67-2 CAPLUS

CN Benzeneacetamide, N-[4,5,6,7-tetrahydro-5-(phenylacetyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-68-3 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1,4,6,7-tetrahydro-3-[(phenylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398494-69-4 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, N-butyl-1,4,6,7-tetrahydro-3-[(phenylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398494-70-7 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, N-ethyl-1,4,6,7-tetrahydro-3-[(phenylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398494-71-8 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1,4,6,7-tetrahydro-N-phenyl-3-[(phenylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398494-72-9 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1,4,6,7-tetrahydro-3-[(phenylacetyl)amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398494-73-0 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, N-ethyl-1,4,6,7-tetrahydro-3-[(2-naphthalenylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398494-74-1 CAPLUS

CN 2-Naphthaleneacetamide, N-[4,5,6,7-tetrahydro-5-(2-methoxybenzoyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-75-2 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1,4,6,7-tetrahydro-3-[(2-naphthalenylacetyl)amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 398494-76-3 CAPLUS

CN 2-Naphthaleneacetamide, N-(5-benzoyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 398494-77-4 CAPLUS

CN 2-Naphthaleneacetamide, N-[4,5,6,7-tetrahydro-5-(phenylacetyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-78-5 CAPLUS

CN 2-Naphthaleneacetamide, N-(5-acetyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 398494-79-6 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, N-butyl-1,4,6,7-tetrahydro-3-[(2-naphthalenylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398494-80-9 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1,4,6,7-tetrahydro-3-[(2-naphthalenylacetyl)amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398494-81-0 CAPLUS

CN 2-Naphthaleneacetamide, N-[5-(2-furanylcarbonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-82-1 CAPLUS

CN Butanamide, N-(5-acetyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-methyl- (9CI) (CA INDEX NAME)




RN 398494-83-2 CAPLUS

CN Butanamide, N-(5-benzoyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-methyl- (9CI) (CA INDEX NAME)




RN 398494-84-3 CAPLUS

CN Butanamide, 3-methyl-N-[4,5,6,7-tetrahydro-5-(phenylacetyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-85-4 CAPLUS

CN Butanamide, N-[5-(2-furanylcarbonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 398494-86-5 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1,4,6,7-tetrahydro-N-(1-methylethyl)-3-[(3-methyl-1-oxobutyl)amino]- (9CI) (CA INDEX NAME)




RN 398494-87-6 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1,4,6,7-tetrahydro-3-[(3-methyl-1-oxobutyl)amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398494-89-8 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, N-butyl-1,4,6,7-tetrahydro-3-[(3-methyl-1-oxobutyl)amino]- (9CI) (CA INDEX NAME)




RN 398494-90-1 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1,4,6,7-tetrahydro-3-[(3-methyl-1-oxobutyl)amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 398494-91-2 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, N-ethyl-1,4,6,7-tetrahydro-3-[(3-methyl-1-oxobutyl)amino]- (9CI) (CA INDEX NAME)




RN 398494-92-3 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-[[[1,1'-biphenyl]-4-ylacetyl]amino]-N-ethyl-1,4,6,7-tetrahydro- (9CI) (CA INDEX NAME)




RN 398494-93-4 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-[[[1,1'-biphenyl]-4-ylacetyl]amino]-1,4,6,7-tetrahydro-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 398494-94-5 CAPLUS

CN [1,1'-Biphenyl]-4-acetamide, N-(5-benzoyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 398494-95-6 CAPLUS

CN [1,1'-Biphenyl]-4-acetamide, N-[5-(2-furanylcarbonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-96-7 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-[[[1,1'-biphenyl]-4-ylacetyl)amino]-1,4,6,7-tetrahydro-N-propyl- (9CI) (CA INDEX NAME)




RN 398494-97-8 CAPLUS


CN [1,1'-Biphenyl]-4-acetamide, N-[4,5,6,7-tetrahydro-5-(2-methoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398494-98-9 CAPLUS
 CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-[[[1,1'-biphenyl]-4-ylacetyl)amino]-1,4,6,7-tetrahydro-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398494-99-0 CAPLUS
 CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-[[[1,1'-biphenyl]-4-ylacetyl)amino]-1,4,6,7-tetrahydro-N-phenyl- (9CI) (CA INDEX NAME)



RN 398495-00-6 CAPLUS
 CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1,4,6,7-tetrahydro-N-(1-methylethyl)-3-[[[4-(2-oxo-1-pyrrolidinyl)phenyl]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 398495-01-7 CAPLUS
 CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, N-ethyl-1,4,6,7-tetrahydro-3-[[2-(2-naphthalenyl)-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)




RN 398495-02-8 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1,4,6,7-tetrahydro-N-(1-methylethyl)-3-[[2-(2-naphthalenyl)-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)




RN 398495-03-9 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, N-butyl-1,4,6,7-tetrahydro-3-[[2-(2-naphthalenyl)-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)




RN 398495-04-0 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1,4,6,7-tetrahydro-3-[[2-(2-naphthalenyl)-1-oxopropyl]amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 398495-05-1 CAPLUS


CN Propanamide, N-[5-(2-furanylcarbonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 398495-06-2 CAPLUS


CN Benzeneacetamide, 4-(2-oxo-1-pyrrolidinyl)-N-[4,5,6,7-tetrahydro-5-(2-

methoxybenzoyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398495-07-3 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, N-ethyl-3-[[2-(2-fluoro[1,1'-biphenyl]-4-yl)-1-oxopropyl]amino]-1,4,6,7-tetrahydro- (9CI) (CA INDEX NAME)




RN 398495-08-4 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-[[2-(2-fluoro[1,1'-biphenyl]-4-yl)-1-oxopropyl]amino]-1,4,6,7-tetrahydro-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 398495-09-5 CAPLUS


CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, N-butyl-3-[[2-(2-fluoro[1,1'-biphenyl]-4-yl)-1-oxopropyl]amino]-1,4,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 398495-10-8 CAPLUS


CN [1,1'-Biphenyl]-4-acetamide, 2-fluoro-N-[5-(2-furanylcarbonyl)-4,5,6,7-

tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]- α -methyl- (9CI) (CA INDEX NAME)




RN 398495-11-9 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1,4,6,7-tetrahydro-N-(1-methylethyl)-3-[[1-(4-fluorophenyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 398495-12-0 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-[(1,3-benzodioxol-5-ylacetyl)amino]-1,4,6,7-tetrahydro-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 398495-13-1 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-[(1,3-benzodioxol-5-ylacetyl)amino]-1,4,6,7-tetrahydro-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 398495-14-2 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, N-ethyl-1,4,6,7-tetrahydro-3-[[2-(6-methoxy-2-naphthalenyl)-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)




RN 398495-15-3 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1,4,6,7-tetrahydro-3-[[2-(6-methoxy-2-naphthalenyl)-1-oxopropyl]amino]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 398495-16-4 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, N-butyl-1,4,6,7-tetrahydro-3-[[2-(6-methoxy-2-naphthalenyl)-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)




RN 398495-17-5 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1,4,6,7-tetrahydro-3-[[2-(6-methoxy-2-naphthalenyl)-1-oxopropyl]amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398495-18-6 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-[(3-fluorobenzoyl)amino]-1,4,6,7-tetrahydro-N-phenyl- (9CI) (CA INDEX NAME)




RN 398495-20-0 CAPLUS

CN Cyclopropanecarboxamide, N-[4,5,6,7-tetrahydro-5-(phenylsulfonyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398495-22-2 CAPLUS

CN Benzamide, 3-fluoro-N-[4,5,6,7-tetrahydro-5-(8-quinolinylsulfonyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398495-23-3 CAPLUS

CN Benzamide, N-[4,5,6,7-tetrahydro-5-[(phenylmethyl)sulfonyl]-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398495-24-4 CAPLUS

CN Benzamide, 3-bromo-N-[4,5,6,7-tetrahydro-5-(phenylsulfonyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398495-25-5 CAPLUS

CN Benzamide, 3-bromo-N-[4,5,6,7-tetrahydro-5-[(phenylmethyl)sulfonyl]-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398495-26-6 CAPLUS

CN Benzamide, 3-bromo-N-[5-[(4-fluorophenyl)sulfonyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398495-27-7 CAPLUS

CN Benzamide, 3-bromo-N-[4,5,6,7-tetrahydro-5-[[3-(trifluoromethyl)phenyl]sulfonyl]-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI)
(CA INDEX NAME)




RN 398495-28-8 CAPLUS

CN Benzamide, 3-bromo-N-[4,5,6,7-tetrahydro-5-[(4-methylphenyl)sulfonyl]-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398495-29-9 CAPLUS

CN Benzamide, 3-bromo-N-[4,5,6,7-tetrahydro-5-[(4-methoxyphenyl)sulfonyl]-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398495-30-2 CAPLUS

CN Benzamide, 3-bromo-N-[5-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398495-31-3 CAPLUS

CN Benzamide, 3-bromo-N-[5-[(4-chlorophenyl)sulfonyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398495-32-4 CAPLUS

CN Benzamide, 3-bromo-N-[4,5,6,7-tetrahydro-5-(2-naphthalenylsulfonyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398495-33-5 CAPLUS

CN Benzamide, 4-fluoro-N-[4,5,6,7-tetrahydro-5-(2-thienylacetyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398495-34-6 CAPLUS

CN Benzamide, 3-methoxy-N-[4,5,6,7-tetrahydro-5-(2-thienylacetyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398495-35-7 CAPLUS

CN Benzamide, N-[5-(1,3-benzodioxol-5-ylcarbonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-4-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 398495-36-8 CAPLUS

CN Benzamide, N-[5-(1,3-benzodioxol-5-ylcarbonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 398495-37-9 CAPLUS

CN Benzamide, N-[5-(1,3-benzodioxol-5-ylcarbonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-3-phenoxy- (9CI) (CA INDEX NAME)




RN 398495-38-0 CAPLUS

CN Benzamide, 3-methoxy-N-[4,5,6,7-tetrahydro-5-(phenylacetyl)-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398495-39-1 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1,4,6,7-tetrahydro-3-[(3-methoxybenzoyl)amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398495-40-4 CAPLUS

CN Benzamide, 3-methoxy-N-[4,5,6,7-tetrahydro-5-[(phenylmethyl)sulfonyl]-1H-pyrazolo[4,3-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398495-41-5 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1,4,6,7-tetrahydro-3-[(3-methoxybenzoyl)amino]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 398495-43-7 CAPLUS

CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 1,4,6,7-tetrahydro-N-(1-methylethyl)-3-[[2-(4-methoxyphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)




RN 398495-45-9 CAPLUS

CN Benzamide, N-(5-acetyl-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl)-3-bromo- (9CI) (CA INDEX NAME)




RN 398495-46-0 CAPLUS

CN 2-Naphthaleneacetamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-(2-thienylacetyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398495-47-1 CAPLUS

CN Cyclopropanecarboxamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-(2-thienylacetyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398495-48-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-6,6-dimethyl-3-[(2-naphthalenylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398495-49-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(cyclopropylcarbonyl)amino]-N-ethyl-4,6-dihydro-6,6-dimethyl- (9CI) (CA INDEX NAME)




RN 398495-50-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-3-[[4-(4-fluorophenyl)acetyl]amino]-4,6-dihydro-6,6-dimethyl- (9CI) (CA INDEX NAME)




RN 398495-51-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[[4-(1,1-dimethylethyl)phenyl]acetyl]amino]-N-ethyl-4,6-dihydro-6,6-dimethyl- (9CI) (CA INDEX NAME)




RN 398495-52-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-butyl-4,6-dihydro-6,6-dimethyl-3-[(2-naphthalenylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398495-53-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-butyl-3-[(cyclopropylcarbonyl)amino]-4,6-dihydro-6,6-dimethyl- (9CI) (CA INDEX NAME)




RN 398495-54-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-butyl-3-[[4-(4-fluorophenyl)acetyl]amino]-4,6-dihydro-6,6-dimethyl- (9CI) (CA INDEX NAME)




RN 398495-55-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-butyl-3-[[[4-(1,1-dimethylethyl)phenyl]acetyl]amino]-4,6-dihydro-6,6-dimethyl- (9CI) (CA INDEX NAME)




RN 398495-56-2 CAPLUS

CN 6H-Pyrazolo[3,4-c]pyridine-6-carboxamide, 3-[[4-(1,1-dimethylethyl)benzoyl]amino]-1,4,5,7-tetrahydro-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 398495-57-3 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[4,5,6,7-tetrahydro-6-(2-thienylacetyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398495-58-4 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[4,5,6,7-tetrahydro-6-(methylsulfonyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398495-59-5 CAPLUS

CN 6H-Pyrazolo[3,4-c]pyridine-6-carboxamide, 3-[[4-(1,1-dimethylethyl)benzoyl]amino]-N-ethyl-1,4,5,7-tetrahydro- (9CI) (CA INDEX NAME)




RN 398495-60-8 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[4,5,6,7-tetrahydro-6-(3-methyl-1-oxobutyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398495-61-9 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[6-(2-furanylcarbonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398495-62-0 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[4,5,6,7-tetrahydro-6-(phenylacetyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398495-63-1 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[4,5,6,7-tetrahydro-6-(8-quinolinylsulfonyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398495-64-2 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-5-[2-(2-thienyl)ethyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398495-68-6 CAPLUS

CN 1,3-Benzodioxole-5-carboxamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 398495-69-7 CAPLUS

CN Butanamide, N-[5-(1,3-benzodioxol-5-ylacetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 398495-70-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(3-bromobenzoyl)amino]-4,6-dihydro-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 398495-71-1 CAPLUS

CN Benzamide, 3-bromo-N-[1,4,5,6-tetrahydro-5-(phenylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398495-72-2 CAPLUS

CN Benzamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-4-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 398495-73-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(3-bromobenzoyl)amino]-N-ethyl-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398495-74-4 CAPLUS

CN Benzamide, 4-methyl-N-[1,4,5,6-tetrahydro-5-(8-quinolinylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398495-75-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(3-bromobenzoyl)amino]-4,6-dihydro-N-phenyl- (9CI) (CA INDEX NAME)




RN 398495-77-7 CAPLUS

CN Benzamide, 3-bromo-N-[1,4,5,6-tetrahydro-5-(2-oxo-2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398495-79-9 CAPLUS

CN Benzamide, 3-bromo-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398495-80-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-N-(1-methylethyl)-3-[[4-(2-oxo-1-pyrrolidinyl)benzoyl]amino]- (9CI) (CA INDEX NAME)




RN 398495-81-3 CAPLUS

CN Benzamide, 4-methyl-N-[1,4,5,6-tetrahydro-5-(8-quinolinylcarbonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398495-82-4 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-[1,4,5,6-tetrahydro-5-(1-naphthalenylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398495-83-5 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-[1,4,5,6-tetrahydro-5-(1-naphthalenylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398495-84-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-([(1,1'-biphenyl]-4-ylcarbonyl)amino]-4,6-dihydro-N-phenyl- (9CI) (CA INDEX NAME)




RN 398495-85-7 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-[1,4,5,6-tetrahydro-5-(2-oxo-2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398495-86-8 CAPLUS

CN Benzamide, 4-methyl-N-[1,4,5,6-tetrahydro-5-(1-naphthalenylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398495-88-0 CAPLUS

CN Benzamide, 4-methyl-N-[1,4,5,6-tetrahydro-5-(1-naphthalenylcarbonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398495-89-1 CAPLUS

CN Benzamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-3-phenoxy- (9CI) (CA INDEX NAME)




RN 398495-91-5 CAPLUS

CN 2-Naphthaleneacetamide, N-[5-(1,2-dioxopropyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398495-92-6 CAPLUS

CN Benzamide, N-[5-[(2-fluorophenyl)acetyl]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 398495-93-7 CAPLUS

CN Acetamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-
(9CI) (CA INDEX NAME)




RN 398495-94-8 CAPLUS

CN Cyclopropanecarboxamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 398495-95-9 CAPLUS

CN Propanamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-2-methyl- (9CI) (CA INDEX NAME)




RN 398495-96-0 CAPLUS

CN Cyclopentanecarboxamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 398495-97-1 CAPLUS

CN Benzamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-
(9CI) (CA INDEX NAME)




RN 398495-98-2 CAPLUS

CN 2-Pyridinecarboxamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 398495-99-3 CAPLUS

CN 3-Pyridinecarboxamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 398496-00-9 CAPLUS

CN 4-Pyridinecarboxamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 398496-01-0 CAPLUS

CN 2-Furancarboxamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-3-methyl- (9CI) (CA INDEX NAME)




RN 398496-02-1 CAPLUS

CN 2-Thiophenecarboxamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 398496-03-2 CAPLUS

CN 3-Thiophenecarboxamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 398496-04-3 CAPLUS

CN Benzamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-2-methyl- (9CI) (CA INDEX NAME)




RN 398496-05-4 CAPLUS

CN Benzamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-3-methyl- (9CI) (CA INDEX NAME)




RN 398496-06-5 CAPLUS

CN Benzamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-4-methyl- (9CI) (CA INDEX NAME)




RN 398496-07-6 CAPLUS

CN Benzamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)




RN 398496-08-7 CAPLUS

CN Benzamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-2-fluoro- (9CI) (CA INDEX NAME)




RN 398496-09-8 CAPLUS

CN Benzamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-3-fluoro- (9CI) (CA INDEX NAME)




RN 398496-10-1 CAPLUS

CN Benzamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-4-fluoro- (9CI) (CA INDEX NAME)




RN 398496-11-2 CAPLUS

CN 2-Thiopheneacetamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 398496-12-3 CAPLUS

CN 3-Thiopheneacetamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 398496-13-4 CAPLUS

CN 2-Propynamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-3-phenyl- (9CI) (CA INDEX NAME)




RN 398496-14-5 CAPLUS

CN Benzamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-3-cyano- (9CI) (CA INDEX NAME)



RN 398496-15-6 CAPLUS


CN Benzamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-4-cyano- (9CI) (CA INDEX NAME)



RN 398496-16-7 CAPLUS

CN 2-Propenamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-3-phenyl-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 398496-17-8 CAPLUS


CN 2-Propenamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-3-phenyl-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 398496-18-9 CAPLUS

CN 2-Propenamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 398496-20-3 CAPLUS

CN 2-Propenamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 398496-21-4 CAPLUS

CN Benzeneacetamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)- α -methyl- (9CI) (CA INDEX NAME)




RN 398496-22-5 CAPLUS

CN Benzeneacetamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-2-methyl- (9CI) (CA INDEX NAME)




RN 398496-23-6 CAPLUS

CN Benzeneacetamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-3-methyl- (9CI) (CA INDEX NAME)




RN 398496-24-7 CAPLUS

CN Benzeneacetamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-4-methyl- (9CI) (CA INDEX NAME)



RN 398496-25-8 CAPLUS


CN Benzeneacetamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)



RN 398496-26-9 CAPLUS


CN Benzamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-3-

methoxy- (9CI) (CA INDEX NAME)




RN 398496-27-0 CAPLUS

CN Benzamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-4-methoxy- (9CI) (CA INDEX NAME)




RN 398496-28-1 CAPLUS

CN Acetamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-2-phenoxy- (9CI) (CA INDEX NAME)




RN 398496-29-2 CAPLUS

CN Benzeneacetamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-2-fluoro- (9CI) (CA INDEX NAME)




RN 398496-30-5 CAPLUS

CN Benzeneacetamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-3-fluoro- (9CI) (CA INDEX NAME)




RN 398496-31-6 CAPLUS

CN Benzeneacetamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-4-fluoro- (9CI) (CA INDEX NAME)




RN 398496-32-7 CAPLUS

CN 2-Propenamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-3-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 398496-33-8 CAPLUS

CN 2-Propenamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-3-(3-thienyl)- (9CI) (CA INDEX NAME)




RN 398496-34-9 CAPLUS

CN 2-Thiophenepropanamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)- (9CI) (CA INDEX NAME)



RN 398496-35-0 CAPLUS


CN Benzamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-2-chloro- (9CI) (CA INDEX NAME)



RN 398496-36-1 CAPLUS


CN Benzamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-3-chloro- (9CI) (CA INDEX NAME)

chloro- (9CI) (CA INDEX NAME)




RN 398496-37-2 CAPLUS

CN Benzamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-4-chloro- (9CI) (CA INDEX NAME)




RN 398496-38-3 CAPLUS

CN 1-Piperidinepropanamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 398496-39-4 CAPLUS

CN Benzamide, 2-acetyl-N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)- (9CI) (CA INDEX NAME)



RN 398496-40-7 CAPLUS


CN Benzamide, 4-acetyl-N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)- (9CI) (CA INDEX NAME)



RN 398496-41-8 CAPLUS


CN 1-Naphthalenecarboxamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-

c]pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 398496-42-9 CAPLUS

CN 2-Naphthalenecarboxamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 398496-43-0 CAPLUS

CN Benzenecarboxamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-γ-oxo- (9CI) (CA INDEX NAME)




RN 398496-44-1 CAPLUS

CN Benzamide, 4-(acetylamino)-N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 398496-45-2 CAPLUS

CN Benzamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-2,5-dimethoxy- (9CI) (CA INDEX NAME)




RN 398496-46-3 CAPLUS

CN Benzamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-2,6-dimethoxy- (9CI) (CA INDEX NAME)




RN 398496-47-4 CAPLUS

CN Benzamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-3,4-dimethoxy- (9CI) (CA INDEX NAME)




RN 398496-48-5 CAPLUS

CN Benzamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-3,5-dimethoxy- (9CI) (CA INDEX NAME)




RN 398496-49-6 CAPLUS


CN 2-Thiophenebutanamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-γ-oxo- (9CI) (CA INDEX NAME)




RN 398496-50-9 CAPLUS
 CN 1-Naphthaleneacetamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 398496-51-0 CAPLUS
 CN [1,1'-Biphenyl]-4-carboxamide, N-(5-acetyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 398496-52-1 CAPLUS
 CN Acetamide, N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398496-53-2 CAPLUS
 CN Cyclopropanecarboxamide, N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398496-54-3 CAPLUS
 CN Propanamide, 2-methyl-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398496-55-4 CAPLUS

CN Cyclopentanecarboxamide, N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



IT 398496-56-5P, N-(5-Benzyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)benzamide 398496-57-6P 398496-58-7P
 398496-59-8P 398496-60-1P, N-(5-Benzyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-methyl-2-furoic amide 398496-61-2P
 , N-(5-Benzyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-2-carboxamide 398496-62-3P, N-(5-Benzyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-3-carboxamide 398496-63-4P
 398496-64-5P 398496-65-6P 398496-66-7P,
 N-(5-Benzyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)phenylacetamide
 398496-67-8P 398496-68-9P, N-(5-Benzyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-fluorobenzamide 398496-69-0P,
 N-(5-Benzyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-fluorobenzamide
 398496-70-3P, N-(5-Benzyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-fluorobenzamide 398496-71-4P, N-(5-Benzyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-2-acetamide 398496-72-5P,
 N-(5-Benzyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-3-acetamide 398496-73-6P 398496-74-7P,
 N-(5-Benzyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-cyanobenzamide
 398496-75-8P, N-(5-Benzyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-cyanobenzamide 398496-76-9P 398496-77-0P
 398496-78-1P 398496-79-2P, N-(5-Benzyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-phenylpropionamide 398496-80-5P
 398496-81-6P 398496-82-7P 398496-83-8P
 398496-84-9P, N-(5-Benzyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-methoxybenzamide 398496-85-0P 398496-86-1P
 398496-87-2P 398496-88-3P 398496-89-4P
 398496-90-7P 398496-91-8P 398496-92-9P,
 N-(5-Benzyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-(2-thienyl)propanoic amide 398496-93-0P, N-(5-Benzyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-chlorobenzamide 398496-94-1P,
 N-(5-Benzyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-chlorobenzamide
 398496-95-2P, N-(5-Benzyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-chlorobenzamide 398496-97-4P 398496-99-6P,
 N-(5-Benzyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-acetylbenzamide
 398497-00-2P, N-(5-Benzyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-acetylbenzamide 398497-01-3P, N-(5-Benzyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-1-naphthoic amide 398497-03-5P,
 N-(5-Benzyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-naphthoic amide
 398497-05-7P 398497-06-8P 398497-07-9P,
 N-(5-Benzyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2,5-dimethoxybenzamide 398497-09-1P, N-(5-Benzyl-4,6-dihydro-1H-

pyrrolo[3,4-c]pyrazol-3-yl)-2,6-dimethoxybenzamide 398497-11-5P,
N-(5-Benzyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3,4-
dimethoxybenzamide 398497-12-6P, N-(5-Benzyl-4,6-dihydro-1H-
pyrrolo[3,4-c]pyrazol-3-yl)-3,5-dimethoxybenzamide 398497-13-7P
398497-14-8P 398497-15-9P 398497-16-0P,
N-(5-Benzyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-phenylbenzamide
398497-17-1P 398497-18-2P 398497-19-3P
398497-20-6P 398497-21-7P 398497-22-8P
398497-24-0P 398497-25-1P 398497-26-2P,
N-(5-Phenethyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-methyl-2-
furoic amide 398497-28-4P, N-(5-Phenethyl-4,6-dihydro-1H-
pyrrolo[3,4-c]pyrazol-3-yl)thiophene-2-carboxamide 398497-29-5P,
N-(5-Phenethyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-3-
carboxamide 398497-30-8P 398497-31-9P
398497-32-0P 398497-33-1P, N-(5-Phenethyl-4,6-dihydro-1H-
pyrrolo[3,4-c]pyrazol-3-yl)phenylacetamide 398497-34-2P
398497-35-3P, N-(5-Phenethyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-
3-yl)-2-fluorobenzamide 398497-36-4P, N-(5-Phenethyl-4,6-dihydro-
1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-fluorobenzamide 398497-37-5P,
N-(5-Phenethyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-
fluorobenzamide 398497-38-6P, N-(5-Phenethyl-4,6-dihydro-1H-
pyrrolo[3,4-c]pyrazol-3-yl)thiophene-2-acetamide 398497-39-7P,
N-(5-Phenethyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-3-
acetamide 398497-40-0P 398497-41-1P,
N-(5-Phenethyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-cyanobenzamide
398497-42-2P, N-(5-Phenethyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-
3-yl)-4-cyanobenzamide 398497-43-3P 398497-44-4P
398497-45-5P 398497-46-6P 398497-47-7P,
N-(5-Phenethyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-
phenylpropionamide 398497-48-8P 398497-49-9P
398497-50-2P 398497-51-3P 398497-52-4P,
N-(5-Phenethyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-
methoxybenzamide 398497-53-5P 398497-54-6P
398497-55-7P, N-(5-Phenethyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-
3-yl)-2-fluorophenylacetamide 398497-56-8P, N-(5-Phenethyl-4,6-
dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-fluorophenylacetamide
398497-57-9P, N-(5-Phenethyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-
3-yl)-4-fluorophenylacetamide 398497-58-0P 398497-59-1P
398497-60-4P, N-(5-Phenethyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-
3-yl)-3-(2-thienyl)propanoic amide 398497-61-5P,
N-(5-Phenethyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-
chlorobenzamide 398497-62-6P, N-(5-Phenethyl-4,6-dihydro-1H-
pyrrolo[3,4-c]pyrazol-3-yl)-3-chlorobenzamide 398497-63-7P,
N-(5-Phenethyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-
chlorobenzamide 398497-64-8P 398497-66-0P,
N-(5-Phenethyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-
acetylbenzamide 398497-68-2P, N-(5-Phenethyl-4,6-dihydro-1H-
pyrrolo[3,4-c]pyrazol-3-yl)-4-acetylbenzamide 398497-69-3P,
N-(5-Phenethyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-1-naphthoic
amide 398497-70-6P, N-(5-Phenethyl-4,6-dihydro-1H-pyrrolo[3,4-
c]pyrazol-3-yl)-2-naphthoic amide 398497-71-7P
398497-72-8P 398497-74-0P, N-(5-Phenethyl-4,6-dihydro-1H-
pyrrolo[3,4-c]pyrazol-3-yl)-2,5-dimethoxybenzamide 398497-76-2P,
N-(5-Phenethyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2,6-
dimethoxybenzamide 398497-78-4P, N-(5-Phenethyl-4,6-dihydro-1H-
pyrrolo[3,4-c]pyrazol-3-yl)-3,4-dimethoxybenzamide 398497-80-8P,
N-(5-Phenethyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3,5-
dimethoxybenzamide 398497-82-0P 398497-83-1P
398497-85-3P 398497-86-4P, N-(5-Phenethyl-4,6-dihydro-1H-
pyrrolo[3,4-c]pyrazol-3-yl)-4-phenylbenzamide 398497-87-5P
398497-89-7P 398497-90-0P, N-(5-Methylsulfonyl-4,6-
dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)isobutyramide 398497-91-1P
, N-(5-Methylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-

yl)cyclopentanecarboxamide 398497-92-2P, N-(5-Methylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)benzamide 398497-93-3P
398497-94-4P 398497-95-5P 398497-96-6P,
N-(5-Methylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-methyl-2-furoic amide 398497-97-7P, N-(5-Methylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-2-carboxamide 398497-98-8P,
N-(5-Methylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-3-carboxamide 398497-99-9P 398498-00-5P
398498-01-6P 398498-02-7P, N-(5-Methylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)phenylacetamide 398498-03-8P
398498-04-9P, N-(5-Methylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-fluorobenzamide 398498-05-0P,
N-(5-Methylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-fluorobenzamide 398498-06-1P, N-(5-Methylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-fluorobenzamide 398498-07-2P,
N-(5-Methylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-2-acetamide 398498-08-3P, N-(5-Methylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-3-acetamide 398498-09-4P
398498-10-7P, N-(5-Methylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-cyanobenzamide 398498-11-8P,
N-(5-Methylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-cyanobenzamide 398498-12-9P 398498-13-0P
398498-14-1P 398498-15-2P 398498-16-3P,
N-(5-Methylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-phenylpropionamide 398498-17-4P 398498-18-5P
398498-19-6P 398498-20-9P, N-(5-Methylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-methoxybenzamide
398498-21-0P 398498-22-1P 398498-23-2P,
N-(5-Methylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-fluorophenylacetamide 398498-24-3P, N-(5-Methylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-fluorophenylacetamide
398498-26-5P, N-(5-Methylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-fluorophenylacetamide 398498-28-7P
398498-30-1P 398498-32-3P, N-(5-Methylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-(2-thienyl)propanoic amide
398498-34-5P, N-(5-Methylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-chlorobenzamide 398498-36-7P,
N-(5-Methylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-chlorobenzamide 398498-38-9P, N-(5-Methylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-chlorobenzamide 398498-40-3P
398498-42-5P, N-(5-Methylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-acetylbenzamide 398498-44-7P,
N-(5-Methylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-acetylbenzamide 398498-45-8P, N-(5-Methylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-1-naphthoic amide 398498-46-9P,
N-(5-Methylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-naphthoic amide 398498-47-0P 398498-48-1P, N-(5-Methylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-(acetylamino)benzamide
398498-49-2P, N-(5-Methylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2,5-dimethoxybenzamide 398498-50-5P,
N-(5-Methylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2,6-dimethoxybenzamide 398498-52-7P, N-(5-Methylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3,4-dimethoxybenzamide 398498-54-9P
, N-(5-Methylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3,5-dimethoxybenzamide 398498-56-1P 398498-58-3P
398498-60-7P 398498-62-9P, N-(5-Methylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-phenylbenzamide
398498-64-1P, N-(5-Ethylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)acetamide 398498-66-3P, N-(5-Ethylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)cyclopropanecarboxamide
398498-68-5P, N-(5-Ethylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)isobutyramide 398498-70-9P, N-(5-Ethylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-


yl)cyclopentanecarboxamide 398498-72-1P, N-(5-Ethylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)benzamide 398498-74-3P 398498-76-5P 398498-78-7P 398498-80-1P, N-(5-Ethylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-methyl-2-furoic amide 398498-82-3P, N-(5-Ethylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-2-carboxamide 398498-84-5P, N-(5-Ethylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-3-carboxamide 398498-86-7P 398498-88-9P 398498-89-0P 398498-91-4P, N-(5-Ethylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-fluorobenzamide 398498-93-6P, N-(5-Ethylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-fluorobenzamide 398498-95-8P, N-(5-Ethylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-fluorobenzamide 398498-97-0P, N-(5-Ethylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-2-acetamide 398498-99-2P, N-(5-Ethylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-3-acetamide 398499-01-9P 398499-03-1P, N-(5-Ethylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-cyanobenzamide 398499-05-3P, N-(5-Ethylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-cyanobenzamide 398499-07-5P 398499-09-7P 398499-11-1P 398499-13-3P 398499-15-5P, N-(5-Ethylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-phenylpropionamide 398499-17-7P 398499-19-9P 398499-21-3P 398499-23-5P 398499-31-5P, N-(5-Ethylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-methoxybenzamide 398499-33-7P 398499-35-9P 398499-37-1P, N-(5-Ethylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-fluorophenylacetamide 398499-39-3P, N-(5-Ethylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-fluorophenylacetamide 398499-41-7P, N-(5-Ethylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-fluorophenylacetamide 398499-43-9P 398499-45-1P 398499-47-3P, N-(5-Ethylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-(2-thienyl)propanoic amide 398499-49-5P, N-(5-Ethylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-chlorobenzamide 398499-51-9P, N-(5-Ethylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-chlorobenzamide 398499-53-1P, N-(5-Ethylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-chlorobenzamide 398499-55-3P 398499-57-5P, N-(5-Ethylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-acetylbenzamide 398499-59-7P, N-(5-Ethylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-acetylbenzamide 398499-61-1P, N-(5-Ethylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-1-naphthoic amide 398499-63-3P, N-(5-Ethylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-naphthoic amide 398499-65-5P 398499-67-7P, N-(5-Ethylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-(acetylamino)benzamide 398499-69-9P, N-(5-Ethylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2,5-dimethoxybenzamide 398499-71-3P, N-(5-Ethylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2,6-dimethoxybenzamide 398499-73-5P, N-(5-Ethylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3,4-dimethoxybenzamide 398499-75-7P, N-(5-Ethylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3,5-dimethoxybenzamide 398499-76-8P 398499-77-9P 398499-78-0P 398499-79-1P, N-(5-Ethylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-phenylbenzamide 398499-80-4P, N-(5-Phenylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)acetamide

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)

(kinase inhibitor; combinatorial preparation of bicyclo pyrazoles as kinase inhibitors for treatment of cancer and other proliferative disorders)


RN 398496-56-5 CAPLUS

CN Benzamide, N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398496-57-6 CAPLUS

CN 2-Pyridinecarboxamide, N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398496-58-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398496-59-8 CAPLUS

CN 4-Pyridinecarboxamide, N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398496-60-1 CAPLUS

CN 2-Furancarboxamide, 3-methyl-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398496-61-2 CAPLUS

CN 2-Thiophenecarboxamide, N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398496-62-3 CAPLUS

CN 3-Thiophenecarboxamide, N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398496-63-4 CAPLUS

CN Benzamide, 2-methyl-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398496-64-5 CAPLUS


CN Benzamide, 3-methyl-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398496-65-6 CAPLUS
CN Benzamide, 4-methyl-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398496-66-7 CAPLUS
CN Benzeneacetamide, N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398496-67-8 CAPLUS
CN Benzamide, 2-hydroxy-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398496-68-9 CAPLUS
CN Benzamide, 2-fluoro-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398496-69-0 CAPLUS
CN Benzamide, 3-fluoro-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398496-70-3 CAPLUS

CN Benzamide, 4-fluoro-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398496-71-4 CAPLUS

CN 2-Thiopheneacetamide, N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398496-72-5 CAPLUS

CN 3-Thiopheneacetamide, N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398496-73-6 CAPLUS

CN 2-Propynamide, 3-phenyl-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398496-74-7 CAPLUS

CN Benzamide, 3-cyano-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398496-75-8 CAPLUS


CN Benzamide, 4-cyano-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398496-76-9 CAPLUS


CN 2-Propenamide, 3-phenyl-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 398496-77-0 CAPLUS

CN 2-Propenamide, 3-(3-pyridinyl)-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398496-78-1 CAPLUS

CN 2-Propenamide, 3-(4-pyridinyl)-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398496-79-2 CAPLUS

CN Benzeneacetamide, alpha-methyl-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398496-80-5 CAPLUS

CN Benzeneacetamide, 2-methyl-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398496-81-6 CAPLUS

CN Benzeneacetamide, 3-methyl-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398496-82-7 CAPLUS

CN Benzeneacetamide, 4-methyl-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398496-83-8 CAPLUS

CN Benzeneacetamide, 2-methoxy-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398496-84-9 CAPLUS

CN Benzamide, 3-methoxy-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398496-85-0 CAPLUS

CN Benzamide, 4-methoxy-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398496-86-1 CAPLUS

CN Acetamide, 2-phenoxy-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398496-87-2 CAPLUS

CN Benzeneacetamide, 2-fluoro-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398496-88-3 CAPLUS

CN Benzeneacetamide, 3-fluoro-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398496-89-4 CAPLUS

CN Benzeneacetamide, 4-fluoro-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398496-90-7 CAPLUS

CN 2-Propenamide, N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]-3-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 398496-91-8 CAPLUS

CN 2-Propenamide, N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]-3-(3-thienyl)- (9CI) (CA INDEX NAME)




RN 398496-92-9 CAPLUS

CN 2-Thiophenepropanamide, N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398496-93-0 CAPLUS


CN Benzamide, 2-chloro-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398496-94-1 CAPLUS


CN Benzamide, 3-chloro-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-

c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398496-95-2 CAPLUS

CN Benzamide, 4-chloro-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398496-97-4 CAPLUS

CN 1-Piperidinepropanamide, N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398496-99-6 CAPLUS

CN Benzamide, 2-acetyl-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398497-00-2 CAPLUS


CN Benzamide, 4-acetyl-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398497-01-3 CAPLUS


CN 1-Naphthalenecarboxamide, N-[1,4,5,6-tetrahydro-5-

(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-03-5 CAPLUS

CN 2-Naphthalenecarboxamide, N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-05-7 CAPLUS

CN Benzenebutanamide, gamma-oxo-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-06-8 CAPLUS

CN Benzamide, 4-(acetilamino)-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-07-9 CAPLUS

CN Benzamide, 2,5-dimethoxy-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-09-1 CAPLUS

CN Benzamide, 2,6-dimethoxy-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-11-5 CAPLUS

CN Benzamide, 3,4-dimethoxy-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-12-6 CAPLUS

CN Benzamide, 3,5-dimethoxy-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-13-7 CAPLUS

CN 2-Thiophenebutanamide, γ-oxo-N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-14-8 CAPLUS

CN 2-Naphthaleneacetamide, N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-15-9 CAPLUS

CN 1-Naphthaleneacetamide, N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-16-0 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-17-1 CAPLUS

CN Acetamide, N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-18-2 CAPLUS

CN Cyclopropanecarboxamide, N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-19-3 CAPLUS

CN Propanamide, 2-methyl-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-20-6 CAPLUS

CN Cyclopentanecarboxamide, N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-21-7 CAPLUS

CN Benzamide, N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398497-22-8 CAPLUS


CN 2-Pyridinecarboxamide, N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398497-24-0 CAPLUS


CN 3-Pyridinecarboxamide, N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)

c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-25-1 CAPLUS

CN 4-Pyridinecarboxamide, N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-26-2 CAPLUS

CN 2-Furancarboxamide, 3-methyl-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-28-4 CAPLUS

CN 2-Thiophenecarboxamide, N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-29-5 CAPLUS

CN 3-Thiophenecarboxamide, N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-30-8 CAPLUS

CN Benzamide, 2-methyl-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-31-9 CAPLUS

CN Benzamide, 3-methyl-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-32-0 CAPLUS

CN Benzamide, 4-methyl-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398497-33-1 CAPLUS


CN Benzeneacetamide, N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398497-34-2 CAPLUS


CN Benzamide, 2-hydroxy-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-

c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-35-3 CAPLUS

CN Benzamide, 2-fluoro-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-36-4 CAPLUS

CN Benzamide, 3-fluoro-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-37-5 CAPLUS

CN Benzamide, 4-fluoro-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-38-6 CAPLUS

CN 2-Thiopheneacetamide, N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-39-7 CAPLUS

CN 3-Thiopheneacetamide, N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-40-0 CAPLUS

CN 2-Propynamide, 3-phenyl-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-41-1 CAPLUS

CN Benzamide, 3-cyano-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398497-42-2 CAPLUS


CN Benzamide, 4-cyano-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398497-43-3 CAPLUS

CN 2-Propenamide, 3-phenyl-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 398497-44-4 CAPLUS


CN 2-Propenamide, 3-phenyl-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 398497-45-5 CAPLUS

CN 2-Propenamide, 3-(3-pyridinyl)-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-46-6 CAPLUS

CN 2-Propenamide, 3-(4-pyridinyl)-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-47-7 CAPLUS

CN Benzeneacetamide, α-methyl-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-48-8 CAPLUS

CN Benzeneacetamide, 2-methyl-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-49-9 CAPLUS

CN Benzeneacetamide, 3-methyl-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-50-2 CAPLUS

CN Benzeneacetamide, 4-methyl-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-51-3 CAPLUS

CN Benzamide, 2-methoxy-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-52-4 CAPLUS

CN Benzamide, 3-methoxy-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-53-5 CAPLUS

CN Benzamide, 4-methoxy-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-54-6 CAPLUS

CN Acetamide, 2-phenoxy-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-55-7 CAPLUS

CN Benzeneacetamide, 2-fluoro-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-56-8 CAPLUS

CN Benzeneacetamide, 3-fluoro-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-57-9 CAPLUS

CN Benzeneacetamide, 4-fluoro-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-58-0 CAPLUS

CN 2-Propenamide, N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]-3-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 398497-59-1 CAPLUS

CN 2-Propenamide, N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]-3-(3-thienyl)- (9CI) (CA INDEX NAME)




RN 398497-60-4 CAPLUS

CN 2-Thiophenepropanamide, N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-61-5 CAPLUS

CN Benzamide, 2-chloro-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-62-6 CAPLUS

CN Benzamide, 3-chloro-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-63-7 CAPLUS

CN Benzamide, 4-chloro-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-64-8 CAPLUS

CN 1-Piperidinepropanamide, N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-66-0 CAPLUS

CN Benzamide, 2-acetyl-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-68-2 CAPLUS

CN Benzamide, 4-acetyl-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-69-3 CAPLUS

CN 1-Naphthalenecarboxamide, N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-70-6 CAPLUS

CN 2-Naphthalenecarboxamide, N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-71-7 CAPLUS

CN Benzenebutanamide, γ -oxo-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-72-8 CAPLUS

CN Benzamide, 4-(acetylamino)-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-74-0 CAPLUS

CN Benzamide, 2,5-dimethoxy-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-76-2 CAPLUS

CN Benzamide, 2,6-dimethoxy-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-78-4 CAPLUS

CN Benzamide, 3,4-dimethoxy-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-80-8 CAPLUS

CN Benzamide, 3,5-dimethoxy-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-82-0 CAPLUS

CN 2-Thiophenebutanamide, γ-oxo-N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-83-1 CAPLUS

CN 2-Naphthaleneacetamide, N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-85-3 CAPLUS

CN 1-Naphthaleneacetamide, N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-86-4 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-[1,4,5,6-tetrahydro-5-(2-phenylethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-87-5 CAPLUS

CN Acetamide, N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-89-7 CAPLUS

CN Cyclopropanecarboxamide, N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-90-0 CAPLUS

CN Propanamide, 2-methyl-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-91-1 CAPLUS

CN Cyclopentanecarboxamide, N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-92-2 CAPLUS

CN Benzamide, N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-93-3 CAPLUS

CN 2-Pyridinecarboxamide, N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-94-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-95-5 CAPLUS

CN 4-Pyridinecarboxamide, N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-96-6 CAPLUS

CN 2-Furancarboxamide, 3-methyl-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-97-7 CAPLUS

CN 2-Thiophenecarboxamide, N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-98-8 CAPLUS

CN 3-Thiophenecarboxamide, N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398497-99-9 CAPLUS

CN Benzamide, 2-methyl-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-00-5 CAPLUS

CN Benzamide, 3-methyl-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-01-6 CAPLUS

CN Benzamide, 4-methyl-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-02-7 CAPLUS

CN Benzeneacetamide, N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-03-8 CAPLUS

CN Benzamide, 2-hydroxy-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-04-9 CAPLUS

CN Benzamide, 2-fluoro-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-05-0 CAPLUS

CN Benzamide, 3-fluoro-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-06-1 CAPLUS

CN Benzamide, 4-fluoro-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-07-2 CAPLUS

CN 2-Thiopheneacetamide, N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-08-3 CAPLUS

CN 3-Thiopheneacetamide, N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-09-4 CAPLUS

CN 2-Propynamide, 3-phenyl-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-10-7 CAPLUS

CN Benzamide, 3-cyano-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398498-11-8 CAPLUS


CN Benzamide, 4-cyano-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398498-12-9 CAPLUS

CN 2-Propenamide, 3-phenyl-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 398498-13-0 CAPLUS


CN 2-Propenamide, 3-phenyl-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 398498-14-1 CAPLUS

CN 2-Propenamide, 3-(3-pyridinyl)-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-15-2 CAPLUS

CN 2-Propenamide, 3-(4-pyridinyl)-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-16-3 CAPLUS

CN Benzeneacetamide, α -methyl-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-17-4 CAPLUS

CN Benzeneacetamide, 2-methyl-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-18-5 CAPLUS

CN Benzeneacetamide, 3-methyl-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-19-6 CAPLUS

CN Benzeneacetamide, 4-methyl-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-20-9 CAPLUS

CN Benzamide, 3-methoxy-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-21-0 CAPLUS

CN Benzamide, 4-methoxy-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-22-1 CAPLUS


CN Acetamide, 2-phenoxy-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-23-2 CAPLUS
 CN Benzeneacetamide, 2-fluoro-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-24-3 CAPLUS
 CN Benzeneacetamide, 3-fluoro-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-26-5 CAPLUS
 CN Benzeneacetamide, 4-fluoro-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398498-28-7 CAPLUS
 CN 2-Propenamide, N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]-3-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 398498-30-1 CAPLUS
 CN 2-Propenamide, N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]-3-(3-thienyl)- (9CI) (CA INDEX NAME)




RN 398498-32-3 CAPLUS

CN 2-Thiophenepropanamide, N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI). (CA INDEX NAME)




RN 398498-34-5 CAPLUS

CN Benzamide, 2-chloro-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-36-7 CAPLUS

CN Benzamide, 3-chloro-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-38-9 CAPLUS

CN Benzamide, 4-chloro-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-40-3 CAPLUS

CN 1-Piperidinepropanamide, N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-42-5 CAPLUS

CN Benzamide, 2-acetyl-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-44-7 CAPLUS

CN Benzamide, 4-acetyl-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-45-8 CAPLUS


CN 1-Naphthalenecarboxamide, N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-46-9 CAPLUS
 CN 2-Naphthalenecarboxamide, N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-47-0 CAPLUS
 CN Benzenebutamide, γ -oxo-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-48-1 CAPLUS
 CN Benzamide, 4-(acetylamino)-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398498-49-2 CAPLUS
 CN Benzamide, 2,5-dimethoxy-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-50-5 CAPLUS
 CN Benzamide, 2,6-dimethoxy-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-52-7 CAPLUS

CN Benzamide, 3,4-dimethoxy-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-54-9 CAPLUS

CN Benzamide, 3,5-dimethoxy-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-56-1 CAPLUS

CN 2-Thiophenebutanamide, γ-oxo-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-58-3 CAPLUS

CN 2-Naphthaleneacetamide, N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-60-7 CAPLUS

CN 1-Naphthaleneacetamide, N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-62-9 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398498-64-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-(acetylamino)-N-ethyl-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398498-66-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(cyclopropylcarbonyl)amino]-N-ethyl-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398498-68-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[(2-methyl-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)




RN 398498-70-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(cyclopentylcarbonyl)amino]-N-ethyl-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398498-72-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-(benzoylamino)-N-ethyl-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398498-74-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[(2-pyridinylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 398498-76-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[(3-pyridinylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 398498-78-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[(4-pyridinylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 398498-80-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[[3-methyl-2-furanylcarbonyl]amino]- (9CI) (CA INDEX NAME)




RN 398498-82-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[(2-thienylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 398498-84-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[(3-thienylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 398498-86-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[(3-methylbenzoyl)amino]- (9CI) (CA INDEX NAME)




RN 398498-88-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[(4-methylbenzoyl)amino]- (9CI) (CA INDEX NAME)




RN 398498-89-0 CAPLUS


CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[(2-hydroxybenzoyl)amino]- (9CI) (CA INDEX NAME)




RN 398498-91-4 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-3-[(2-fluorobenzoyl)amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398498-93-6 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-3-[(3-fluorobenzoyl)amino]-4,6-dihydro- (9CI) (CA INDEX NAME)



RN 398498-95-8 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-3-[(4-fluorobenzoyl)amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398498-97-0 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[(2-thienylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398498-99-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[(3-thienylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398499-01-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[(1-oxo-3-phenyl-2-propynyl)amino]- (9CI) (CA INDEX NAME)




RN 398499-03-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(3-cyanobenzoyl)amino]-N-ethyl-4,6-dihydro- (9CI) (CA INDEX NAME)



RN 398499-05-3 CAPLUS


CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(4-cyanobenzoyl)amino]-N-ethyl-4,6-dihydro- (9CI) (CA INDEX NAME)



RN 398499-07-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[[(2E)-1-oxo-3-phenyl-2-propenyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 398499-09-7 CAPLUS


CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[[(2Z)-1-oxo-3-phenyl-2-propenyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 398499-11-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[[1-oxo-3-(3-pyridinyl)-2-propenyl]amino]- (9CI) (CA INDEX NAME)




RN 398499-13-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[[1-oxo-3-(4-pyridinyl)-2-propenyl]amino]- (9CI) (CA INDEX NAME)




RN 398499-15-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[(1-oxo-2-phenylpropyl)amino]- (9CI) (CA INDEX NAME)




RN 398499-17-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[[(2-methylphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)




RN 398499-19-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[[(3-methylphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)




RN 398499-21-3 CAPLUS


CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[[(4-methylphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)




RN 398499-23-5 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[(2-methoxybenzoyl)amino]- (9CI) (CA INDEX NAME)




RN 398499-31-5 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[(3-methoxybenzoyl)amino]- (9CI) (CA INDEX NAME)




RN 398499-33-7 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[(4-methoxybenzoyl)amino]- (9CI) (CA INDEX NAME)



RN 398499-35-9 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[(phenoxyacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398499-37-1 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-3-[[2-(2-fluorophenyl)acetyl]amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398499-39-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-3-[[3-fluorophenyl)acetyl]amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398499-41-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-3-[[4-fluorophenyl)acetyl]amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398499-43-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[[1-oxo-3-(2-thienyl)-2-propenyl]amino]- (9CI) (CA INDEX NAME)




RN 398499-45-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[[1-oxo-3-(3-thienyl)-2-propenyl]amino]- (9CI) (CA INDEX NAME)




RN 398499-47-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[[1-oxo-3-(2-thienyl)propyl]amino]- (9CI) (CA INDEX NAME)




RN 398499-49-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(2-chlorobenzoyl)amino]-N-ethyl-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398499-51-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(3-chlorobenzoyl)amino]-N-ethyl-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398499-53-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(4-chlorobenzoyl)amino]-N-ethyl-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398499-55-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[[1-oxo-3-(1-piperidinyl)propyl]amino]- (9CI) (CA INDEX NAME)




RN 398499-57-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(2-acetylbenzoyl)amino]-N-ethyl-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398499-59-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(4-acetylbenzoyl)amino]-N-ethyl-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398499-61-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[(1-naphthalenylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 398499-63-3 CAPLUS


CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[(2-naphthalenylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 398499-65-5 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(1,4-dioxo-4-phenylbutyl)amino]-N-ethyl-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398499-67-7 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[4-(acetamido)benzoyl]amino]-N-ethyl-4,6-dihydro- (9CI) (CA INDEX NAME)



RN 398499-69-9 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(2,5-dimethoxybenzoyl)amino]-N-ethyl-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398499-71-3 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(2,6-dimethoxybenzoyl)amino]-N-ethyl-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398499-73-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(3,4-dimethoxybenzoyl)amino]-N-ethyl-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398499-75-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(3,5-dimethoxybenzoyl)amino]-N-ethyl-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398499-76-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[1,4-dioxo-4-(2-thienyl)butyl]amino]-N-ethyl-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398499-77-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[(2-naphthalenylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398499-78-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-3-[(1-naphthalenylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398499-79-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[[1,1'-biphenyl]-4-ylcarbonyl]amino]-N-ethyl-4,6-dihydro- (9CI) (CA INDEX NAME)



RN 398499-80-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-(acetylaminocarbonyl)-4,6-dihydro-N-phenyl- (9CI) (CA INDEX NAME)



IT 398499-82-6P, N-(5-Phenylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)cyclopropanecarboxamide 398499-84-8P, N-(5-Phenylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)isobutyramide 398499-86-0P, N-(5-Phenylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)cyclopentanecarboxamide 398499-88-2P, N-(5-Phenylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)benzamide 398499-90-6P 398499-92-8P 398499-94-0P 398499-96-2P, N-(5-Phenylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-methyl-2-furoic amide 398499-98-4P, N-(5-Phenylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-

c]pyrazol-3-yl)thiophene-2-carboxamide 398500-00-0P,
N-(5-Phenylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-3-carboxamide 398500-02-2P 398500-04-4P
398500-06-6P 398500-08-8P, N-(5-Phenylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)phenylacetamide 398500-10-2P
398500-12-4P, N-(5-Phenylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-fluorobenzamide 398500-14-6P,
N-(5-Phenylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-fluorobenzamide 398500-16-8P, N-(5-Phenylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-fluorobenzamide
398500-18-0P, N-(5-Phenylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-2-acetamide 398500-20-4P,
N-(5-Phenylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-3-acetamide 398500-22-6P 398500-24-8P,
N-(5-Phenylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-cyanobenzamide 398500-26-0P, N-(5-Phenylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-cyanobenzamide
398500-28-2P 398500-30-6P 398500-32-8P
398500-34-0P 398500-36-2P, N-(5-Phenylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-phenylpropionamide
398500-38-4P 398500-40-8P 398500-42-0P
398500-44-2P 398500-46-4P, N-(5-Phenylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-methoxybenzamide
398500-48-6P 398500-50-0P 398500-52-2P,
N-(5-Phenylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-fluorophenylacetamide 398500-54-4P, N-(5-Phenylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-fluorophenylacetamide
398500-56-6P, N-(5-Phenylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-fluorophenylacetamide 398500-58-8P
398500-60-2P 398500-62-4P, N-(5-Phenylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-(2-thienyl)propanoic amide
398500-64-6P, N-(5-Phenylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-chlorobenzamide 398500-66-8P,
N-(5-Phenylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-chlorobenzamide 398500-68-0P, N-(5-Phenylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-chlorobenzamide
398500-70-4P 398500-72-6P, N-(5-Phenylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-acetylbenzamide
398500-74-8P, N-(5-Phenylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-acetylbenzamide 398500-76-0P,
N-(5-Phenylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-1-naphthoic amide 398500-78-2P, N-(5-Phenylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-naphthoic amide
398500-80-6P 398500-82-8P, N-(5-Phenylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-(acetylamino)benzamide
398500-84-0P, N-(5-Phenylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2,5-dimethoxybenzamide 398500-86-2P,
N-(5-Phenylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2,6-dimethoxybenzamide 398500-88-4P, N-(5-Phenylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3,4-dimethoxybenzamide
398500-89-5P, N-(5-Phenylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3,5-dimethoxybenzamide 398500-91-9P
398500-93-1P 398500-95-3P 398500-98-6P,
N-(5-Benzylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)acetamide 398501-00-3P, N-(5-Benzylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)cyclopropanecarboxamide 398501-02-5P
, N-(5-Benzylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)isobutyramide 398501-04-7P, N-(5-Benzylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)cyclopentanecarboxamide
398501-06-9P, N-(5-Benzylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)benzamide 398501-07-0P 398501-09-2P
398501-10-5P 398501-12-7P, N-(5-Benzylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-methyl-2-furoic amide

398501-14-9P, N-(5-Benzylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-2-carboxamide 398501-16-1P,
N-(5-Benzylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-3-carboxamide 398501-18-3P 398501-20-7P
398501-22-9P 398501-24-1P 398501-26-3P,
N-(5-Benzylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-fluorobenzamide 398501-28-5P, N-(5-Benzylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-fluorobenzamide
398501-30-9P, N-(5-Benzylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-fluorobenzamide 398501-32-1P,
N-(5-Benzylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-2-acetamide 398501-34-3P, N-(5-Benzylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-3-acetamide
398501-36-5P 398501-38-7P, N-(5-Benzylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-cyanobenzamide
398501-40-1P, N-(5-Benzylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-cyanobenzamide 398501-42-3P
398501-44-5P 398501-46-7P 398501-48-9P
398501-50-3P, N-(5-Benzylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-phenylpropionamide 398501-52-5P
398501-54-7P 398501-56-9P 398501-58-1P
398501-60-5P, N-(5-Benzylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-methoxybenzamide 398501-62-7P
398501-64-9P 398501-66-1P, N-(5-Benzylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-fluorophenylacetamide
398501-68-3P, N-(5-Benzylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-fluorophenylacetamide 398501-69-4P,
N-(5-Benzylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-fluorophenylacetamide 398501-71-8P 398501-73-0P
398501-75-2P, N-(5-Benzylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-(2-thienyl)propanoic amide 398501-77-4P,
N-(5-Benzylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-chlorobenzamide 398501-79-6P, N-(5-Benzylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-chlorobenzamide
398501-80-9P, N-(5-Benzylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-chlorobenzamide 398501-81-0P
398501-82-1P, N-(5-Benzylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-acetylbenzamide 398501-84-3P,
N-(5-Benzylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-acetylbenzamide 398501-86-5P, N-(5-Benzylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-1-naphthoic amide
398501-88-7P, N-(5-Benzylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-naphthoic amide 398501-90-1P
398501-92-3P, N-(5-Benzylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-(acetylamino)benzamide 398501-94-5P,
N-(5-Benzylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2,5-dimethoxybenzamide 398501-96-7P, N-(5-Benzylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2,6-dimethoxybenzamide
398501-98-9P, N-(5-Benzylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3,4-dimethoxybenzamide 398502-00-6P,
N-(5-Benzylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3,5-dimethoxybenzamide 398502-02-8P 398502-04-0P
398502-06-2P 398502-08-4P, N-(5-Benzylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-phenylbenzamide
398502-10-8P, N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)acetamide 398502-12-0P, N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)cyclopropanecarboxamide
398502-14-2P, N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)isobutyramide 398502-16-4P, N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)cyclopentanecarboxamide 398502-18-6P, N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)benzamide
398502-20-0P, N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-

c]pyrazol-3-yl)picolinic amide 398502-21-1P,
N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)nicotinic amide 398502-23-3P, N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)isonicotinic amide 398502-25-5P, N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-methyl-2-furoic amide 398502-27-7P,
N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-2-carboxamide 398502-30-2P,
N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-3-carboxamide 398502-34-6P 398502-37-9P
398502-41-5P 398502-46-0P, N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)phenylacetamide 398502-48-2P,
N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)salicylic amide 398502-51-7P, N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-fluorobenzamide 398502-54-0P, N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-fluorobenzamide 398502-56-2P,
N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-fluorobenzamide 398502-64-2P, N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-2-acetamide 398502-66-4P, N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-3-acetamide 398502-68-6P,
N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)phenylpropionic amide 398502-70-0P, N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-cyanobenzamide 398502-72-2P, N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-cyanobenzamide 398502-74-4P,
N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)trans-cinnamic amide 398502-76-6P 398502-78-8P,
N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-(3-pyridyl)acrylic amide 398502-80-2P, N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-(4-pyridyl)acrylic amide 398502-82-4P, N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-phenylpropionamide 398502-84-6P
398502-86-8P 398502-88-0P 398502-90-4P
398502-92-6P, N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-methoxybenzamide 398502-94-8P
398502-96-0P, N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)phenoxyacetamide 398502-98-2P,
N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-fluorophenylacetamide 398503-00-9P, N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-fluorophenylacetamide 398503-02-1P, N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-fluorophenylacetamide 398503-04-3P,
N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-(2-thienyl)acrylic amide 398503-05-4P, N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-(3-thienyl)acrylic amide 398503-07-6P, N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-(2-thienyl)propanoic amide 398503-09-8P,
N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-chlorobenzamide 398503-11-2P, N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-chlorobenzamide 398503-13-4P, N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-chlorobenzamide 398503-15-6P,
N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-1-piperidinepropionamide 398503-17-8P, N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-acetylbenzamide 398503-19-0P, N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-acetylbenzamide 398503-21-4P,
N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-1-naphthoic amide 398503-23-6P, N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-naphthoic amide 398503-25-8P, N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-

c]pyrazol-3-yl)-3-benzoylpropionamide 398503-27-0P,
N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-(
acetylaminobenzamide 398503-28-1P, N-(5-Benzoylaminocarbonyl-
4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2,5-dimethoxybenzamide
398503-29-2P, N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-
c]pyrazol-3-yl)-2,6-dimethoxybenzamide 398503-31-6P,
N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3,4-
dimethoxybenzamide 398503-33-8P, N-(5-Benzoylaminocarbonyl-4,6-
dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3,5-dimethoxybenzamide
398503-34-9P, N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-
c]pyrazol-3-yl)-3-(2-thenoyl)propionamide 398503-36-1P,
N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-
naphthylacetamide 398503-38-3P, N-(5-Benzoylaminocarbonyl-4,6-
dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-1-naphthylacetamide
398503-39-4P, N-(5-Benzoylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-
c]pyrazol-3-yl)-4-phenylbenzamide 398503-41-8P,
N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)acetamide
398503-42-9P, N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-
c]pyrazol-3-yl)cyclopropanecarboxamide 398503-44-1P,
N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)isobutyramide
398503-46-3P, N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-
c]pyrazol-3-yl)cyclopentanecarboxamide 398503-48-5P,
N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)benzamide
398503-50-9P, N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-
c]pyrazol-3-yl)picolinic amide 398503-52-1P,
N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)nicotinic
amide 398503-54-3P, N-(5-Aminocarbonyl-4,6-dihydro-1H-
pyrrolo[3,4-c]pyrazol-3-yl)isonicotinic amide 398503-56-5P,
N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-methyl-2-
furoic amide 398503-58-7P, N-(5-Aminocarbonyl-4,6-dihydro-1H-
pyrrolo[3,4-c]pyrazol-3-yl)thiophene-2-carboxamide 398503-60-1P,
N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-3-
carboxamide 398503-62-3P 398503-63-4P
398503-65-6P 398503-67-8P, N-(5-Aminocarbonyl-4,6-
dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)phenylacetamide 398503-69-0P
, N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)salicylic
amide 398503-71-4P, N-(5-Aminocarbonyl-4,6-dihydro-1H-
pyrrolo[3,4-c]pyrazol-3-yl)-2-fluorobenzamide 398503-73-6P,
N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-
fluorobenzamide 398503-75-8P, N-(5-Aminocarbonyl-4,6-dihydro-1H-
pyrrolo[3,4-c]pyrazol-3-yl)-4-fluorobenzamide 398503-77-0P,
N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-2-
acetamide 398503-78-1P, N-(5-Aminocarbonyl-4,6-dihydro-1H-
pyrrolo[3,4-c]pyrazol-3-yl)thiophene-3-acetamide 398503-80-5P,
N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-
yl)phenylpropionic amide 398503-82-7P, N-(5-Aminocarbonyl-4,6-
dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-cyanobenzamide
398503-84-9P, N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-
c]pyrazol-3-yl)-4-cyanobenzamide 398503-86-1P,
N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)trans-
cinnamic amide 398503-88-3P 398503-90-7P,
N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-(3-
pyridyl)acrylic amide 398503-92-9P, N-(5-Aminocarbonyl-4,6-
dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-(4-pyridyl)acrylic amide
398503-94-1P, N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-
c]pyrazol-3-yl)-2-phenylpropionamide 398503-96-3P
398503-98-5P 398504-00-2P 398504-02-4P
398504-04-6P, N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-
c]pyrazol-3-yl)-3-methoxybenzamide 398504-06-8P
398504-08-0P, N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-
c]pyrazol-3-yl)phenoxyacetamide 398504-10-4P,
N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-
fluorophenylacetamide 398504-12-6P, N-(5-Aminocarbonyl-4,6-

dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-fluorophenylacetamide 398504-13-7P, N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-fluorophenylacetamide 398504-14-8P, N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-(2-thienyl)acrylic amide 398504-16-0P, N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-(3-thienyl)acrylic amide 398504-17-1P, N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-(2-thienyl)propanoic amide 398504-18-2P, N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-chlorobenzamide 398504-20-6P, N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-chlorobenzamide 398504-22-8P, N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-chlorobenzamide 398504-24-0P, N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-1-piperidinepropionamide 398504-26-2P, N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-acetylbenzamide 398504-28-4P, N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-acetylbenzamide 398504-30-8P, N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-1-naphthoic amide 398504-32-0P, N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-naphthoic amide 398504-33-1P, N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-benzoylpropionamide 398504-35-3P, N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-(acetylamino)benzamide 398504-36-4P, N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2,5-dimethoxybenzamide 398504-38-6P, N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2,6-dimethoxybenzamide 398504-40-0P


, N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3,4-dimethoxybenzamide 398504-41-1P, N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3,5-dimethoxybenzamide

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)

(kinase inhibitor; combinatorial preparation of bicyclo pyrazoles as kinase inhibitors for treatment of cancer and other proliferative disorders)


RN 398499-82-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(cyclopropylcarbonyl)amino]-4,6-dihydro-N-phenyl- (9CI) (CA INDEX NAME)




RN 398499-84-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(2-methyl-1-oxopropyl)amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 398499-86-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(cyclopentylcarbonyl)amino]-4,6-dihydro-N-phenyl- (9CI) (CA INDEX NAME)




RN 398499-88-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-(benzoylamino)-4,6-dihydro-N-phenyl- (9CI) (CA INDEX NAME)




RN 398499-90-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-N-phenyl-3-[(2-pyridinylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 398499-92-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-N-phenyl-3-[(3-pyridinylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 398499-94-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-N-phenyl-3-[(4-pyridinylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 398499-96-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[3-methyl-2-furanyl]carbonyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 398499-98-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-N-phenyl-3-[(2-thienyl)carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 398500-00-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-N-phenyl-3-[(3-thienyl)carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 398500-02-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(2-methylbenzoyl)amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-04-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(3-methylbenzoyl)amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-06-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(4-methylbenzoyl)amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-08-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-N-phenyl-3-[(phenylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398500-10-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(2-hydroxybenzoyl)amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-12-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(2-fluorobenzoyl)amino]-4,6-dihydro-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-14-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(3-fluorobenzoyl)amino]-4,6-dihydro-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-16-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(4-fluorobenzoyl)amino]-4,6-dihydro-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-18-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-N-phenyl-3-[(2-thienylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398500-20-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-N-phenyl-3-[(3-thienylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398500-22-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(1-oxo-3-phenyl-2-propynyl)amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-24-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(3-cyanobenzoyl)amino]-4,6-dihydro-N-phenyl- (9CI) (CA INDEX NAME)



RN 398500-26-0 CAPLUS


CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(4-cyanobenzoyl)amino]-4,6-dihydro-N-phenyl- (9CI) (CA INDEX NAME)



RN 398500-28-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[(2E)-1-oxo-3-phenyl-2-propenyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 398500-30-6 CAPLUS


CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[(2Z)-1-oxo-3-phenyl-2-propenyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 398500-32-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[1-oxo-3-(3-pyridinyl)-2-propenyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-34-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[1-oxo-3-(4-pyridinyl)-2-propenyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-36-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(1-oxo-2-phenylpropyl)amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-38-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[(2-methylphenyl)acetyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-40-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[(3-methylphenyl)acetyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-42-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[(4-methylphenyl)acetyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-44-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(2-methoxybenzoyl)amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-46-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(3-methoxybenzoyl)amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-48-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(4-methoxybenzoyl)amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-50-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(phenoxyacetyl)amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-52-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[(2-fluorophenyl)acetyl]amino]-4,6-dihydro-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-54-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[[3-fluorophenyl]acetyl]amino]-4,6-dihydro-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-56-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[[4-fluorophenyl]acetyl]amino]-4,6-dihydro-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-58-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[[1-oxo-3-(2-thienyl)-2-propenyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-60-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[[1-oxo-3-(3-thienyl)-2-propenyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-62-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[1-oxo-3-(2-thienyl)propyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-64-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(2-chlorobenzoyl)amino]-4,6-dihydro-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-66-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(3-chlorobenzoyl)amino]-4,6-dihydro-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-68-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(4-chlorobenzoyl)amino]-4,6-dihydro-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-70-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[1-oxo-3-(1-piperidinyl)propyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-72-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(2-acetylbenzoyl)amino]-4,6-dihydro-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-74-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(4-acetylbenzoyl)amino]-4,6-dihydro-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-76-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(1-naphthalenylcarbonyl)amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-78-2 CAPLUS


CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(2-naphthalenylcarbonyl)amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-80-6 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(1,4-dioxo-4-phenylbutyl)amino]-4,6-dihydro-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-82-8 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[4-(acetamido)benzoyl]amino]-4,6-dihydro-N-phenyl- (9CI) (CA INDEX NAME)



RN 398500-84-0 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(2,5-dimethoxybenzoyl)amino]-4,6-dihydro-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-86-2 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(2,6-dimethoxybenzoyl)amino]-4,6-dihydro-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-88-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(3,4-dimethoxybenzoyl)amino]-4,6-dihydro-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-89-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(3,5-dimethoxybenzoyl)amino]-4,6-dihydro-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-91-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[1,4-dioxo-4-(2-thienyl)butyl]amino]-4,6-dihydro-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-93-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(2-naphthalenylacetyl)amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-95-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(1-naphthalenylacetyl)amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 398500-98-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-(acetylamino)-4,6-dihydro-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-00-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(cyclopropylcarbonyl)amino]-4,6-dihydro-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-02-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(2-methyl-1-oxopropyl)amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-04-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(cyclopentylcarbonyl)amino]-4,6-dihydro-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-06-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-(benzoylamino)-4,6-dihydro-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-07-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-N-(phenylmethyl)-3-[(2-pyridinylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 398501-09-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-N-(phenylmethyl)-3-[(3-pyridinylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 398501-10-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-N-(phenylmethyl)-3-[(4-pyridinylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 398501-12-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[(3-methyl-2-furanyl) carbonyl] amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-14-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-N-(phenylmethyl)-3-[(2-thienylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 398501-16-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-N-(phenylmethyl)-3-[(3-thienylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 398501-18-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(2-methylbenzoyl)amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-20-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(3-methylbenzoyl)amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-22-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(4-methylbenzoyl)amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-24-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(2-hydroxybenzoyl)amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-26-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(2-fluorobenzoyl)amino]-4,6-dihydro-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-28-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(3-fluorobenzoyl)amino]-4,6-dihydro-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-30-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(4-fluorobenzoyl)amino]-4,6-dihydro-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-32-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-N-(phenylmethyl)-3-[(2-thienylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398501-34-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-N-(phenylmethyl)-3-[(3-thienylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398501-36-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(1-oxo-3-phenyl-2-propynyl)amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-38-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(3-cyanobenzoyl)amino]-4,6-dihydro-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 398501-40-1 CAPLUS


CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(4-cyanobenzoyl)amino]-4,6-dihydro-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 398501-42-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[(2E)-1-oxo-3-phenyl-2-propenyl]amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 398501-44-5 CAPLUS


CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[(2Z)-1-oxo-3-phenyl-2-propenyl]amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 398501-46-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[1-oxo-3-(3-pyridinyl)-2-propenyl]amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-48-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[1-oxo-3-(4-pyridinyl)-2-propenyl]amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-50-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(1-oxo-2-phenylpropyl)amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-52-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[(2-methylphenyl)acetyl]amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-54-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[(3-methylphenyl)acetyl]amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-56-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[(4-methylphenyl)acetyl]amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-58-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(2-methoxybenzoyl)amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-60-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(3-methoxybenzoyl)amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-62-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(4-methoxybenzoyl)amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-64-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(phenoxyacetyl)amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-66-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[[2-fluorophenyl)acetyl]amino]-4,6-dihydro-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-68-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[3-(3-fluorophenyl)acetyl]amino]-4,6-dihydro-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-69-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[4-(3-fluorophenyl)acetyl]amino]-4,6-dihydro-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-71-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[1-oxo-3-(2-thienyl)-2-propenyl]amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-73-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[1-oxo-3-(3-thienyl)-2-propenyl]amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-75-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[1-oxo-3-(2-thienyl)propyl]amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-77-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(2-chlorobenzoyl)amino]-4,6-dihydro-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-79-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(3-chlorobenzoyl)amino]-4,6-dihydro-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-80-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(4-chlorobenzoyl)amino]-4,6-dihydro-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-81-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[1-oxo-3-(1-phenylmethyl)propyl]amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-82-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(2-acetylbenzoyl)amino]-4,6-dihydro-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-84-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(4-acetylbenzoyl)amino]-4,6-dihydro-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-86-5 CAPLUS


CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(1-naphthalenylcarbonyl)amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-88-7 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(2-naphthalenylcarbonyl)amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-90-1 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(1,4-dioxo-4-phenylbutyl)amino]-4,6-dihydro-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 398501-92-3 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[4-(acetamido)benzoyl]amino]-4,6-dihydro-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-94-5 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(2,5-dimethoxybenzoyl)amino]-4,6-dihydro-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-96-7 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(2,6-dimethoxybenzoyl)amino]-

4,6-dihydro-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398501-98-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(3,4-dimethoxybenzoyl)amino]-4,6-dihydro-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398502-00-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(3,5-dimethoxybenzoyl)amino]-4,6-dihydro-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398502-02-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[1,4-dioxo-4-(2-thienyl)butyl]amino]-4,6-dihydro-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398502-04-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(2-naphthalenylacetyl)amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398502-06-2 CAPLUS

CN	Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(1-naphthalenylacetyl)amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)
----	---




RN 398502-08-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[[1,1'-biphenyl]-4-ylcarbonyl]amino]-4,6-dihydro-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398502-10-8 CAPLUS

CN Pyrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-(acetylamino)-N-benzoyl-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398502-12-0 CAPLUS

CN	Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-3-[(cyclopropylcarbonyl)amino]-4,6-dihydro-	(9CI)	(CA INDEX NAME)
----	---	-------	-----------------




RN 398502-14-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-4,6-dihydro-3-[(2-methyl-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)




RN 398502-16-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-3-[(cyclopentylcarbonyl)amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398502-18-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-3-(benzoylamino)-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398502-20-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-4,6-dihydro-3-[(2-pyridinylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 398502-21-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-4,6-dihydro-3-[(3-pyridinylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 398502-23-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-4,6-dihydro-3-[(4-pyridinylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 398502-25-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-4,6-dihydro-3-[[3-methyl-2-furanylcarbonyl]amino]- (9CI) (CA INDEX NAME)




RN 398502-27-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-4,6-dihydro-3-[(2-thienylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 398502-30-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-4,6-dihydro-3-[(3-thienylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 398502-34-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-4,6-dihydro-3-[(2-methylbenzoyl)amino]- (9CI) (CA INDEX NAME)




RN 398502-37-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-4,6-dihydro-3-[(3-methylbenzoyl)amino]- (9CI) (CA INDEX NAME)




RN 398502-41-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-4,6-dihydro-3-[(4-methylbenzoyl)amino]- (9CI) (CA INDEX NAME)




RN 398502-46-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-4,6-dihydro-3-[(phenylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398502-48-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-4,6-dihydro-3-[(2-hydroxybenzoyl)amino]- (9CI) (CA INDEX NAME)




RN 398502-51-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-3-[(2-fluorobenzoyl)amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398502-54-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-3-[(3-fluorobenzoyl)amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398502-56-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-3-[(4-fluorobenzoyl)amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398502-64-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-4,6-dihydro-3-[(2-thienylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398502-66-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-4,6-dihydro-3-[(3-thienylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398502-68-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-4,6-dihydro-3-[(1-oxo-3-phenyl-2-propynyl)amino]- (9CI) (CA INDEX NAME)




RN 398502-70-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-3-[(3-cyanobenzoyl)amino]-4,6-dihydro- (9CI) (CA INDEX NAME)



RN 398502-72-2 CAPLUS


CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-3-[(4-cyanobenzoyl)amino]-4,6-dihydro- (9CI) (CA INDEX NAME)



RN 398502-74-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-4,6-dihydro-3-[[(2E)-1-oxo-3-phenyl-2-propenyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 398502-76-6 CAPLUS


CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-4,6-dihydro-3-[[(2Z)-1-oxo-3-phenyl-2-propenyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 398502-78-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-4,6-dihydro-3-[[1-oxo-3-(3-pyridinyl)-2-propenyl]amino]- (9CI) (CA INDEX NAME)




RN 398502-80-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-4,6-dihydro-3-[[1-oxo-3-(4-pyridinyl)-2-propenyl]amino]- (9CI) (CA INDEX NAME)




RN 398502-82-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-4,6-dihydro-3-[[1-oxo-2-phenylpropyl]amino]- (9CI) (CA INDEX NAME)




RN 398502-84-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-4,6-dihydro-3-[[2-methylphenyl]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 398502-86-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-4,6-dihydro-3-[[(3-methylphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)




RN 398502-88-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-4,6-dihydro-3-[[(4-methylphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)




RN 398502-90-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-4,6-dihydro-3-[(2-methoxybenzoyl)amino]- (9CI) (CA INDEX NAME)




RN 398502-92-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-4,6-dihydro-3-[(3-methoxybenzoyl)amino]- (9CI) (CA INDEX NAME)




RN 398502-94-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-4,6-dihydro-3-[(4-methoxybenzoyl)amino]- (9CI) (CA INDEX NAME)




RN 398502-96-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-4,6-dihydro-3-[(phenoxyacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398502-98-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-3-[[2-(2-fluorophenyl)acetyl]amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398503-00-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-3-[[2-(3-fluorophenyl)acetyl]amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398503-02-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-3-[[4-(3-fluorophenyl)acetyl]amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398503-04-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-4,6-dihydro-3-[[1-oxo-3-(2-thienyl)-2-propenyl]amino]- (9CI) (CA INDEX NAME)




RN 398503-05-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-4,6-dihydro-3-[[1-oxo-3-(3-thienyl)-2-propenyl]amino]- (9CI) (CA INDEX NAME)




RN 398503-07-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-4,6-dihydro-3-[[1-oxo-3-(2-thienyl)propyl]amino]- (9CI) (CA INDEX NAME)




RN 398503-09-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-3-[(2-chlorobenzoyl)amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398503-11-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-3-[(3-chlorobenzoyl)amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398503-13-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-3-[(4-chlorobenzoyl)amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398503-15-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-4,6-dihydro-3-[[1-oxo-3-(1-piperidinyl)propyl]amino]- (9CI) (CA INDEX NAME)




RN 398503-17-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(2-acetylbenzoyl)amino]-N-benzoyl-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398503-19-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(4-acetylbenzoyl)amino]-N-benzoyl-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398503-21-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-4,6-dihydro-3-[(1-naphthalenylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 398503-23-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-4,6-dihydro-3-[(2-naphthalenylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 398503-25-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-4,6-dihydro-3-[(1-oxopropyl)amino]- (9CI) (CA INDEX NAME)




RN 398503-27-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[4-(acetamino)benzoyl]amino]-N-benzoyl-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398503-28-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-3-[(2,5-dimethoxybenzoyl)amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398503-29-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-3-[(2,6-dimethoxybenzoyl)amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398503-31-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-3-[(3,4-dimethoxybenzoyl)amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398503-33-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-3-[(3,5-dimethoxybenzoyl)amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398503-34-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-3-[[1,4-dioxo-4-(2-thienyl)butyl]amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398503-36-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-4,6-dihydro-3-[(2-naphthalenylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398503-38-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-4,6-dihydro-3-[(1-naphthalenylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398503-39-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-benzoyl-3-[[[1,1'-biphenyl]-4-ylcarbonyl]amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398503-41-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-(acetylamino)-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398503-42-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(cyclopropylcarbonyl)amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398503-44-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(2-methyl-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)




RN 398503-46-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(cyclopentylcarbonyl)amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398503-48-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-(benzoylamino)-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398503-50-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(2-pyridinylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 398503-52-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(3-pyridinylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 398503-54-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(4-pyridinylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 398503-56-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[3-methyl-2-furanylcarbonyl]amino]- (9CI) (CA INDEX NAME)




RN 398503-58-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(2-thienylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 398503-60-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(3-thienylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 398503-62-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(2-methylbenzoyl)amino]- (9CI) (CA INDEX NAME)




RN 398503-63-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(3-methylbenzoyl)amino]- (9CI) (CA INDEX NAME)




RN 398503-65-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(4-methylbenzoyl)amino]- (9CI) (CA INDEX NAME)




RN 398503-67-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(phenylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398503-69-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(2-hydroxybenzoyl)amino]- (9CI) (CA INDEX NAME)




RN 398503-71-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(2-fluorobenzoyl)amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398503-73-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(3-fluorobenzoyl)amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398503-75-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(4-fluorobenzoyl)amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398503-77-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(2-thienylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398503-78-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(3-thienylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398503-80-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(1-oxo-3-phenyl-2-propynyl)amino]- (9CI) (CA INDEX NAME)




RN 398503-82-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(3-cyanobenzoyl)amino]-4,6-dihydro- (9CI) (CA INDEX NAME)



RN 398503-84-9 CAPLUS


CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(4-cyanobenzoyl)amino]-4,6-dihydro- (9CI) (CA INDEX NAME)



RN 398503-86-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[(2E)-1-oxo-3-phenyl-2-propenyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 398503-88-3 CAPLUS


CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[(2Z)-1-oxo-3-phenyl-2-propenyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 398503-90-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[1-oxo-3-(3-pyridinyl)-2-propenyl]amino]- (9CI) (CA INDEX NAME)




RN 398503-92-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[1-oxo-3-(4-pyridinyl)-2-propenyl]amino]- (9CI) (CA INDEX NAME)




RN 398503-94-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(1-oxo-2-phenylpropyl)amino]- (9CI) (CA INDEX NAME)




RN 398503-96-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[2-methylphenyl]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 398503-98-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[3-methylphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)




RN 398504-00-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[4-methylphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)




RN 398504-02-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(2-methoxybenzoyl)amino]- (9CI) (CA INDEX NAME)




RN 398504-04-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(3-methoxybenzoyl)amino]- (9CI) (CA INDEX NAME)




RN 398504-06-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(4-methoxybenzoyl)amino]- (9CI) (CA INDEX NAME)




RN 398504-08-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(phenoxyacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398504-10-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[2-(2-fluorophenyl)acetyl]amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398504-12-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[2-(3-fluorophenyl)acetyl]amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398504-13-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[4-(4-fluorophenyl)acetyl]amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398504-14-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[1-oxo-3-(2-thienyl)-2-propenyl]amino]- (9CI) (CA INDEX NAME)




RN 398504-16-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[1-oxo-3-(3-thienyl)-2-propenyl]amino]- (9CI) (CA INDEX NAME)




RN 398504-17-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[1-oxo-3-(2-thienyl)propyl]amino]- (9CI) (CA INDEX NAME)




RN 398504-18-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(2-chlorobenzoyl)amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398504-20-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(3-chlorobenzoyl)amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398504-22-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(4-chlorobenzoyl)amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398504-24-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[[1-oxo-3-(1-piperidinyl)propyl]amino]- (9CI) (CA INDEX NAME)




RN 398504-26-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(2-acetylbenzoyl)amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398504-28-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(4-acetylbenzoyl)amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398504-30-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(1-naphthalenylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 398504-32-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(2-naphthalenylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 398504-33-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(1,4-dioxo-4-phenylbutyl)amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398504-35-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[4-(acetamidophenyl)amino]benzoyl]amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398504-36-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(2,5-dimethoxybenzoyl)amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398504-38-6 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(2,6-dimethoxybenzoyl)amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398504-40-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(3,4-dimethoxybenzoyl)amino]-4,6-dihydro- (9CI) (CA INDEX NAME)



RN 398504-41-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(3,5-dimethoxybenzoyl)amino]-4,6-dihydro- (9CI) (CA INDEX NAME)



IT 398504-43-3P, N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-(2-thenoyl)propionamide 398504-44-4P, N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-naphthylacetamide 398504-45-5P, N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-1-naphthylacetamide 398504-47-7P, N-(5-Aminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-phenylbenzamide 398504-49-9P, N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)acetamide 398504-51-3P, N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)cyclopropanecarboxamide 398504-53-5P, N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)isobutyramide 398504-55-7P, N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)cyclopentanecarboxamide 398504-57-9P, N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)benzamide 398504-59-1P, N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)picolinic amide 398504-61-5P, N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)nicotinic amide 398504-63-7P, N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)isonicotinic amide 398504-65-9P, N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-methyl-2-furoic amide 398504-67-1P, N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-2-carboxamide 398504-69-3P, N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-3-carboxamide 398504-70-6P, 398504-73-9P 398504-74-0P 398504-76-2P, N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-


yl)phenylacetamide 398504-78-4P, N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)salicylic amide 398504-80-8P
398504-82-0P, N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-fluorobenzamide 398504-84-2P,
N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-fluorobenzamide 398504-86-4P, N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-2-acetamide 398504-88-6P,
N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-3-acetamide 398504-90-0P, N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)phenylpropionic amide 398504-92-2P,
N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-cyanobenzamide 398504-94-4P, N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-cyanobenzamide 398504-96-6P,
N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)trans-cinnamic amide 398504-98-8P 398505-00-5P,
N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-(3-pyridyl)acrylic amide 398505-01-6P, N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-(4-pyridyl)acrylic amide 398505-03-8P,
N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-phenylpropionamide 398505-05-0P
398505-11-8P 398505-13-0P 398505-15-2P
398505-17-4P, N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-methoxybenzamide 398505-19-6P
398505-21-0P, N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)phenoxyacetamide 398505-23-2P,
N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-fluorophenylacetamide 398505-25-4P, N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-fluorophenylacetamide 398505-27-6P,
N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-fluorophenylacetamide 398505-29-8P,
N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-(2-thienyl)acrylic amide 398505-31-2P, N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-(3-thienyl)acrylic amide 398505-32-3P,
N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-(2-thienyl)propanoic amide 398505-34-5P,
N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-chlorobenzamide 398505-36-7P, N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-chlorobenzamide 398505-38-9P,
N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-chlorobenzamide 398505-40-3P, N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-1-piperidinepropionamide 398505-42-5P,
N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-acetylbenzamide 398505-44-7P, N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-acetylbenzamide 398505-45-8P,
N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-1-naphthoic amide 398505-47-0P, N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-naphthoic amide 398505-49-2P,
N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-benzoylpropionamide 398505-51-6P, N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-(acetylamino)benzamide 398505-53-8P,
N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2,5-dimethoxybenzamide 398505-55-0P,
N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2,6-dimethoxybenzamide 398505-56-1P, N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3,4-dimethoxybenzamide 398505-58-3P,
N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3,5-dimethoxybenzamide 398505-60-7P, N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-(2-thenoyl)propionamide 398505-62-9P,
N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-naphthylacetamide 398505-64-1P,
N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-1-naphthylacetamide 398505-66-3P, N-(5-Aminosulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-phenylbenzamide 398505-68-5P,

N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)acetamide 398505-70-9P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)cyclopropanecarboxamide 398505-72-1P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)isobutyramide 398505-74-3P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)cyclopentanecarboxamide 398505-76-5P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)benzamide 398505-78-7P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)picolinic amide 398505-80-1P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)nicotinic amide 398505-82-3P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)isonicotinic amide 398505-84-5P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-methyl-2-furoic amide 398505-86-7P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-2-carboxamide 398505-87-8P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-3-carboxamide 398505-88-9P 398505-89-0P 398505-90-3P 398505-91-4P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)salicylic amide 398505-92-5P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-fluorobenzamide 398505-93-6P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-fluorobenzamide 398505-94-7P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-fluorobenzamide 398505-95-8P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-2-acetamide 398505-96-9P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-3-acetamide 398505-97-0P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)phenylpropionic amide 398505-98-1P 398505-99-2P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-cyanobenzamide 398506-00-8P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)trans-cinnamic amide 398506-01-9P 398506-02-0P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-(3-pyridyl)acrylic amide 398506-03-1P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-(4-pyridyl)acrylic amide 398506-04-2P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-phenylpropionamide 398506-05-3P 398506-06-4P 398506-07-5P 398506-08-6P 398506-09-7P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-methoxybenzamide 398506-10-0P 398506-11-1P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)phenoxyacetamide 398506-12-2P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-fluorophenylacetamide 398506-13-3P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-fluorophenylacetamide 398506-14-4P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-fluorophenylacetamide 398506-15-5P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-(2-thienyl)acrylic amide 398506-16-6P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-(3-thienyl)acrylic amide 398506-17-7P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-(2-thienyl)propanoic amide 398506-18-8P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-chlorobenzamide 398506-19-9P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-chlorobenzamide 398506-20-2P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-chlorobenzamide 398506-21-3P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-1-piperidinepropionamide 398506-22-4P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-acetylbenzamide 398506-23-5P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-acetylbenzamide 398506-24-6P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-1-naphthoic amide 398506-25-7P, N-(5-Toluensulfonyl-4,6-dihydro-1H-


pyrrolo[3,4-c]pyrazol-3-yl)-2-naphthoic amide 398506-26-8P,
 N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-
 benzoylpropionamide 398506-27-9P, N-(5-Toluensulfonyl-4,6-
 dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-(acetylamino)benzamide
 398506-28-0P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-
 c]pyrazol-3-yl)-2,5-dimethoxybenzamide 398506-29-1P,
 N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2,6-
 dimethoxybenzamide 398506-30-4P, N-(5-Toluensulfonyl-4,6-dihydro-
 1H-pyrrolo[3,4-c]pyrazol-3-yl)-3,4-dimethoxybenzamide 398506-31-5P
 , N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3,5-
 dimethoxybenzamide 398506-32-6P, N-(5-Toluensulfonyl-4,6-dihydro-
 1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-(2-thenoyl)propionamide
 398506-33-7P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-
 c]pyrazol-3-yl)-2-naphthylacetamide 398506-34-8P,
 N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-1-
 naphthylacetamide 398506-35-9P, N-(5-Toluensulfonyl-4,6-dihydro-
 1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-phenylbenzamide 398506-36-0P,
 N-(5-Benzylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)acetamide
 398506-37-1P, N-(5-Benzylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-
 c]pyrazol-3-yl)cyclopropanecarboxamide 398506-38-2P,
 N-(5-Benzylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-
 yl)isobutyramide 398506-39-3P, N-(5-Benzylsulfonyl-4,6-dihydro-
 1H-pyrrolo[3,4-c]pyrazol-3-yl)cyclopentanecarboxamide 398506-40-6P
 , N-(5-Benzylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)benzamide
 398506-41-7P, N-(5-Benzylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-
 c]pyrazol-3-yl)picolinic amide 398506-42-8P,
 N-(5-Benzylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)nicotinic
 amide 398506-43-9P 398506-44-0P, N-(5-Benzylsulfonyl-
 4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-methyl-2-furoic amide
 398506-45-1P, N-(5-Benzylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-
 c]pyrazol-3-yl)thiophene-2-carboxamide 398506-46-2P,
 N-(5-Benzylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-3-
 carboxamide 398506-47-3P 398506-48-4P
 398506-49-5P 398506-50-8P, N-(5-Benzylsulfonyl-4,6-
 dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)phenylacetamide 398506-51-9P
 , N-(5-Benzylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)salicylic
 amide 398506-52-0P, N-(5-Benzylsulfonyl-4,6-dihydro-1H-
 pyrrolo[3,4-c]pyrazol-3-yl)-2-fluorobenzamide 398506-53-1P,
 N-(5-Benzylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-
 fluorobenzamide 398506-54-2P, N-(5-Benzylsulfonyl-4,6-dihydro-1H-
 pyrrolo[3,4-c]pyrazol-3-yl)-4-fluorobenzamide 398506-55-3P,
 N-(5-Benzylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)thiophene-2-
 acetamide 398506-56-4P, N-(5-Benzylsulfonyl-4,6-dihydro-1H-
 pyrrolo[3,4-c]pyrazol-3-yl)thiophene-3-acetamide 398506-57-5P,
 N-(5-Benzylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-
 yl)phenylpropionic amide 398506-58-6P, N-(5-Benzylsulfonyl-4,6-
 dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-cyanobenzamide
 398506-59-7P, N-(5-Benzylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-
 c]pyrazol-3-yl)-4-cyanobenzamide 398506-60-0P
 398506-61-1P 398506-62-2P, N-(5-Benzylsulfonyl-4,6-
 dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-(3-pyridyl)acrylic amide
 398506-63-3P, N-(5-Benzylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-
 c]pyrazol-3-yl)-3-(4-pyridyl)acrylic amide 398506-64-4P,
 N-(5-Benzylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-
 phenylpropionamide 398506-65-5P 398506-66-6P
 398506-67-7P 398506-68-8P, N-(5-Benzylsulfonyl-4,6-
 dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-methoxybenzamide
 398506-69-9P 398506-70-2P, N-(5-Benzylsulfonyl-4,6-
 dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)phenoxyacetamide
 398506-71-3P, N-(5-Benzylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-
 c]pyrazol-3-yl)-2-fluorophenylacetamide 398506-72-4P,
 N-(5-Benzylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-
 fluorophenylacetamide 398506-73-5P, N-(5-Benzylsulfonyl-4,6-

dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-fluorophenylacetamide
 398506-74-6P, N-(5-Benzylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-
 c]pyrazol-3-yl)-3-(2-thienyl)acrylic amide 398506-75-7P,
 N-(5-Benzylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-(3-
 thienyl)acrylic amide 398506-76-8P, N-(5-Benzylsulfonyl-4,6-
 dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-(2-thienyl)propanoic amide
 398506-77-9P, N-(5-Benzylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-
 c]pyrazol-3-yl)-2-chlorobenzamide 398506-78-0P,
 N-(5-Benzylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-
 chlorobenzamide 398506-79-1P, N-(5-Benzylsulfonyl-4,6-dihydro-1H-
 pyrrolo[3,4-c]pyrazol-3-yl)-4-chlorobenzamide 398506-80-4P,
 N-(5-Benzylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-1-
 piperidinepropionamide 398506-81-5P, N-(5-Benzylsulfonyl-4,6-
 dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2-acetylbenzamide
 398506-82-6P, N-(5-Benzylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-
 c]pyrazol-3-yl)-4-acetylbenzamide 398506-83-7P,
 N-(5-Benzylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-1-naphthoic
 amide 398506-84-8P, N-(5-Benzylsulfonyl-4,6-dihydro-1H-
 pyrrolo[3,4-c]pyrazol-3-yl)-2-naphthoic amide 398506-85-9P,
 N-(5-Benzylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-
 benzoylpropionamide 398506-86-0P, N-(5-Benzylsulfonyl-4,6-
 dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-(acetylamino)benzamide
 398506-87-1P, N-(5-Benzylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-
 c]pyrazol-3-yl)-2,5-dimethoxybenzamide 398506-88-2P,
 N-(5-Benzylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-2,6-
 dimethoxybenzamide 398506-89-3P, N-(5-Benzylsulfonyl-4,6-dihydro-
 1H-pyrrolo[3,4-c]pyrazol-3-yl)-3,4-dimethoxybenzamide 398506-90-6P
 , N-(5-Benzylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-3,5-
 dimethoxybenzamide 398506-91-7P, N-(5-Benzylsulfonyl-4,6-dihydro-
 1H-pyrrolo[3,4-c]pyrazol-3-yl)-3-(2-thenoyl)propionamide
 398506-92-8P, N-(5-Benzylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-
 c]pyrazol-3-yl)-2-naphthylacetamide 398506-93-9P,
 N-(5-Benzylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-1-
 naphthylacetamide 398506-94-0P, N-(5-Benzylsulfonyl-4,6-dihydro-
 1H-pyrrolo[3,4-c]pyrazol-3-yl)-4-phenylbenzamide 398506-95-1P,
 N-(5-Acetyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-N'-(4-
 chlorobenzyl)urea 398506-96-2P, N-(5-Benzyl-4,6-dihydro-1H-
 pyrrolo[3,4-c]pyrazol-3-yl)-N'-(4-chlorobenzyl)urea 398506-97-3P
 , N-(5-Phenyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-N'-(4-
 chlorobenzyl)urea 398506-98-4P, N-(5-Aminocarbonyl-4,6-dihydro-
 1H-pyrrolo[3,4-c]pyrazol-3-yl)-N'-(4-chlorobenzyl)urea
 398506-99-5P, N-(5-Ethylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-
 c]pyrazol-3-yl)-N'-(4-chlorobenzyl)urea 398507-00-1P,
 N-(5-Methylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-N'-(4-
 chlorobenzyl)urea 398507-01-2P, N-(5-Benzylsulfonyl-4,6-dihydro-
 1H-pyrrolo[3,4-c]pyrazol-3-yl)-N'-(4-chlorobenzyl)urea
 398507-02-3P, N-(5-Toluensulfonyl-4,6-dihydro-1H-pyrrolo[3,4-
 c]pyrazol-3-yl)-N'-(4-chlorobenzyl)urea 398507-03-4P,
 N-(5-Benzylaminocarbonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-N'-(4-
 chlorobenzyl)urea 398507-04-5P, N-(5-Phenylaminocarbonyl-4,6-
 dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-N'-(4-chlorobenzyl)urea
 398507-05-6P, N-[5-(2-Furoyl)-4,5,6,7-tetrahydro-1H-pyridine[4,3-
 c]pyrazol-3-yl]-2-(2-naphthyl)propanamide 398507-06-7P
 398507-07-8P 398507-08-9P 398507-09-0P
 398507-10-3P 398507-11-4P 398507-12-5P
 398507-13-6P, N-[5-(2-Thienylacetyl)-6,6-dimethyl-4,6-dihydro-1H-
 pyrrolo[3,4-c]pyrazol-3-yl](4-tert-butyl)benzamide 398507-14-7P,
 N-[5-(2-Thienylacetyl)-6,6-dimethyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-
 yl]phenylacetamide 398507-15-8P 398507-16-9P
 398507-17-0P 398507-18-1P, N-[5-(4-Fluorobenzoyl)-6,6-
 dimethyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl](4-tert-butyl)benzamide
 398507-19-2P, N-[5-(4-Fluorobenzoyl)-6,6-dimethyl-4,6-dihydro-1H-
 pyrrolo[3,4-c]pyrazol-3-yl]cyclopropanecarboxamide 398507-20-5P,


N-[5-(4-Fluorobenzoyl)-6,6-dimethyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl]phenylacetamide 398507-21-6P 398507-22-7P,
 N-(5-Acetyl-6,6-dimethyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-(4-fluoro)benzamide 398507-23-8P, N-(5-Acetyl-6,6-dimethyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)-(4-tert-butyl)benzamide 398507-24-9P, N-(5-Acetyl-6,6-dimethyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)cyclopropanecarboxamide 398507-25-0P, N-(5-Acetyl-6,6-dimethyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl)phenylacetamide 398507-26-1P 398507-27-2P 398507-28-3P 398507-29-4P 398507-30-7P 398507-31-8P, N-(6-Acetyl-4,5,6,7-tetrahydro-1H-pyridine[3,4-c]pyrazol-3-yl)-4-tert-butylbenzamide 398507-32-9P,
 N-(6-Phenylsulfonyl-4,5,6,7-tetrahydro-1H-pyridine[3,4-c]pyrazol-3-yl)-4-tert-butylbenzamide 398507-33-0P 398509-35-8P
 RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
 (kinase inhibitor; combinatorial preparation of bicyclo pyrazoles as kinase inhibitors for treatment of cancer and other proliferative disorders)
 RN 398504-43-3 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[1,4-dioxo-4-(2-thienyl)butyl]amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398504-44-4 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(2-naphthalenylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398504-45-5 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 4,6-dihydro-3-[(1-naphthalenylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398504-47-7 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[[1,1'-biphenyl]-4-ylcarbonyl]amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398504-49-9 CAPLUS
 CN Acetamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398504-51-3 CAPLUS
 CN Cyclopropanecarboxamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398504-53-5 CAPLUS
 CN Propanamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 398504-55-7 CAPLUS
 CN Cyclopentanecarboxamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398504-57-9 CAPLUS

CN Benzamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398504-59-1 CAPLUS

CN 2-Pyridinecarboxamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398504-61-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398504-63-7 CAPLUS


CN 4-Pyridinecarboxamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398504-65-9 CAPLUS
 CN 2-Furancarboxamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 398504-67-1 CAPLUS
 CN 2-Thiophenecarboxamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398504-69-3 CAPLUS
 CN 3-Thiophenecarboxamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398504-70-6 CAPLUS
 CN Benzamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 398504-73-9 CAPLUS

CN Benzamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 398504-74-0 CAPLUS

CN Benzamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-methyl- (9CI) (CA INDEX NAME)




RN 398504-76-2 CAPLUS

CN Benzeneacetamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398504-78-4 CAPLUS


CN Benzamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-2-hydroxy- (9CI) (CA INDEX NAME)




RN 398504-80-8 CAPLUS
 CN Benzamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 398504-82-0 CAPLUS
 CN Benzamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 398504-84-2 CAPLUS
 CN Benzamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 398504-86-4 CAPLUS
 CN 2-Thiopheneacetamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398504-88-6 CAPLUS

CN 3-Thiopheneacetamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398504-90-0 CAPLUS

CN 2-Propynamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 398504-92-2 CAPLUS

CN Benzamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-3-cyano- (9CI) (CA INDEX NAME)



RN 398504-94-4 CAPLUS


CN Benzamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-cyano- (9CI) (CA INDEX NAME)



RN 398504-96-6 CAPLUS

CN 2-Propenamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-3-phenyl-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 398504-98-8 CAPLUS


CN 2-Propenamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-3-phenyl-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 398505-00-5 CAPLUS

CN 2-Propenamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 398505-01-6 CAPLUS

CN 2-Propenamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 398505-03-8 CAPLUS

CN Benzeneacetamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-α-methyl- (9CI) (CA INDEX NAME)




RN 398505-05-0 CAPLUS

CN Benzeneacetamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 398505-11-8 CAPLUS

CN Benzeneacetamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 398505-13-0 CAPLUS


CN Benzeneacetamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-methyl- (9CI) (CA INDEX NAME)




RN 398505-15-2 CAPLUS
 CN Benzamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 398505-17-4 CAPLUS
 CN Benzamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 398505-19-6 CAPLUS
 CN Benzamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 398505-21-0 CAPLUS
 CN Acetamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-2-phenoxy- (9CI) (CA INDEX NAME)




RN 398505-23-2 CAPLUS
 CN Benzeneacetamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 398505-25-4 CAPLUS
 CN Benzeneacetamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 398505-27-6 CAPLUS
 CN Benzeneacetamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 398505-29-8 CAPLUS
 CN 2-Propenamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-3-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 398505-31-2 CAPLUS
 CN 2-Propenamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-3-(3-thienyl)- (9CI) (CA INDEX NAME)




RN 398505-32-3 CAPLUS

CN 2-Thiophenepropanamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398505-34-5 CAPLUS

CN Benzamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-2-chloro- (9CI) (CA INDEX NAME)




RN 398505-36-7 CAPLUS

CN Benzamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-3-chloro- (9CI) (CA INDEX NAME)




RN 398505-38-9 CAPLUS

CN Benzamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-chloro- (9CI) (CA INDEX NAME)




RN 398505-40-3 CAPLUS

CN 1-Piperidinepropanamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398505-42-5 CAPLUS

CN Benzamide, 2-acetyl-N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398505-44-7 CAPLUS

CN Benzamide, 4-acetyl-N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398505-45-8 CAPLUS

CN 1-Naphthalenecarboxamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398505-47-0 CAPLUS


CN 2-Naphthalenecarboxamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398505-49-2 CAPLUS
 CN Benzenebutanamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-γ-oxo- (9CI) (CA INDEX NAME)




RN 398505-51-6 CAPLUS
 CN Benzamide, 4-(acetylamino)-N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398505-53-8 CAPLUS
 CN Benzamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-2,5-dimethoxy- (9CI) (CA INDEX NAME)




RN 398505-55-0 CAPLUS
 CN Benzamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-2,6-dimethoxy- (9CI) (CA INDEX NAME)




RN 398505-56-1 CAPLUS

CN Benzamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-3,4-dimethoxy- (9CI) (CA INDEX NAME)




RN 398505-58-3 CAPLUS

CN Benzamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-3,5-dimethoxy- (9CI) (CA INDEX NAME)




RN 398505-60-7 CAPLUS

CN 2-Thiophenebutanamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-γ-oxo- (9CI) (CA INDEX NAME)




RN 398505-62-9 CAPLUS

CN 2-Naphthaleneacetamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398505-64-1 CAPLUS

CN 1-Naphthaleneacetamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398505-66-3 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-[5-(aminosulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398505-68-5 CAPLUS

CN Acetamide, N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398505-70-9 CAPLUS

CN Cyclopropanecarboxamide, N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398505-72-1 CAPLUS

CN Propanamide, 2-methyl-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398505-74-3 CAPLUS

CN Cyclopentanecarboxamide, N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398505-76-5 CAPLUS

CN Benzamide, N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398505-78-7 CAPLUS


CN 2-Pyridinecarboxamide, N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398505-80-1 CAPLUS
 CN 3-Pyridinecarboxamide, N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398505-82-3 CAPLUS
 CN 4-Pyridinecarboxamide, N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398505-84-5 CAPLUS
 CN 2-Furancarboxamide, 3-methyl-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398505-86-7 CAPLUS
 CN 2-Thiophenecarboxamide, N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398505-87-8 CAPLUS
 CN 3-Thiophenecarboxamide, N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398505-88-9 CAPLUS

CN Benzamide, 2-methyl-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398505-89-0 CAPLUS

CN Benzamide, 3-methyl-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398505-90-3 CAPLUS

CN Benzamide, 4-methyl-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398505-91-4 CAPLUS

CN Benzamide, 2-hydroxy-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398505-92-5 CAPLUS

CN Benzamide, 2-fluoro-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398505-93-6 CAPLUS

CN Benzamide, 3-fluoro-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398505-94-7 CAPLUS

CN Benzamide, 4-fluoro-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398505-95-8 CAPLUS

CN 2-Thiopheneacetamide, N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398505-96-9 CAPLUS

CN 3-Thiopheneacetamide, N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398505-97-0 CAPLUS

CN 2-Propynamide, 3-phenyl-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398505-98-1 CAPLUS

CN Benzamide, 3-cyano-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398505-99-2 CAPLUS


CN Benzamide, 4-cyano-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398506-00-8 CAPLUS

CN 2-Propenamide, 3-phenyl-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 398506-01-9 CAPLUS


CN 2-Propenamide, 3-phenyl-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 398506-02-0 CAPLUS

CN 2-Propenamide, 3-(3-pyridinyl)-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-03-1 CAPLUS

CN 2-Propenamide, 3-(4-pyridinyl)-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-04-2 CAPLUS

CN Benzeneacetamide, α-methyl-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-05-3 CAPLUS

CN Benzeneacetamide, 2-methyl-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-06-4 CAPLUS

CN Benzeneacetamide, 3-methyl-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-07-5 CAPLUS


CN Benzeneacetamide, 4-methyl-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-08-6 CAPLUS
 CN Benzamide, 2-methoxy-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-09-7 CAPLUS
 CN Benzamide, 3-methoxy-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-10-0 CAPLUS
 CN Benzamide, 4-methoxy-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398506-11-1 CAPLUS
 CN Acetamide, 2-phenoxy-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-12-2 CAPLUS
 CN Benzeneacetamide, 2-fluoro-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-13-3 CAPLUS

CN Benzeneacetamide, 3-fluoro-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-14-4 CAPLUS

CN Benzeneacetamide, 4-fluoro-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-15-5 CAPLUS

CN 2-Propenamide, N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]-3-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 398506-16-6 CAPLUS

CN 2-Propenamide, N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]-3-(3-thienyl)- (9CI) (CA INDEX NAME)




RN 398506-17-7 CAPLUS

CN 2-Thiophenepropanamide, N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-18-8 CAPLUS

CN Benzamide, 2-chloro-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-19-9 CAPLUS

CN Benzamide, 3-chloro-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-20-2 CAPLUS

CN Benzamide, 4-chloro-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-21-3 CAPLUS

CN 1-Piperidinepropanamide, N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-22-4 CAPLUS

CN Benzamide, 2-acetyl-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-23-5 CAPLUS

CN Benzamide, 4-acetyl-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-24-6 CAPLUS

CN 1-Naphthalenecarboxamide, N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-25-7 CAPLUS

CN 2-Naphthalenecarboxamide, N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-26-8 CAPLUS

CN Benzenebutanamide, γ-oxo-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-27-9 CAPLUS

CN Benzamide, 4-(acetylamino)-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-28-0 CAPLUS

CN Benzamide, 2,5-dimethoxy-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-29-1 CAPLUS

CN Benzamide, 2,6-dimethoxy-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-30-4 CAPLUS

CN Benzamide, 3,4-dimethoxy-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-31-5 CAPLUS

CN Benzamide, 3,5-dimethoxy-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-32-6 CAPLUS

CN 2-Thiophenebutanamide, γ-oxo-N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-33-7 CAPLUS

CN 2-Naphthaleneacetamide, N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-34-8 CAPLUS

CN 1-Naphthaleneacetamide, N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-35-9 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-[1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-36-0 CAPLUS

CN Acetamide, N-[1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-37-1 CAPLUS


CN Cyclopropanecarboxamide, N-[1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-38-2 CAPLUS
 CN Propanamide, 2-methyl-N-[1,4,5,6-tetrahydro-5-
 [(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX
 NAME)




RN 398506-39-3 CAPLUS
 CN Cyclopentanecarboxamide, N-[1,4,5,6-tetrahydro-5-
 [(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX
 NAME)



RN 398506-40-6 CAPLUS
 CN Benzamide, N-[1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-
 c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-41-7 CAPLUS
 CN 2-Pyridinecarboxamide, N-[1,4,5,6-tetrahydro-5-
 [(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX
 NAME)




RN 398506-42-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[1,4,5,6-tetrahydro-5-
[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX
NAME)




RN 398506-43-9 CAPLUS

CN 4-Pyridinecarboxamide, N-[1,4,5,6-tetrahydro-5-
[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX
NAME)




RN 398506-44-0 CAPLUS

CN 2-Furancarboxamide, 3-methyl-N-[1,4,5,6-tetrahydro-5-
[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX
NAME)




RN 398506-45-1 CAPLUS


CN 2-Thiophenecarboxamide, N-[1,4,5,6-tetrahydro-5-
[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX
NAME)




RN 398506-46-2 CAPLUS
 CN 3-Thiophenecarboxamide, N-[1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-47-3 CAPLUS
 CN Benzamide, 2-methyl-N-[1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-48-4 CAPLUS
 CN Benzamide, 3-methyl-N-[1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-49-5 CAPLUS
 CN Benzamide, 4-methyl-N-[1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-50-8 CAPLUS
 CN Benzeneacetamide, N-[1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-51-9 CAPLUS
 CN Benzamide, 2-phenyl-N-[1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398506-52-0 CAPLUS
 CN Benzamide, 2-fluoro-N-[1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-53-1 CAPLUS
 CN Benzamide, 3-fluoro-N-[1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-54-2 CAPLUS

CN Benzamide, 4-fluoro-N-[1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-55-3 CAPLUS

CN 2-Thiopheneacetamide, N-[(1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl)]- (9CI) (CA INDEX NAME)




RN 398506-56-4 CAPLUS

CN 3-Thiopheneacetamide, N-[(1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl)]- (9CI) (CA INDEX NAME)




RN 398506-57-5 CAPLUS

CN 2-Propynamide, 3-phenyl-N-[(1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl)]- (9CI) (CA INDEX NAME)




RN 398506-58-6 CAPLUS

CN Benzamide, 3-cyano-N-[1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398506-59-7 CAPLUS


CN Benzamide, 4-cyano-N-[1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398506-60-0 CAPLUS

CN 2-Propenamide, 3-phenyl-N-[1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 398506-61-1 CAPLUS

CN 2-Propenamide, 3-phenyl-N-[1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]-, (2Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 398506-62-2 CAPLUS
 CN 2-Propenamide, 3-(3-pyridinyl)-N-[1,4,5,6-tetrahydro-5-
 [(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX
 NAME)




RN 398506-63-3 CAPLUS
 CN 2-Propenamide, 3-(4-pyridinyl)-N-[1,4,5,6-tetrahydro-5-
 [(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX
 NAME)



RN 398506-64-4 CAPLUS
 CN Benzeneacetamide, alpha-methyl-N-[1,4,5,6-tetrahydro-5-
 [(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX
 NAME)




RN 398506-65-5 CAPLUS
 CN Benzeneacetamide, 3-methyl-N-[1,4,5,6-tetrahydro-5-
 [(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX
 NAME)




RN 398506-66-6 CAPLUS

CN Benzeneacetamide, 4-methyl-N-[1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-67-7 CAPLUS

CN Benzamide, 2-methoxy-N-[1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-68-8 CAPLUS

CN Benzamide, 3-methoxy-N-[1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-69-9 CAPLUS

CN Benzamide, 4-methoxy-N-[1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-70-2 CAPLUS

CN Acetamide, 2-phenoxy-N-[1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-71-3 CAPLUS

CN Benzeneacetamide, 2-fluoro-N-[1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-72-4 CAPLUS

CN Benzeneacetamide, 3-fluoro-N-[1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-73-5 CAPLUS

CN Benzeneacetamide, 4-fluoro-N-[1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-74-6 CAPLUS

CN 2-Propenamide, N-[1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]-3-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 398506-75-7 CAPLUS

CN 2-Propenamide, N-[1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]-3-(3-thienyl)- (9CI) (CA INDEX NAME)




RN 398506-76-8 CAPLUS

CN 2-Thiophenepropanamide, N-[1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-77-9 CAPLUS

CN Benzamide, 2-chloro-N-[1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-78-0 CAPLUS

CN Benzamide, 3-chloro-N-[1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-79-1 CAPLUS

CN Benzamide, 4-chloro-N-[1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-80-4 CAPLUS

CN 1-Piperidinepropanamide, N-[1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-81-5 CAPLUS

CN Benzamide, 2-acetyl-N-[1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-82-6 CAPLUS

CN Benzamide, 4-acetyl-N-[1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]-. (9CI) (CA INDEX NAME)




RN 398506-83-7 CAPLUS

CN 1-Naphthalenecarboxamide, N-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-84-8 CAPLUS

CN 2-Naphthalenecarboxamide, N-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-85-9 CAPLUS


CN Benzenebutanamide, gamma-oxo-N-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-86-0 CAPLUS
 CN Benzamide, 4-(acetylaminomethyl)-N-[1,4,5,6-tetrahydro-5-
 [(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX
 NAME)




RN 398506-87-1 CAPLUS
 CN Benzamide, 2,5-dimethoxy-N-[1,4,5,6-tetrahydro-5-
 [(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX
 NAME)




RN 398506-88-2 CAPLUS
 CN Benzamide, 2,6-dimethoxy-N-[1,4,5,6-tetrahydro-5-
 [(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX
 NAME)




RN 398506-89-3 CAPLUS
 CN Benzamide, 3,4-dimethoxy-N-[1,4,5,6-tetrahydro-5-
 [(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX
 NAME)




RN 398506-90-6 CAPLUS
 CN Benzamide, 3,5-dimethoxy-N-[1,4,5,6-tetrahydro-5-
 [(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX
 NAME)




RN 398506-91-7 CAPLUS
 CN 2-Thiophenebutanamide, γ -oxo-N-[1,4,5,6-tetrahydro-5-
 [(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX
 NAME)



RN 398506-92-8 CAPLUS
 CN 2-Naphthaleneacetamide, N-[1,4,5,6-tetrahydro-5-
 [(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX
 NAME)




RN 398506-93-9 CAPLUS
 CN 1-Naphthaleneacetamide, N-[1,4,5,6-tetrahydro-5-
 [(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX
 NAME)




RN 398506-94-0 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-[1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-95-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, 5-acetyl-N-[[[(4-chlorophenyl)methyl]amino]carbonyl]-1,4,5,6-tetrahydro- (9CI) (CA INDEX NAME)




RN 398506-96-2 CAPLUS

CN Urea, N-[(4-chlorophenyl)methyl]-N'-[1,4,5,6-tetrahydro-5-(phenylmethyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398506-97-3 CAPLUS

CN Urea, N-[(4-chlorophenyl)methyl]-N'-(1,4,5,6-tetrahydro-5-phenylpyrrolo[3,4-c]pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 398506-98-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[[(4-chlorophenyl)methyl]amino]carbonyl]amino]-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398506-99-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[[(4-chlorophenyl)methyl]amino]carbonyl]amino]-N-ethyl-4,6-dihydro- (9CI) (CA INDEX NAME)




RN 398507-00-1 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, N-[[[(4-chlorophenyl)methyl]amino]carbonyl]-1,4,5,6-tetrahydro-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 398507-01-2 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, N-[[[(4-chlorophenyl)methyl]amino]carbonyl]-1,4,5,6-tetrahydro-5-[(phenylmethyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 398507-02-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazol-3-amine, N-[[[(4-chlorophenyl)methyl]amino]carbonyl]-1,4,5,6-tetrahydro-5-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 398507-03-4 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[[(4-chlorophenyl)methyl]amino]carbonyl]amino]-4,6-dihydro-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 398507-04-5 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[[(4-chlorophenyl)methyl]amino]carbonyl]amino]-4,6-dihydro-N-phenyl- (9CI) (CA INDEX NAME)




RN 398507-05-6 CAPLUS

CN 2-Naphthaleneacetamide, N-[5-(2-furanylcarbonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-α-methyl- (9CI) (CA INDEX NAME)




RN 398507-06-7 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(3-bromobenzoyl)amino]-N-butyl-4,6-dihydro-6,6-dimethyl- (9CI) (CA INDEX NAME)




RN 398507-07-8 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-butyl-3-[[4-(1,1-dimethylethyl)benzoyl]amino]-4,6-dihydro-6,6-dimethyl- (9CI) (CA INDEX NAME)




RN 398507-08-9 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-butyl-4,6-dihydro-6,6-dimethyl-3-[(phenylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398507-09-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[[4-(1,1-dimethylethyl)benzoyl]amino]-N-ethyl-4,6-dihydro-6,6-dimethyl- (9CI) (CA INDEX NAME)




RN 398507-10-3 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-ethyl-4,6-dihydro-6,6-dimethyl-3-[(phenylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 398507-11-4 CAPLUS

CN Benzamide, 3-bromo-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-(2-thienylacetyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398507-12-5 CAPLUS

CN Benzamide, 4-fluoro-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-(2-thienylacetyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398507-13-6 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-(2-thienylacetyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398507-14-7 CAPLUS

CN Benzeneacetamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-(2-thienylacetyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398507-15-8 CAPLUS

CN Benzamide, 3-bromo-N-[5-(4-fluorobenzoyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398507-16-9 CAPLUS

CN Benzamide, 4-fluoro-N-[5-(4-fluorobenzoyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398507-17-0 CAPLUS

CN 2-Naphthaleneacetamide, N-[5-(4-fluorobenzoyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398507-18-1 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[5-(4-fluorobenzoyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398507-19-2 CAPLUS

CN Cyclopropanecarboxamide, N-[5-(4-fluorobenzoyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398507-20-5 CAPLUS

CN Benzeneacetamide, N-[5-(4-fluorobenzoyl)-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398507-21-6 CAPLUS

CN 2-Naphthaleneacetamide, N-(5-acetyl-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 398507-22-7 CAPLUS

CN Benzamide, N-(5-acetyl-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl)-4-fluoro- (9CI) (CA INDEX NAME)




RN 398507-23-8 CAPLUS

CN Benzamide, N-(5-acetyl-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl)-4-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 398507-24-9 CAPLUS

CN Cyclopropanecarboxamide, N-(5-acetyl-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 398507-25-0 CAPLUS

CN Benzeneacetamide, N-(5-acetyl-1,4,5,6-tetrahydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 398507-26-1 CAPLUS

CN 2-Naphthaleneacetamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-(phenylacetyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398507-27-2 CAPLUS


CN Benzamide, 3-bromo-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-(phenylacetyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398507-28-3 CAPLUS
 CN Benzamide, 4-fluoro-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-(phenylacetyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398507-29-4 CAPLUS
 CN Benzamide, 4-(1,1-dimethylethyl)-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-(phenylacetyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 398507-30-7 CAPLUS
 CN Cyclopropanecarboxamide, N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-(phenylacetyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 398507-31-8 CAPLUS
 CN Benzamide, N-(6-acetyl-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-3-yl)-4-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 398507-32-9 CAPLUS
 CN Enzamide, 4-(1,1-dimethylethyl)-N-[4,5,6,7-tetrahydro-6-(phenylsulfonyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 398507-33-0 CAPLUS

CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, 3-[(3-bromobenzoyl)amino]-N-ethyl-4,6-dihydro-6,6-dimethyl- (9CI) (CA INDEX NAME)



RN 398509-35-8 CAPLUS

CN Benzamide, 2-methoxy-N-[1,4,5,6-tetrahydro-5-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)




IT 398491-65-1D, resin bound

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; combinatorial preparation of bicyclo pyrazoles as kinase inhibitors for treatment of cancer and other proliferative disorders)

RN 398491-65-1 CAPLUS

CN Benzeneacetamide, N-[1,4,5,6-tetrahydro-5-(phenylacetyl)pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)



L4 ANSWER 23 OF 40 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:816647 CAPLUS


DOCUMENT NUMBER: 135:357948

TITLE: Preparation of heterocyclic compounds as

phosphodiesterase V (PDE V) inhibitors
 INVENTOR(S): Yamada, Koichiro; Matsuki, Kenji; Omori, Kenji;
 Kikkawa, Kohei
 PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 207 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001083460	A1	20011108	WO 2001-JP2034	20010315
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
AU 2001041142	A5	20011112	AU 2001-41142	20010315
CA 2407231	AA	20021023	CA 2001-2407231	20010315
EP 1277741	A1	20030122	EP 2001-912373	20010315
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR	
NZ 522217	A	20040430	NZ 2001-522217	20010315
CN 1657523	A	20050824	CN 2004-10098098	20010315
US 2003229089	A1	20031211	US 2002-258545	20021025
US 2004142930	A1	20040722	US 2003-699804	20031104
AU 2005203687	A1	20050908	AU 2005-203687	20050817
PRIORITY APPLN. INFO.:			JP 2000-130371	A 20000428
			JP 2000-277652	A 20000913
			AU 2001-41142	A3 20010315
			WO 2001-JP2034	W 20010315
			US 2002-258545	A2 20021025

OTHER SOURCE(S): MARPAT 135:357948
 GI



AB Compds. of the general formula (I) or pharmacol. acceptable salts thereof [wherein X is :CH or N; Y is NH, NR₄, S, O, CH:N, N:CH, N:N, CH:CH, or the like; R₁ is lower alkoxy, amino, a nitrogenous heterocyclic group, or a hydroxyl group substituted with a heterocyclic group (wherein each group may be substituted); R₂ is either a lower alkylamino or lower alkoxy group which may be substituted with aryl, or a lower alkoxy group substituted with a nitrogenous aromatic heterocyclic group; and R₃ is aryl, a nitrogenous heterocyclic group, lower alkyl, lower alkoxy, lower cycloalkoxy, a hydroxyl group substituted with a nitrogenous heterocyclic group, or amino (wherein each group may be substituted), or alternatively, R₃ and the substituent of Y may be united to form a lactone ring] or pharmacol.

acceptable salts thereof are prepared These compds. exhibit excellent PDE V inhibitory activity and are useful as preventive or therapeutic agents for various diseases due to dysfunction of the signal transduction through cGMP, in particular impotence, pulmonary hypertension, and diabetic renal failure paralysis (no data). Thus, 2-(hydroxymethyl)pyridine was treated with NaH in THF at room temperature for 30 min and then condensed with 2-chloro-5-(3,4,5-trimethoxyphenylcarbonyl)-4-(3-chloro-4-methoxybenzylamino)pyrimidine (preparation given) in THF at room temperature for 1 h

to give 2-(2-pyridylmethoxy)-5-(3,4,5-trimethoxyphenylcarbonyl)-4-(3-chloro-4-methoxybenzylamino)pyrimidine.


IT 372113-78-5P 372114-34-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic compds. as phosphodiesterase V inhibitors preventive or therapeutic agents for various diseases due to dysfunction of signal transduction through cGMP)


RN 372113-78-5 CAPLUS

CN 3H-Pyrazolo[4,3-c]pyridin-3-one, 5-[4-[(3-chloro-4-methoxyphenyl)methyl]amino]-5-(3,4,5-trimethoxybenzoyl)-2-pyrimidinyl]-1,2,4,5,6,7-hexahydro- (9CI) (CA INDEX NAME)



RN 372114-34-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(octahydro-3-oxo-5H-pyrazolo[4,3-c]pyridin-5-yl)-, ethyl ester (9CI) (CA INDEX NAME)





REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 24 OF 40 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:208252 CAPLUS


DOCUMENT NUMBER: 134:252363
 TITLE: Preparation and effect of nitrogen-containing-six-membered aromatic compounds as PDE V activity inhibitors
 INVENTOR(S): Yamada, Koichiro; Matsuki, Kenji; Omori, Kenji; Kikkawa, Kohei
 PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 91 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001019802	A1	20010322	WO 2000-JP6258	20000913
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2383466	AA	20010322	CA 2000-2383466	20000913
AU 2000073118	A5	20010417	AU 2000-73118	20000913
AU 767558	B2	20031113		
BR 2000014526	A	20020618	BR 2000-14526	20000913
TR 200200701	T2	20020621	TR 2002-701	20000913
EP 1219609	A1	20020703	EP 2000-960979	20000913
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
HU 200202795	A2	20030228	HU 2002-2795	20000913
RU 2233273	C2	20040727	RU 2002-109792	20000913
US 2003032647	A1	20030213	US 2001-925892	20010810
US 6656935	B2	20031202		
ZA 2002001499	A	20020902	ZA 2002-1499	20020222
NO 2002001308	A	20020424	NO 2002-1308	20020315
NO 322038	B1	20060807		
BG 106566	A	20030228	BG 2002-106566	20020402
US 2003229095	A1	20031211	US 2003-426884	20030501
US 6797709	B2	20040928		
PRIORITY APPLN. INFO.:			JP 1999-261852	A 19990916
			JP 2000-130371	A 20000428
			WO 2000-JP6258	W 20000913
			US 2001-925892	A3 20010810
OTHER SOURCE(S):	MARPAT 134:252363			
GI				




- AB Title compds. [I; A is an optionally substituted nitrogenous heterocyclic group; R1 is optionally substituted lower alkyl, NHQR3 (wherein R3 is an optionally substituted nitrogenous heterocyclic group; and Q is lower alkylene or a single bond), or NHR4 (wherein R4 is optionally substituted cycloalkyl); R2 is optionally substituted aryl; and either of Y and Z is CH and the other is N], pharmacol. acceptable salts are prepared and are exhibiting an excellent selective inhibitory activity against PDE V and being useful as preventive or therapeutic drugs for erectile dysfunction (no data). Thus, the title compound II was prepared
- IT 330784-63-9P 330784-77-5P 330784-84-4P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and effect of heteroarom. compds. as PDE V activity inhibitors)
- RN 330784-63-9 CAPLUS
- CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(1,2,3,4,6,7-hexahydro-3-oxo-5H-pyrazolo[4,3-c]pyridin-5-yl)-N-(trans-4-hydroxycyclohexyl)]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




- RN 330784-77-5 CAPLUS
- CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(1,2,3,4,6,7-hexahydro-3-oxo-5H-pyrazolo[4,3-c]pyridin-5-yl)-N-[2-(4-morpholinyl)ethyl]]- (9CI) (CA INDEX NAME)



RN 330784-84-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[3-chloro-4-methoxyphenyl)methyl]amino]-2-(1,2,3,4,6,7-hexahydro-3-oxo-5H-pyrazolo[4,3-c]pyridin-5-yl)-N-(2-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 25 OF 40 CAPLUS. COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1997:625289 CAPLUS

DOCUMENT NUMBER: 127:293161

TITLE: A facile synthesis of 3-amino-1(2)H-pyrazolo[3,4-c]pyridine

AUTHOR(S): Dunn, A. D.

CORPORATE SOURCE: Beilstein Institut fur Literatur der Organischen Chemie, Frankfurt am Main, Germany

SOURCE: Organic Preparations and Procedures International (1997), 29(5), 577-579

CODEN: OPPIAK; ISSN: 0030-4948

PUBLISHER: Organic Preparations and Procedures, Inc.


DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 127:293161


AB The title compound was prepared in 87% yield by reaction 3-bromopyridine-4-carboxylic acid with NEt_3/THF and EtO_2CCl followed by POCl_3 , NaN_3/DMF , and cyclization with $\text{H}_2\text{NNH}_2/\text{EtOH}$ under reflux.

IT 76006-17-2P, 1H-Pyrazolo[3,4-c]pyridin-3-amine
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of aminopyrazolopyridine)
 RN 76006-17-2 CAPLUS
 CN 1H-Pyrazolo[3,4-c]pyridin-3-amine (9CI) (CA INDEX NAME)




REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 26 OF 40 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1994:323364 CAPLUS
 DOCUMENT NUMBER: 120:323364
 TITLE: Palladium-catalyzed allylation of 3-hydroxyisoxazole, 5-isoxazolone and 5-pyrazolone systems
 AUTHOR(S): Moreno-Manas, Marcial; Perez, Montserrat; Pleixats, Roser
 CORPORATE SOURCE: Dep. Chem., Univ. Auton. Barcelona, Barcelona, 08193, Spain
 SOURCE: Tetrahedron (1994), 50(2), 515-28
 CODEN: TETRAB; ISSN: 0040-4020
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB Kinetic vs. thermodyn. control and steric hindrance are factors that determine the regioselectivity of the Pd(0)-catalyzed allylation of ambident heterocycles of the 3-hydroxyisoxazole, 5-isoxazolone and 5-pyrazolone series. Thus, allylation of tetrahydroisoxazolopyridine I with ROCO₂Et (R = PhCH:CHCH₂, CH₂:CMeCH₂, 2-cyclohexen-1-yl) gave hexahydroisoxazolopyridines II.
 IT 152559-30-3P 152559-31-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and palladium-catalyzed allylation of)
 RN 152559-30-3 CAPLUS
 CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 1,2,3,4,6,7-hexahydro-3-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 152559-31-4 CAPLUS
 CN 6H-Pyrazolo[3,4-c]pyridine-6-carboxylic acid, 1,2,3,4,5,7-hexahydro-3-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 27 OF 40 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1994:106942 CAPLUS
 DOCUMENT NUMBER: 120:106942
 TITLE: Palladium(0)-catalyzed allylation of
 5-hydroxyisoxazole and 3-pyrazolone systems
 AUTHOR(S): Moreno-Manas, Marcial; Perez, Montserrat; Pleixats,
 Roser
 CORPORATE SOURCE: Dep. Chem., Univ. Auton. Barcelona, Bellaterra, 08193,
 Spain
 SOURCE: Anales de Quimica (1993), 89(1), 109-12
 CODEN: ANQUEX; ISSN: 1130-2283
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




I



II


AB The allylation of a fused 5-hydroxyisoxazole I was achieved in the
 presence of a palladium(0) catalyst. For a fused 3-pyrazolone II wherein
 enamine and amide moieties compete chemoselective C-alkylation at the
 enamine was observed
 IT 152559-30-3 152559-31-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (palladium-catalyzed chemoselective allylation of)
 RN 152559-30-3 CAPLUS
 CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 1,2,3,4,6,7-hexahydro-3-oxo-

, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 152559-31-4 CAPLUS

CN 6H-Pyrazolo[3,4-c]pyridine-6-carboxylic acid, 1,2,3,4,5,7-hexahydro-3-oxo-
, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 28 OF 40 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1984:51566 CAPLUS

DOCUMENT NUMBER: 100:51566

TITLE: Pharmacologically active pyrazolo[4,3-c]pyridines

INVENTOR(S): Winters, Giorgio; Sala, Alberto; Barone, Domenico

PATENT ASSIGNEE(S): Gruppo Lepetit S.p.A. , Italy

SOURCE: Eur. Pat. Appl., 85 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 86422	A2	19830824	EP 1983-101109	19830206
EP 86422	A3	19840328		
EP 86422	B1	19870930		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
DK 8300273	A	19830818	DK 1983-273	19830125
ZA 8300628	A	19831228	ZA 1983-628	19830131
AT 30027	E	19871015	AT 1983-101109	19830206
AU 8311305	A1	19830825	AU 1983-11305	19830210
AU 563591	B2	19870716		
US 4500525	A	19850219	US 1983-466701	19830215
ES 519832	A1	19841001	ES 1983-519832	19830216
CA 1225646	A1	19870818	CA 1983-421751	19830216
JP 58152885	A2	19830910	JP 1983-23893	19830217
JP 04012269	B4	19920304		
ES 531980	A1	19850901	ES 1984-531980	19840427
ES 531981	A1	19850901	ES 1984-531981	19840427
PRIORITY APPLN. INFO.:			GB 1982-4722	A 19820217
			EP 1983-101109	A 19830206

OTHER SOURCE(S): MARPAT 100:51566

GI



AB I (R, R1 = H, alkyl, cycloalkyl, aryl, etc.; Ar = aryl or C5-6 heteroaryl) were prepared (.apprx.200) and shown to have analgesic, antihypertensive, cardiostonic, depressant, and neuroleptic activity. Thus, N-acetyl-4-piperidone was converted into the morpholine enamine, acylated with 4-FC6H4COCl, and cyclized with N2H4 to give II, which was reduced with LiAlH4 to the alc.

IT 87664-13-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as pharmacol. agent)

RN 87664-13-9 CAPLUS


CN Pyrazolo[4,3-c]pyridine, 5-acetyl-3-(4-fluorophenyl)tetrahydro-1(or 2)-phenyl- (9CI) (CA INDEX NAME)

CM 1

CRN 87664-12-8

CMF C20 H22 F N3 O

CCI IDS



D1-Ph

L4 ANSWER 29 OF 40 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1981:15636 CAPLUS

DOCUMENT NUMBER: 94:15636

TITLE: Pyrazolopyridines. Part 5. Preparation and reactions of pyrazolo[3,4-c]pyridines

AUTHOR(S): Chapman, David; Hurst, Jim

CORPORATE SOURCE: Sch. Pharm., Sunderland Polytech., Sunderland, SR1 3SD, UK

SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1980), (11), 2398-404


CODEN: JCPRB4; ISSN: 0300-922X

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 94:15636

GI




AB Pyrazolopyridines I (R = H, R1 = Me, OMe, Cl; R = OMe, Cl, R1 = H) were prepared in good yield by nitrosation of the corresponding pyridines II, followed by rearrangement, cyclization and hydrolysis. The ring system readily underwent electrophilic substitution in the 3-position; I (R = Cl, R1 = H) was more susceptible to nucleophilic substitution than its isomer I (R = H, R1 = Cl). The 1- and 2-Ac and -Bz derivs. of I were prepared and their structures determined from spectral data.

IT 76006-17-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 76006-17-2 CAPLUS

CN 1H-Pyrazolo[3,4-c]pyridin-3-amine (9CI) (CA INDEX NAME)



L4 ANSWER 30 OF 40 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1980:426379 CAPLUS

DOCUMENT NUMBER: 93:26379

TITLE: Synthesis of isomeric pyridopyrrolo[1,2-a]pyrimidines

AUTHOR(S): Tisler, Miha; Stanovnik, Branko; Zrimsek, Zdenka


CORPORATE SOURCE: Dep. Chem., Univ. Ljubljana, Ljubljana, 61000,
Yugoslavia

SOURCE: Heterocycles (1979), 13(Spec. Issue), 217-19
CODEN: HTCYAM; ISSN: 0385-5414

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB Pyridopyrrolopyrimidinone I (RR1 = NH) was prepared by treating Me 2-aminonicotinate with 2,5-diethoxytetrahydrofuran to give I (R = OMe, R1 = H) which was treated with N2H4-EtOH to give I (R = NHNH2, R1 = H). Diazotization of the hydrazide gave 28% I (RR1 = NH). II and III was


similarly prepared Treatment of Et 4-(1-pyrrolyl)nicotinate with N2H4 gave 91% 3-pyrazolo[4,3-c]pyridinone.

IT 3268-73-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 3268-73-3 CAPLUS

CN 3H-Pyrazolo[4,3-c]pyridin-3-one, 1,2-dihydro- (9CI) (CA INDEX NAME)



L4 ANSWER 31 OF 40 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1976:478045 CAPLUS

DOCUMENT NUMBER: 85:78045

TITLE: Antituberculous compounds. XXVIII. Synthesis of pyrazolopyridines

AUTHOR(S): Sekikawa, Isao; Nishie, Jun; Tonooka, Shuichi; Tanaka, Yorie; Kakimoto, Shichiro

CORPORATE SOURCE: Hokkaido Univ., Sapporo, Japan

SOURCE: Hokkaido Daigaku Men'eki Kagaku Kenkyusho Kiyo (1975), 35, 24-5


CODEN: HDMKDN; ISSN: 0385-504X

DOCUMENT TYPE: Journal


LANGUAGE: Japanese

OTHER SOURCE(S): CASREACT 85:78045


GI




I



II



III



IV


AB Potential tuberculostatics I-IV were prepared by cyclization of the appropriate o-hydrazinopyridinecarboxylic acids.

IT 3268-70-0P 51617-95-9P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 3268-70-0 CAPLUS

CN 3H-Pyrazolo[4,3-c]pyridin-3-one, 1,2-dihydro-, 5-oxide (9CI) (CA INDEX NAME)




RN 51617-95-9 CAPLUS
 CN 3H-Pyrazolo[3,4-c]pyridin-3-one, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L4 ANSWER 32 OF 40 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1974:552151 CAPLUS
 DOCUMENT NUMBER: 81:152151
 TITLE: Degradative ring opening of pyrido- and
 pyrazino-3-benzenesulfonyloxyuracils and their
 conversion to condensed pyrazolones and triazolones
 AUTHOR(S): Tserng, Kou-Yi; Bauer, Ludwig
 CORPORATE SOURCE: Med. Cent., Univ. Illinois, Chicago, IL, USA
 SOURCE: Journal of Heterocyclic Chemistry (1974), 11(2), 163-6
 CODEN: JHTCAD; ISSN: 0022-152X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI For diagram(s), see printed CA Issue.
 AB Ring opening, followed by an immediate Lossen rearrangement, of
 3-benzenesulfonyloxyprido-[3,2-d, 3,4-d and 4,3-d]pyrimidine-
 2,4(1H,3H)diones I, II, and III with NaOMe in MeOH gave good yields of
 the Me esters of 3-[2-(methoxycarbonyl)hydrazino]-2-, 3-[2-
 (methoxycarbonyl)-hydrazino]-4- and 4-[2-(methoxycarbonyl)hydrazino]-3-
 pyridinecarboxylic acids, resp. The hydrazino esters were cyclized to the
 corresponding pyridopyrazolones. The reaction of 3-
 benzenesulfonyloxyprido[2,3 - d]pyrimidine - 2,4(1H,3H)dione with NaOMe
 produced 8-methoxycarbonyl-s-triazolo[4,3-a]-pyridin-3(2H)one (IV, X =
 CH). NaOMe converted 3-benzene-sulfonyloxylumazine to
 8-methoxycarbonyl-s-triazolo[4,3-a]-pyrazin-3(2H)one IV (X = N).
 IT 3268-73-3P 51617-95-9P 53975-70-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 3268-73-3 CAPLUS
 CN 3H-Pyrazolo[4,3-c]pyridin-3-one, 1,2-dihydro- (9CI) (CA INDEX NAME)




RN 51617-95-9 CAPLUS
 CN 3H-Pyrazolo[3,4-c]pyridin-3-one, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 53975-70-5 CAPLUS
 CN 3H-Pyrazolo[3,4-c]pyridin-3-one, 1,2-dihydro- (9CI) (CA INDEX NAME)




L4 ANSWER 33 OF 40 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1974:95817 CAPLUS
 DOCUMENT NUMBER: 80:95817
 TITLE: Antituberculous compounds. XXVIII. Synthesis of pyrazolopyridines
 AUTHOR(S): Sekikawa, Isao; Nishie, Jun; Tonooka, Shuichi; Tanaka, Yorie; Kakimoto, Shichiro
 CORPORATE SOURCE: Res. Inst. Tuber., Hokkaido Univ., Sapporo, Japan
 SOURCE: Journal of Heterocyclic Chemistry (1973), 10(6), 931-2
 CODEN: JHTCAD; ISSN: 0022-152X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 80:95817
 GI For diagram(s), see printed CA Issue.
 AB Cyclization of 3-hydrazinopicolinic and 3-hydrazinoisonicotinic acids with HCl gave the pyrazolopyridines I and II, resp. III was prepared by heating Me 2-chloronicotinate with NH₂NH₂ in MeOH. Refluxing 4-nitronicotinic acid 1-oxide with NH₂NH₂ in EtOH followed by cyclization with HCl gave IV. I and II had antitubercular activity.
 IT 3427-29-0P 51617-95-9P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 3427-29-0 CAPLUS
 CN 3H-Pyrazolo[4,3-c]pyridin-3-one, 1,2-dihydro-, 5-oxide, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 51617-95-9 CAPLUS
CN 3H-Pyrazolo[3,4-c]pyridin-3-one, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L4 ANSWER 34 OF 40 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1973:159597 CAPLUS
DOCUMENT NUMBER: 78:159597
TITLE: 4,5,6,7-Tetrahydro-1(or 2)H-pyrazolo-4,3-C-pyridine derivatives
INVENTOR(S): Nakanishi, Michio; Arimura, Katsuo; Tsuda, Toshiaki
PATENT ASSIGNEE(S): Yoshitomi Pharmaceutical Industries, Ltd.
SOURCE: Jpn. Tokkyo Koho, 4 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 48003639	B4	19730201	JP 1970-35575	19700423

GI For diagram(s), see printed CA Issue.
AB The title piperidine derivs. (I and II, R1 = alkyl, acyl, aralkyl, alkoxy, R2, R3 = alkyl, Ph, halophenyl) with analgesic and antiinflammatory activities, were prepared by reaction of 3-thiocarbamoyl-4-oxopiperidine derivs. III or 3-thiocarbamoyl-4-cyclic amino-1,2,5,6-tetrahydropyridine derivs. (IV, NR4R5 = pyrrolidinyl, piperidino, morpholino) with RNHNH2 (R = H or R3). IV was prepared by reaction of 4-cyclic amino-1,2,5,6-tetrahydropyridine derivs. with R3NCS, and converted to III by treatment with dilute acid. Thus, a solution of 1-benzyl-4-pyrrolidinyl-1,2,5,6-tetrahydropyridine (18.9 g) and PhNCS in C6H6 was refluxed 1 hr and added 10% HCl to give III (R1 = PhCH2, R2 = Ph), which was suspended in MeOH, NH2NH2.H2O added, and refluxed 2 hr to give 16.2 g I (R1, R2, same as above). Similarly prepared were the following I (R1, R2, given); EtOCO, Ph; PhCH2, Me; Me, p-ClC6H4; Me, Ph; PhCO, Ph. II (R1, R2, and R3 given); Me, Me, Ph; PhCH2, Ph, p-ClC6H4;


PhCH₂, Ph, p-MeC₆H₄; PhCH₂, Ph, Me.
 IT 41270-17-1P 41270-18-2P 41270-19-3P
 41270-20-6P 41270-21-7P 41270-22-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 41270-17-1 CAPLUS
 CN 1H-Pyrazolo[4,3-c]pyridin-3-amine, 4,5,6,7-tetrahydro-N-phenyl-5-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 41270-18-2 CAPLUS
 CN 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-3-(phenylamino)-, ethyl ester (9CI) (CA INDEX NAME)




RN 41270-19-3 CAPLUS
 CN 1H-Pyrazolo[4,3-c]pyridin-3-amine, 4,5,6,7-tetrahydro-N-methyl-5-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 41270-20-6 CAPLUS
 CN 1H-Pyrazolo[4,3-c]pyridin-3-amine, N-(4-chlorophenyl)-4,5,6,7-tetrahydro-5-methyl- (9CI) (CA INDEX NAME)




RN 41270-21-7 CAPLUS
 CN 1H-Pyrazolo[4,3-c]pyridin-3-amine, 4,5,6,7-tetrahydro-5-methyl-N-phenyl- (9CI) (CA INDEX NAME)




RN 41270-22-8 CAPLUS
 CN 1H-Pyrazolo[4,3-c]pyridin-3-amine, 5-benzoyl-4,5,6,7-tetrahydro-N-phenyl-
 (9CI) (CA INDEX NAME)



L4 ANSWER 35 OF 40 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1971:448974 CAPLUS
 DOCUMENT NUMBER: 75:48974
 TITLE: Azoles. LXXXIII. Synthesis of pyrrolo[3,4-c]pyrazoles
 AUTHOR(S): Elguero, Jose; Jacquier, Robert; Shimizu, Bernard
 CORPORATE SOURCE: Lab. Synth. Etude Physicochim. Heterocycl. Azotes, Fac. Sci., Montpellier, Fr.
 SOURCE: Bulletin de la Societe Chimique de France (1971), (4), 1497-9
 CODEN: BSCFAS; ISSN: 0037-8968
 DOCUMENT TYPE: Journal
 LANGUAGE: French
 AB Hydrazines treated with 3-acyl- and 3-(carbethoxy)-4-pyrrolidinones gave pyrrolidino[3,4-c]pyrazoles and pyrrolidino[3,4-c]pyrazoles. The 1-(carbomethoxy)-3-(alkylcarbonyl)-4-pyrrolidinones (I, alkyl = Me or Et) treated with PhNHNH2 gave 1-phenyl-3-alkyl-5-(phenylhydrazido)pyrrolidino[3,4-c]pyrazole; I with MeNHNH2 gave 1,3-dimethyl-5-(carbomethoxy)pyrrolidino[3,4-c]pyrazole; I and NH2NH2 gave 3-alkyl-5-(carbomethoxy)pyrrolidino[3,4-c]pyrazoles. NH2NH2 (1 equivalent) reacted with 1-(carbomethoxy)-3-(carbethoxy)-4-pyrrolidinone gave 5-(carbomethoxy)pyrrolidino[3,4-c]pyrazol-3-one (after treatment with HOAc) via 1-(carbomethoxy)-3-(carbethoxy)-4-pyrrolidinone hydrazone; I and excess NH2NH2 gave the 3-pyrazolone via 1-(carbomethoxy)-3-hydrazino-4-carbohydrazido-3-pyrroline.
 IT 32682-85-2P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 32682-85-2 CAPLUS
 CN Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 2,3,4,6-tetrahydro-3-oxo-, methyl ester (8CI) (CA INDEX NAME)



L4 ANSWER 36 OF 40 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1971:141677 CAPLUS
 DOCUMENT NUMBER: 74:141677
 TITLE: Seven-membered heterocyclic compounds containing nitrogen. X. Syntheses of 5,6,8,9-tetrahydro-7H-pyrimido[4,5-d]azepines
 AUTHOR(S): Yamamoto, Hiroshi; Nakata, Masaru; Morosawa, Shiro; Yokoo, Akira
 CORPORATE SOURCE: Fac. Sci., Okayama Univ., Okayama, Japan
 SOURCE: Bulletin of the Chemical Society of Japan (1971), 44(1), 153-8
 CODEN: BCSJA8; ISSN: 0009-2673
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB 5,6,8,9-Tetrahydro-7H-pyrimido[4,5-d]azepine and some of its derivs. were prepared 6-Acetyl-3-hydroxy-4,5,7,8-tetrahydro-6H-pyrazolo[3,4-d]azepine was also prepared
 IT 31774-80-8P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 31774-80-8 CAPLUS
 CN Pyrazolo[3,4-d]azepin-3-ol, 6-acetyl-1,4,5,6,7,8-hexahydro- (8CI) (CA INDEX NAME)




L4 ANSWER 37 OF 40 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1969:87659 CAPLUS
 DOCUMENT NUMBER: 70:87659
 TITLE: Azaindoles. IV. Preparation of some pyrazolopyridines
 AUTHOR(S): Rao, Ravindra P.
 CORPORATE SOURCE: Univ. Gorakhpur, Gorakhpur, India
 SOURCE: Labdev, Part A: Physical Sciences (1968), 6(4), 214-15
 CODEN: LAPSBF; ISSN: 0368-7430
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB 1H-Pyrazolo[4,3-c]pyridine 5-oxides are prepared Thus, a mixture of 2.4 g. 4-hydrazinonicotinic acid 1-oxide, 6 ml. concentrated HCl, and 50 ml. water is refluxed 2 hrs. to give 1.5 g. 3-hydroxy-1H-pyrazolo[4,3-c]pyridine 5-oxide (I) Na salt, m. 291-2° (decomposition), which is converted to I, m. 252-4°. Similarly, 4-chloronicotinic acid 1-oxide and PhNHNHPh give 1,2-diphenyl-3 - oxo - 1,2-dihydro - 3H- pyrazolo[4,3 - c]pyridine

5-oxide (II).-2H₂O, m. 260-3° (decomposition), which is recrystd. in HCl to give II.HCl.4H₂O, m. 243-5° (decomposition). 1-Phenyl-3-hydroxy-1H-pyrazolo[3,4-b]pyridine-HCl, m. 216-18° (decomposition), is prepared from 2-chloronicotinic acid and PhNHNH₂.

IT 3268-70-0P 21673-06-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 3268-70-0 CAPLUS

CN 3H-Pyrazolo[4,3-c]pyridin-3-one, 1,2-dihydro-, 5-oxide (9CI) (CA INDEX NAME)



RN 21673-06-3 CAPLUS

CN 1H-Pyrazolo[4,3-c]pyridin-3-ol, 5-oxide, sodium salt (8CI) (CA INDEX NAME)



● Na

L4 ANSWER 38 OF 40 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1965:90882 CAPLUS

DOCUMENT NUMBER: 62:90882

ORIGINAL REFERENCE NO.: 62:16227b-g

TITLE: Azaindoles. II. Synthesis of pyrazolo[4,3-c]pyridines

AUTHOR(S): Badger, G. M.; Rao, Ravindra Pratap

CORPORATE SOURCE: Univ. Adelaide

SOURCE: Australian Journal of Chemistry (1965), 18(3), 379-87
 CODEN: AJCHAS; ISSN: 0004-9425

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.


AB cf. CA 62, 7720h. 3-Hydroxy-1H-pyrazolo[4,3-c]pyridine (I), the 1-Ph (II) and 1-Me derivative (III) of I, and their 5-oxides were prepared for testing as tumor inhibitors. The lactam-lactim tautomerism of these compds. is discussed. 4-Chloronicotinic acid 1-oxide (IV) (11.3 g.), 16 cc. N₂H₄.H₂O, and 60 cc. EtOH refluxed 6 hrs. yielded 10.0 g. 4-NHNH₂ analog (V) of IV, yellow, m. 230-1° (decomposition) (H₂O). V (1.18 g.), 3 cc. concentrated HCl, and 35 cc. H₂O refluxed 2 hrs. yielded the 5-oxide (VI) of I, pale yellow amorphous solid, m. 252-4° (decomposition) (AcOH and H₂O); VI.HCl m. 235-7° (decomposition). V (15 g.), 150 cc. H₂O, and 35 cc. concentrated HCl refluxed 2.5 hrs. yielded 15.7 g. VI.HCl, m. 235-7° (decomposition), which dissolved in the min. volume H₂O and adjusted to pH 3.4 with dilute NH₄OH gave 12.6 g. VI, pale yellow, amorphous solid, m.

252-4° (decomposition). 4-Chloronicotinic acid (VII) (1.8 g.), 2.5 cc. N₂H₄.H₂O, and 15 cc. absolute EtOH refluxed 9 hrs. yielded 0.7 g. 4-NHNH₂ analog (VIII) of VII, m. 244-6° (decomposition) (H₂O); the mother liquor boiled with concentrated HCl yielded 0.84 g. I. VII (4.0 g.) in another run yielded 3.2 g. VIII.1.5H₂O, m. 222-4° (decomposition) (H₂O), which readily cyclized to I. VIII (1.0 g.), 3 cc. concentrated HCl, and 30 cc. H₂O refluxed 3.5 hrs. gave 1.0 g. I. I recrystd. from 6N HCl yielded I.HCl, m. 298-300°. I.HCl (0.5 g.) in the min. volume H₂O adjusted to pH 3 precipitated 0.24 g. I, m. 292-4° after sintering (decomposition); picrate m. 260-2° (decomposition) (MeOH). VI (1.0 g.) hydrogenated in 25 cc. MeOH over Raney Ni from 1.5 g. alloy yielded 0.44 g. I, m. 289-91° (decomposition). PhNHNH₂ (6 cc.) added with shaking to 6.0 g. IV in 50 cc. absolute EtOH, refluxed 4.5 hrs., and the product repptd. with acid from dilute NH₄OH yielded 2.25 g. 5-oxide (IX) of II.HCl, m. 230-2° after shrinking (6N HCl). IX.HCl (1.5 g.) basified with NH₄OH yielded 1.42 g. IX, m. 291-3° (decomposition). The original mother liquors deposited on standing 1.6 g. 1-oxide of 4-(α -phenylhydrazino)nicotinic acid (X), amorphous, cream solid, m. 193-5° (decomposition). PhNHNH₂ (1 cc.), 1 g. VII, and 8 cc. absolute EtOH refluxed 8 hrs. yielded 1.1 g. X, lemon yellow, m. 194-7° (decomposition) (MeOH). X (0.5 g.), 15 cc. H₂O, and 1.5 cc. concentrated HCl refluxed 4.5 hrs. yielded 0.32 g. II.HCl, m. 252-4° after shrinking; II, yellow, m. 219-21° after shrinking (MeOH). IX (0.25 g.) in 10 cc. N NaOH hydrogenated 3.5 hrs. over Raney Ni from 1 g. alloy gave 0.15 g. II, m. 214-16° after shrinking. MeNHNH₂ (6 cc.), 3 g. IV, and 20 cc. absolute EtOH refluxed 6 hrs., and the gummy product refluxed 2.5 hrs. with 35 cc. H₂O and 6 cc. concentrated HCl yielded 3 g. 5-oxide (XI) of III.HCl, m. 224-6° (decomposition) (MeOH). XI.HCl treated with Amberlite CG 400 (OH form) gave XI, m. 236-8° (decomposition); picrate m. 206-8° (decomposition) (MeOH). VII (1.5 g.), 10 cc. absolute EtOH, and 3 cc. MeNHNH₂ refluxed 9 hrs., and the gummy product refluxed 3 hrs. with 20 cc. H₂O and 3 cc. concentrated HCl yielded 1.62 g. III.HCl, m. 274-6° after shrinking (MeOH). III.HCl (0.8 g.) treated with Amberlite CG 400 (OH form) in 50 cc. MeOH gave 0.64 g. III, m. 205-7° after shrinking (decomposition) (repptd. from MeOH with dry Me₂CO); picrate m. 242-4° (decomposition) (95% EtOH). XI (92 mg.) in 30 cc. MeOH hydrogenated 2.5 hrs. over Raney Ni from 0.5 g. alloy yielded 82 mg. III, m. 205-6° (decomposition). The uv spectra of I, II, III, VI, IX, and XI are recorded.

IT 3268-70-0, 1H-Pyrazolo[4,3-c]pyridin-3-ol, 5-oxide
 3268-73-3, 1H-Pyrazolo[4,3-c]pyridin-3-ol 3427-29-0,
 1H-Pyrazolo[4,3-c]pyridin-3-ol, 5-oxide, hydrochloride 7257-01-4
 , 1H-Pyrazolo[4,3-c]pyridin-3-ol, picrate 91160-12-2,
 1H-Pyrazolo[4,3-c]pyridin-3-ol, hydrochloride
 (preparation of)


RN 3268-70-0 CAPLUS

CN 3H-Pyrazolo[4,3-c]pyridin-3-one, 1,2-dihydro-, 5-oxide (9CI) (CA INDEX NAME)




RN 3268-73-3 CAPLUS

CN 3H-Pyrazolo[4,3-c]pyridin-3-one, 1,2-dihydro- (9CI) (CA INDEX NAME)



RN 3427-29-0 CAPLUS
 CN 3H-Pyrazolo[4,3-c]pyridin-3-one, 1,2-dihydro-, 5-oxide, monohydrochloride
 (9CI) (CA INDEX NAME)




● HCl

RN 7257-01-4 CAPLUS
 CN 1H-Pyrazolo[4,3-c]pyridin-3-ol, picrate (7CI, 8CI) (CA INDEX NAME)


CM 1

CRN 3268-73-3
 CMF C6 H5 N3 O




CM 2

CRN 88-89-1
 CMF C6 H3 N3 O7



RN 91160-12-2 CAPLUS
 CN 1H-Pyrazolo[4,3-c]pyridin-3-ol, hydrochloride (7CI) (CA INDEX NAME)



● x HCl

L4 ANSWER 39 OF 40 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1957:47052 CAPLUS

DOCUMENT NUMBER: 51:47052

ORIGINAL REFERENCE NO.: 51:8747g-i,8748a-c

TITLE: Pyridopyrazolone derivatives. I. Synthesis of pyrido-[3,4-c]pyrazolones

AUTHOR(S): Sugasawa, Shigehiko; Yoneda, Naoto

CORPORATE SOURCE: Univ. Tokyo

SOURCE: Pharmaceutical Bulletin (1956), 4, 360-3

CODEN: PHBUA9; ISSN: 0369-9471

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

AB The 3-MeO₂CCH₂CH₂ derivative of 1-phenyl-5-pyrazolone (33.5 g.) (Ruggli and Maeder, C.A. 37, 17148) methylated by heating 2.5 hrs. in an oil bath at 160-70° with 20 g. Me₂SO₄, the resulting mixture cooled, heated 30 min. on a H₂O bath with 16 g. NaOH in 75 cc. H₂O, and neutralized with HCl yielded 27 g. 3-HO₂CCH₂CH₂ derivative (I) of 1-phenyl-2-methyl-5-pyrazolone (II), m. 212-13°, esterified by refluxing 2.5 hrs. with 200 cc. absolute EtOH and 40 cc. concentrated H₂SO₄ to 19.8 g. I Et ester, b_{0.25} 182-228°, m. 75-6.5°, and this heated 10 hrs. on a steam bath with anhydrous N₂H₄ gave almost 100% 3-H₂NNHOCCH₂CH₂ derivative (III) of

II, m. 126-7.5°; piperonylidene derivative of III, m. 240-1°. III (14.5 g.) in 12.5 cc. concentrated HCl and 30 cc. H₂O treated dropwise in ice with 3.8 g. NaNO₂ in 10 cc. H₂O, the mixture made alkaline with Na₂CO₃, extracted


with C₆H₆, and the extract refluxed 2 hrs. on a steam bath with 6 cc. PhCH₂OH yielded 9.7 g. 3-PhCH₂O₂CNHCH₂CH₂ derivative of II, m. 99-100°, and this refluxed 1 hr. on an oil bath with 100 cc. glacial AcOH and 100 cc. 20% HCl, steam distilled to remove PhCH₂OH and AcOH, and the residue evaporated in vacuo yielded 7.4 g. di-HCl salt, m. 245-6° (decomposition), of the 3-H₂NCH₂CH₂ derivative (IV) of II; monopicrate of IV, m. 216-17.5° (decomposition); benzoyl derivative (V) of IV, m. 190-1°; veratroyl derivative (VI) of IV, m. 181-2°; homoveratramido derivative of IV, m. 153-4.5°. V (0.5 g.) in 10 cc. C₆H₆ refluxed 1 hr. on a steam bath with 1.5 cc. POCl₃ underwent cyclization to 0.38 g. 1,6-diphenyl-2-methyl-3,4-dihydropyrido[3,4-c]pyrazol-7-one, m. 206-7°. Similarly cyclized, VI yielded 83% 1-phenyl-2-methyl-6-veratryl-3,4-dihydropyrido[3,4-c]pyrazol-7-one (VII), m. 159-60°, whereas IV.2HCl (2 g.) refluxed 2 hrs. on a steam bath with 6 cc. concentrated HCl, 6 cc. 30% CH₂O, and 6 cc. H₂O yielded 1.68 g. 1-phenyl-2-methylpiperido[3,4-c]pyrazol-7-one (VIII), m. 194-5° (decomposition). Catalytic dehydrogenation (20% Pd-C) of 0.4 g. VII in 12 cc. p-cymene in the presence of 0.4 g. Et cinnamate yielded 0.26 g. 1-phenyl-2-methyl-6-veratrylpyrido[3,4-c]pyrazol-7-one (IX), m. 167-8°, and similar treatment of VIII yielded 40% 1-phenyl-2-methylpyrido[3,4-c]pyrazol-7-one (X), m. 154-5°. Ultraviolet absorption curves are shown for VI, VII, IX, and X. Pharmacol. tests of IX and X are in progress.

IT 3268-73-3, 3H-Pyrazolo[4,3-c]pyridin-3-one, 1,2-dihydro-

(derivs.)

RN 3268-73-3 CAPLUS

CN 3H-Pyrazolo[4,3-c]pyridin-3-one, 1,2-dihydro- (9CI) (CA INDEX NAME)



L4 ANSWER 40 OF 40 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1957:47051 CAPLUS

DOCUMENT NUMBER: 51:47051

ORIGINAL REFERENCE NO.: 51:8746d-i,8747a-g

TITLE: Quinone series. IX. Benzodipyrrocolinequinones

AUTHOR(S): Tilak, B. D.; Venkiteswaran, M. R.

CORPORATE SOURCE: Univ. Bombay

SOURCE: Journal of Scientific & Industrial Research (1956), 15B, 561-73

CODEN: JSIRAC; ISSN: 0022-4456

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

GI For diagram(s), see printed CA Issue.

AB cf. C.A. 50, 12971e. To 50 cc. AcCH₂CO₂Et (I) and dry pyridine mixture at 50° was added 4.92 g. chloranil (II) and the mixture refluxed 4 hrs. The brown crystals were washed with alc., triturated with Et₂O, and extracted with boiling H₂O, leaving 1.55 g. crude product, m. 270-5°, which on recrystn. from C₆H₆ gave III, scarlet plates, m. 281-2°, reddish-blue solution in H₂SO₄. Concentrating the mother liquor and pouring

onto dilute HCl gave a precipitate which was extracted with boiling H₂O, leaving 0.95 g.

crude product. On recrystn. from alc. it gave IV, violet plates, m. 220-1°, dark green solution in H₂SO₄. The violet solution of IV in alc. and C₆H₆ showed red fluorescence. The combined H₂O exts. from III and IV gave 1.45 g. OC.CX:C(O-).CO.CX:C(O-) (X = pyridinium group) (V), yellow needles (from H₂O). The same products were obtained with CH₂(CO₂Et)₂ in place of I. Oxidation of III or IV with aqueous alkaline KMnO₄ gave a mixture in

which picolinic acid was detected by BrCN. Refluxing 0.5 g. 2,5-dichloro-p-benzoquinone-3,6-bis(diethyl malonate), 20 cc. absolute alc., and 3 cc. dry pyridine 4 hrs. gave 0.35 g. III. The structure of III is assigned on the basis of this reaction. However, the reaction of 2,6-dichloro-p-benzoquinone with I and pyridine in absolute alc. gave a mixture of III and IV which was separated by chromatography over Al₂O₃ with C₆H₆ as eluant. Adding 1.6 cc. pyridine in 20 min. to a boiling mixture of 2.46 g. II, 1.3 cc. I, and 25 cc. absolute alc. and refluxing 2 hrs. gave a violet solid (0.65 g.) which was extracted with ligroine and the solid obtained on concentration was chromatographed over Al₂O₃ with C₆H₆ as eluant, giving 5-carbethoxy-7,8-dichlorobenzo[1,2-b]pyrrocoline-6,9-quinone (VI), violet needles from alc., m. 165°. VI with I and pyridine gave III and IV. A mixture of 2.6 g. I, 0.46 g. Na, and 5 cc. absolute alc. was heated 15 min. at 60°, a suspension of 3.5 g. 2,5-dichloro-3,6-diphenoxy-p-benzoquinone (VII) in 10 cc. absolute alc. added, the mixture heated 20 min. at 60-70°, and neutralized with HCl to give 1.5 g. 2,5-dichloro-p-benzoquinone-3,6-bis(ethyl acetoacetate) (VIII), yellow needles from alc., m. 126°. Refluxing 0.6 g. VIII, 3 cc. pyridine, and 20 cc. absolute alc. 4 hrs. gave 0.4 g. III. VII with I and pyridine also gave III and IV. Refluxing 0.6 g. III, 2 g. NaOH, 30 cc. alc., and 10 cc.

water 2 hrs., concentrating, diluting, filtering, and acidifying with HCl gave
0.45

g. free acid of III (IX), brown, decompose above 250°, blue color in H₂SO₄, nearly insol. in most organic solvents. Reaction of IX with K₂CO₃ and Et₂SO₄ in acetone gave III. In the same manner IV gave free acid of IV (X), decompose above 250°, blue solution with green fluorescence in aqueous NaOH, green color in H₂SO₄, nearly insol. in organic solvents. Ethylation gave IV. Refluxing 0.4 g. IX, 0.04 g. Cu bronze, and 7 cc. quinoline 1 hr. gave 0.3 g. benzo[1,2-b,4,5-b']dipyrrocoline-6,12-quinone, purified by chromatography over Al₂O₃ with PhMe as eluant, red brown needles, did not m. to 360°, violet solution in H₂SO₄. In the same way X gave benzo[1,2-b,5,4-b']dipyrrocoline-6,12-quinone, violet needles from alc., did not m. to 360°, violet solution in alc. and C₆H₆ which showed red fluorescence, yellow green solution in H₂SO₄. IX with SOCl₂ and PhNH₂ gave 5,11-dicarboxyanilide analog of III (XI), green needles from C₆H₃Cl₃, did not m. to 360°, violet-blue solution in H₂SO₄, violet shade on cotton from a blue vat. In the same way IX gave the bis(p-chloranilide) (XII), bis(β-naphththanilide) (XIII), and bis(dehydrothio-p-toluidide) (XIV), each violet needles from PhNO₂ and did not m. to 360°. The benzidine derivative (XV), probably a polymeric dye, could not be obtained pure due to poor solubility in organic solvents. Similarly X gave benzo[1,2-b,5,4-b']dipyrrocoline-6,12-quinone-5,11-dicarboxyanilide (XVI), violet needles from xylene, did not m. to 360°, dark green solution in H₂SO₄, xylene, and PhCl, olive green shade on cotton from a violet vat. II, PhNHCOCH₂COMe, and pyridine gave a mixture of XI and XVI. A solution of 1.5 cc. CH₂Ac₂ (XVII) in 5 cc. absolute alc. containing 0.23 g. Na was heated


at 60-70° for 15 min. and added to a suspension of 1.23 g. II in 10 cc. absolute alc. Heating at 60-70° 20 min. and neutralizing with dilute HCl gave 0.90 g. 2,5-dichloro-p-benzoquinone-3,6-bis-(acetyl-acetone) (XVIII), yellow needles from alc., m. 198-9°. Similar reaction of VII with XVII also gave XVIII. Refluxing 0.5 g. XVIII and 5 cc. pyridine 6 hrs. gave 0.45 g. 5,11-diacetyl analog of III (XIX), red brown needles from PhCl, decompose above 370° without melting, λ (log E) (in o-C₆H₄Cl₂), 478 (4.280), 362 (4.353), 345 (4.246), violet color in H₂SO₄, unable to be vatted. Refluxing 3 g. p-benzoquinone, 5 cc. XVIII, and 15 cc. pyridine 2 hr. gave 0.47 g. 5,7-diacetyl analog of IV (XX), green needles from o-C₆H₄Cl₂, m. 363-4°, sublimes at 325° and 0.4 mm., λ (log E), 592 (3.995), 368 (4.187), 340 (4.433). II and XVII in pyridine and absolute alc. gave a mixture of XIX and XX which was separated

by chromatography on Al₂O₃ at 100° and elution with (CHCl₂)₂ (Islam and Raphael, C.A. 50, 12052f). Condensation of CH₂Bz₂ and II or VII with NaOEt gave 2,5-dichloro-p-benzoquinone-3,6-bis(benzoylacetone) (XXI), yellow needles from alc., m. 210-11°. Refluxing XXI and pyridine and chromatographing the product on Al₂O₃ with C₆H₆ as eluant gave 5,11-di-Bz analog of III (XXII), scarlet plates, m. 310°, blue color in H₂SO₄. II, CH₂Bz₂ and pyridine gave a mixture of XXII and 5,7-di-Bz analog of II, violet needles, m. 328-9°, green solution in H₂SO₄. The dyeing properties of XI, XII, XIII, XIV, XV, and XVI on cotton were given.

IT 3268-73-3, 3H-Pyrazolo[4,3-c]pyridin-3-one, 1,2-dihydro-
(derivs.)

RN 3268-73-3 CAPLUS

CN 3H-Pyrazolo[4,3-c]pyridin-3-one, 1,2-dihydro- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 10:14:41 ON 22 NOV 2006)

FILE 'REGISTRY' ENTERED AT 10:14:51 ON 22 NOV 2006

L1 STRUCTURE UPLOADED

L2 32 S L1

L3 1672 S L1 FULL

FILE 'CAPLUS' ENTERED AT 10:15:20 ON 22 NOV 2006

L4 40 S L3 FULL

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

205.32

372.47

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-30.00

-30.00

STN INTERNATIONAL LOGOFF AT 10:16:41 ON 22 NOV 2006